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Abstract 
 
Dopamine (DA) besides its action in the nervous system, plays an important role in 
immune cells interactions. Emerging role of DA as a regulator of CD4+ T cells physiology is 
important since dysregulation of different T cell subsets, showing abnormal cell numbers, 
functions, expression of dopamine receptors (DR) and/or response to DA, could contribute to 
the onset and development of some immune-related disorders. Thus, directly and indirectly 
acting dopaminergic therapeutics, currently used in approved clinical indications, could 
represent an attractive source of non-conventional agents for the modulation of CD4+ T cell 
functions. 
The aim of the present work was to develop in vitro methods to investigate the effects 
of dopaminergic agents, currently used in the pharmacotherapy, on the functional responses of 
CD4+ T cells, namely: (i) CD4+ T naïve (Tn), T central memory (TCM) and T effector memory 
(TEM) cells, and their responses to recall antigen (Ag); (ii) CD4+ T regulatory cells (Treg), and 
their suppressive effects on T effector cells (Teff) and (iii) CD4+ T naïve cells, and their ability 
to differentiate towards different T helper (Th) lineages (Th1/Th2/Th17). 
In cultured CD4+ T cells, our results have shown higher expression of DR in apoptotic 
cells in comparison to viable cells and stimulation-induced DR upregulation of all DR on 
viable cells. Addition of high concentrations of DA and L-DOPA (100 μM) have shown 
profound effect on survival of CD4+ T cells. Interestingly, based on preliminary experiments, 
our ex vivo data have shown trend of proliferating cells expressing DR in higher percentages 
that still need to be validated in subsequent studies on more subjects. So far, in vitro tested 
concentrations of dopaminergic agonists have not shown any major effects on proliferation of 
CD4+ T cells. 
In addition, through the use of flow cytometric analysis, expression of DR was 
examined on human: CD4+ naïve T lymphocytes (CD3+CD4+CD45RA+CCR7+), TCM 
(CD3+CD4+CD45RA-CCR7+), TEM (CD3+CD4+CD45RA-CCR7-), Treg cells 
(CD4+CD25highCD127low), and also frequency of different Th subsets: Th1 
(CD4+CXCR3+CCR4-CCR6-), Th2 (CD4+CXCR3-CCR4+CCR6-), Th17 (CD4+CXCR3-
CCR4-CCR6+) and Th1/Th17 (CD4+CXCR3+CCR4-CCR6+) were analysed. DR expression 
of all five DR was confirmed on each subset, present in a different extension potentially 
represents an opportunity to develop targeted immunomodulating strategies. 
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Validated and developed in vitro method to test functional response of memory CD4+ 
T cells towards recall Ag have potential relevance for a wide range of different fields of T cell 
biology research in health and disease. Additionally, obtained preliminary results have 
confirmed in vitro experimental conditions likely appropriate to study commitment of naïve 
CD4+ T cells and factors mimicking specific polarisation routes (Th1/Th2/Th17), which are T 
subsets important in onset and development of some dopamine-related disorders. 
Further, in vitro methods have shown CD4+CD25high T cell-dependent inhibition of 
CD4+ T effector lymphocyte proliferation. Treg cells also suppressed production of IFN-γ and 
TNF-α from Teff cells. In addition, effects of DA and L-DOPA treatments seems to suppress 
Treg suppressive capacity in healthy subjects and in the group of Parkinson’s disease (PD) 
patients who had never been treated (PD-dn), but not in PD patients that were on dopaminergic 
therapy (PD-dt). 
Available evidence supports the possibility to repurpose dopaminergic agents as 
modulators of dopaminergic pathways, shifting the balance towards beneficial outcomes in 
some pathological conditions, such as PD. Over the last decades, an impressive number of 
studies in the animal model of immune diseases and in the clinical setting supported this 
evidence, and strongly required futher testing. The development of therapeutic protocols needs 
to take into account that DR exists in multiple subtypes and their patterns of expression, and 
that fuctional relevance differs among immune cells - and may even depend on the functional 
status (e.g. resting/activated) of specific cells. 
Proposed in vitro methods examined and characterised the various CD4+ T cell 
lineages, providing both the conceptual as well as the experimental framework for more in-
depth investigation of dopaminergic pathways modulating CD4+ T cell function. 
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1.1. Physiopharmacology of dopamine  
1.1.1. Physiology of dopamine 
 
Dopamine was synthesized for the first time in 1910 by George Barger and James 
Ewens in London. It was named DA because it has a monoamine structure, containing nitrogen 
formed from ammonia by replacement of one of the hydrogen atoms by hydrocarbon radicals. 
Later on, the molecule itself was isolated and described as a neurotransmitter of the brain by 
Arvid Carlsson. For this discovery, together with Paul Greengard who described cellular 
signalling mechanisms by DA, these two researchers won the Nobel Prize for Medicine in 
2000.  
Dopamine is known today as one of the principal catecholamine neurotransmitters in 
the central nervous system (CNS). It has a large variety of actions and it is involved in control 
of several key functions such as brain reward, motivation and positive reinforcement (Bressan 
and Crippa, 2005). Overproduction in the “pleasure center” of the brain leads to addiction. 
Natural pleasurable and rewarding stimuli increase DA released in the nucleus accumbens area 
of the basal (“deep”) forebrain. Some drugs (e.g. amphetamine, cocaine), with a high potential 
for abuse and addiction, also increase DA release by acting directly on dopaminergic neurons 
within the reward system, while others (e.g. alcohol, opiates) increase DA indirectly, via 
effects of other neurotransmitter systems. Dopamine in the brain regulates locomotor activity 
and movement (Cenci, 2007), attention span, emotional response, behaviour, cognition 
function, pain perception (Potvin et al., 2009) and neuroendocrine secretion (Missale et al., 
1998). In order to understand the function of DA, it is important to consider sites of action in 
both CNS and peripheral tissues, since it has been shown that DA has a significant 
physiological role in the cardiovascular, renal, hormonal and gastrointestinal systems (Dayan, 
2009). 
Hereafter, the current knowledge on physiopharmacology of DA will firstly be 
reviewed, together with DR’s distribution in CNS, as well as in peripheral tissues, discussing 
key roles and available evidence that DA has in selected pathological conditions, and the 
opportunity to repurpose dopaminergic agents as modulators of dopaminergic pathways 
shifting the balance towards beneficial outcomes.  
Indeed, any directly and indirectly acting dopaminergic therapeutics currently used in 
approved clinical indications could represent an attractive source of non-conventional agents 
for the modulation of the described pathological processes. 
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1.1.2. Dopamine synthesis 
 
DA is a monoamine, classified as a catecholamine (CA) and a member of a group of 
neurotransmitters called “biogenic amines” together with noradrenaline (NA), adrenaline (A) 
and serotonin (5-HT). It originates from a group of catecholamines (CAs), chemical 
compounds containing a catechol moiety with a 3,4-dihydroxyphenyl group (catechol core of 
the molecule is a benzene ring with two adjacent hydroxyl groups) and an amine side chain, 
together define the main functional groups and activity of the molecule.  
Dopamine, together with other CAs, is produced from non-essential amino acid, 
tyrosine. The enzyme dopamine β-hydroxylase (DβH) synthesizes NA from DA, and 
phenyletanolamine N-metyltransferase converts NA to A. Chemical structure and biosynthetic 
pathway is shown in Figure 1. 
 
Figure 1. Dopamine synthesis 
 
Dopamine is synthesized from its metabolic precursor L-tyrosine, a nonessential 
aromatic amino acid that is synthesized from phenylalanine. In DA-producing cells, the rate-
limiting step in CA biosynthesis is the oxidation of L-tyrosine to (S)-2-amino-3-(3,4-
dihydroxyphenyl) propanoic acid (L-DOPA) by tyrosine hydroxylase (TH). This compound is 
subsequently metabolised by aromatic amino acid decarboxylase (AAAD) to produce cytosolic 
DA (Weihe et al., 2006). Tyrosine hydroxylase is a cytosolic enzyme that is present only in 
cells that are producing CAs. Tyrosine hydroxylase is a selective enzyme in the way that is not 
proceding derivatives of indol as substrates, part of other metabolic pathway leading to 
synthesis of 5-HT. This reaction is the key point of controlling the process of synthesis of NA, 
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since NA itself is inhibiting the TH enzyme, thus regulating the final rate of neurotransmitter 
production (rate limiting step reaction) which is indeed the faster way of synthesis regulation 
compared to synthesis of enzyme molecule de novo. The next step is decarboxylation of DOPA 
(dihydroxyphenylalanine) to DA by aromatic L-amino acid decarboxylase, also a cytosolic 
enzyme, that is present in a wide range of cells (not only CAs producing cells), that acts non-
specifically, and does catalitical decarboxylation of amino acids such as L-hystidine and L-
tryptofan, precursors of histamine and serotonin. 
Dopamine is converted to NA in the vesicles by DβH and in adrenal medulla; it is 
further converted to A. 
 
1.1.3. Dopamine store and reuptake  
 
Synthesized DA is normally stored into acidic vesicles. Cytosolic DA, that is either de 
novo synthesized or captured, is mobilised and stored toward intracellular vesicles, mediated 
by type 1 and type 2 vesicular monoamine transporters (VMATs, -1 and -2) (Masson et al., 
1999; Mignini et al., 2006).  
If not stored in the cytosol vesicles, DA can either be oxidised by monoamine oxidases 
(MAO) enzyme (Mignini et al., 2009) or in some cells, DA can adopt the third fate and be 
further processed by DβH to yield NA (Alaniz et al., 1999).  
Dopamine can be also auto-oxidised to quinone and hydrogen peroxide when it is 
released into the neutral pH cytoplasm. The release is usually avoided, but it could occur when 
the system of vesicles is damaged. 
 
1.1.3.1. Dopamine active transporter 
 
Neurotransmitters are packaged into vesicles in presynpatic neurons. The membrane 
and vesicular transport systems for monoamines (DA, NA and 5-HT) are involved in the 
regulation of synaptic communication (Masson et al., 1999). The action of CAs released in the 
synapse is terminated mainly by reuptake of the transmitter into presynaptic neurons or 
postsynaptic cells. 
Dopamine active transporter (DAT) consists of 620-amino acids, organised in 12 
transmembrane domains, with cytoplasmic amino- and carboxy-termini (Giros et al., 1991). It 
is 80 kD glycoprotein that belongs to the large neurotransmitter Na+/Cl- dependent proteins 
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family. This family includes other transporters specific for defined amine transmitters: 
noradrenaline transporter (NAT), serotonin transporter (SERT), GABA transporter (GAT) and 
glycine transporter (Torres et al., 2003). The uptake process of membrane DAT is active 
(requires energy) and the transporter itself is saturable since it obeys Michaelis-Menten 
kinetics. Mechanisms of transport for both DA and NA act as co-transporters of Na+, Cl− and 
the amine in question, using the electrochemical gradient for Na+ as a driving force. 
Under physiological conditions, DA reuptake from the extracellular space of the 
synaptic cleft is controlling half-life of DA and mostly depends on the presence and activity of 
DA transporter. The primary function of DAT is the reuptake of DA, terminating its actions, 
although DAT also weakly interacts with NA. Although present on presynaptic neurons at the 
neurosynapatic junction, DAT is also present in abundance along the neurons, away from the 
synaptic cleft, suggesting that DAT may play a role in the clearance of excess DA in the 
vicinity of neurons. Physiologically, DAT is involved in the various functions that are 
attributed to the dopaminergic system, including mood, behaviour, reward, and cognition. The 
evidence of DAT biological role is shown by the severe cognitive deficits, motor abnormalities, 
and hyperactivity of mice with no dopamine transporters (Gainetdinov et al., 1999) with 
characteristics have striking similarities to the symptoms of attention deficit hyperactivity 
disorder (ADHD). The half-life of DA in the extracellular spaces of the brain is prolonged 
considerably in DAT knockout mice, which are shown to be hyperactive and have sleep 
disorders. 
 
1.1.3.2. Vesicular monoamine transporter and extraneuronal monoamine 
transporter  
 
The packaging of DA, available for synaptic transmission, into vesicles, occurs through 
the vesicular monoamine transporter (VMAT-1 and VMAT-2) (Masson et al., 1999; Mignini et 
al., 2006). VMAT is H+ dependent, so the transport is driven by the proton gradient between 
the cytosol and the vesicle content. The neuronal membrane DAT, EMT, and VMAT-2, are the 
same in all CA neurons and differ in pharmacological properties, chromosomal localisations 
and numbers of amino acids (Table 1). Extraneuronal uptake is performed by the extra 
neuronal monoamine transporter (EMT, also known as the organic cation transporter (OCT)), 
which belongs to a large and widely distributed family of organic cation transporters. The 
organic cation transporters 1, 2, and 3 (OCT1-3, namely SLC22A1-3) mediate the facilitated 
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transport of diverse organic captions, drugs and toxins, having an important role in the 
clearance of xenobiotics. OCTs have also been implicated in the elimination of endogenous 
compounds, such as biogenic amine neurotransmitters: tyrosine-derived catecholamines 
(dopamine, epinephrine, and norepinephrine), serotonin (5-hydroxytryptamine), and histamine 
(Jonker and Schinkel, 2004). Among them, OCT3 was identified as the uptake-2 transporter in 
diverse tissues such as the kidney, heart, vascular system, and central nervous system (Zwart et 
al, 2001), whereas the other two non-neuronal catecholamine transporters (OCT1 and OCT2), 
are mainly localised to the liver, kidneys, and intestine (Eisenhofer et al., 1997). 
Generally, transporter systems are considered as potential pharmacologic targets for 
neuropsychiatric drugs (Gether et al., 2006). Their inhibition, by increasing extracellular and 
synaptic concentrations and lifespan of neurotransmitter may be advantageous from a 
therapeutic point of view and, in the case of DA, represents an important mechanism of action 
of substances abuse (Fritz et al., 1998; Giros and Caron, 1993). VMAT-2 is present in all 
monoaminergic neurons and is less sensitive than DAT to pharmacological alterations (Vander 
Borght et al.,1995; Narendran et al., 2012). Drugs that interact with DAT include cocaine and 
its analogues and amphetamines. DAT is also important system through which toxic 
substances, such as neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), can 
enter into dopaminergic neurons (Javitch et al., 1985; Miller et al., 1999). 
Mounting evidence indicates that DAT and VMAT-2 transporters are probably the most 
specific markers of dopaminergic neurons. The DAT is located primarily in the brain in 
dopaminergic neurons, and thus is the unique marker (Kuhar, 1998). The highest concentration 
of DATs are found in the basal ganglia, corresponding to the amount of DA nerve terminals in 
this brain region. Expression of DAT and VMAT-2 markers in brain can predict vulnerability 
of neurons and it has been shown early alterations in Parkinson’s disease (Miller et al., 1999). 
On the contrary, no association between the tissue density of DAT and the stage of 
parkinsonism degeneration and in schizophrenia was found (Fujiwara et al., 1997). 
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Table 1. Characteristics of DA system transporters 
Transporter Location Other substrates besides 
DA 
Inhibitors 
Neuronal 
(DAT) 
Neuronal 
membrane  
Amphetamine 
(Fleckenstein et al., 2007) 
Phenmetrazine (Solis et 
al., 2016) 
Cocaine (Ferris et al., 2012) 
Atypical benztropine-like DAT 
inhibitors (e.g. benztropine, 
modafinil, and vanoxerine) 
(Schmitt et al., 2013) 
 
Extraneuronal 
(EMT) 
Non-
neuronal 
cell 
membrane 
Noradrenaline 
Serotonin  
Histamine 
MPP+ (Ryan et al., 2014) 
Amphetamine (Schmitt et 
al., 2013) 
Cocaine (Ferris et al., 2012) 
MDMA* (Biezonski et al., 2013) 
PCP* (Cagniard et al., 2014) 
Corticosterone and cortisol 
(Hayer-Zillgen et al., 2002) 
Vesicular 
(VMAT) 
Synaptic 
vesicle 
membrane 
 
Serotonin (Amphoux et al., 
2006) 
Histamine (Amphoux et 
al., 2006) 
Noradrenaline (Amphoux 
et al., 2006) 
Adrenaline 
MPP+ (Ryan et al., 2014) 
Amphetamine (Schmitt et 
al., 2013) 
Reserpine (Chaudhry et al., 2008; 
Bernstein et al., 2014) 
Tetrabenazine (Chaudhry et al., 
2008; Bernstein et al., 2014) 
 
Notes: *MDMA - 3,4-Methylenedioxymethamphetamine; PCP - phencyclidine, MPP+ (1-
methyl-4-phenylpyridinium) is a positively charged molecule of MPTP neurotoxin 
 
DAT ligands have traditionally been divided into two categories: cocaine-like inhibitors 
and amphetamine-like substrates (Table 1). Whereas cocaine-like inhibitors block monoamine 
uptake by the DAT but are not translocated across the membrane, amphetamine-like substrates 
are actively translocated and trigger the DAT-mediated release of DA by reversal of the 
translocation cycle (Schmitt et al., 2013). Finally, both inhibitors and substrates increase 
extraneuronal DA levels. 
20 
 
Interestingly, it has been shown that presynaptic human DA transporter interact with 
alpha-synuclein (α-syn), a protein highly enriched in presynaptic terminals, which mutations 
have been implicated in the expression of familial forms of Parkinson's disease, thereby 
accelerating cellular DA uptake and DA-induced cellular apoptosis (Lee et al., 2001). 
 
1.4. Degradation of dopamine 
 
Circulating DA is degraded by the two main catecholamine-metabolising enzymes that 
are located intracellularly, so uptake into cells necessarily precedes metabolic degradation. 
Dopamine and other CAs are metabolised through two distinct, although partially 
interacting pathways, including MAO and the catechol-O-methyl-transferase (COMT) enzymes 
(Nagatsua and Sawadab, 2009). Monoamineoxidase enzyme, which exists in two distinct 
isoforms, MAO-A and MAO-B, occurs within cells, bound to the surface membrane of 
mitochondria. It is abundant in sympathetic nerve terminals but is also expressed in many other 
tissues, such as liver and intestinal epithelium (Ramonet et al., 2003; Billett, 2004). 
Monoamineoxidase enzyme converts catecholamines to their corresponding aldehydes, 
potentially neurotoxic, and it is thought to play a role in certain neurodegenerative disorders. 
Monoamineoxidase enzyme can also oxidise other monoamines, including NA and 5-HT. It is 
inhibited by various drugs, such as amphetamine. Within sympathetic neurons, MAO controls 
the content of DA and NA, and the releasable store of NA increases if the enzyme is inhibited. 
About 25% of a dose of DA is metabolised to NA within the adrenergic nerve terminals. 
The second major pathway for CA metabolism involves methylation of one of the 
catechol hydroxyl groups by COMT to give a methoxy derivative. COMT is absent from 
noradrenergic neurons, but it is present in the adrenal medulla and many other cells and tissues. 
CAs are widely distributed throughout the body, and are predominantly metabolised in the 
liver, kidneys, and plasma by MAO and COMT enzymes into inactive compounds, 
homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) (Figure 2). 
Dopamine is excreted primarily in the urine, principally as HVA and its sulfate and 
glucuronide conjugates as DOPAC. 
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Figure 2. Metabolic pathways of DA degradation  
(redrawn from the Wikipedia: https://it.wikipedia.org/wiki/Dopammina) 
 
1.2. Dopamine receptors 
 
Dopamine exerts its effects binding DR expressed on the cell surface, which further 
activates second messenger systems inside the cell causing changes in excitability, metabolism 
and gene expression. Until the publication of the dopamine D2 receptor sequence in 1988 
(Bunzow et al, 1988), it was believed that only D1 and D2 dopamine receptors exist. 
Subsequent gene cloning studies revealed 5 different genes coding 5 dopamine receptor 
subtypes identified as D1, D2, D3, D4, and D5 DR (Missale et al, 1998). 
These receptors belong to the family of hepta-spanning transmembrane guanine 
nucleotide-binding proteins (G protein) coupled receptors (GPCRs). So-called large, 
heterotrimeric G proteins consist of three subunits, namely: α, β and γ. When the endogenous 
ligand binds to the receptor, guanosine 5’-triphosphate (GTP) is bound to the α subunit in 
exchange for guanosine 5’- diphosphate (GDP), and the α subunit is then released from the β 
subunit. The α subunit that has been activated in this way is then inactivated by 
dephosphorylation of GTP to GDP (intrinsic GTPase) and can thus be re-associated with the β-
γ subunits. Numerous peptide hormones use cyclic adenosine monophosphate (cAMP) as the 
second messenger in such a way that, mediated by a stimulating G protein (Gs), adenylyl 
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cyclise (AC) is activated and thus more cAMP is formed. cAMP activates protein kinase A 
(PKA), which phosphorylates, among others, enzymes and transport molecules. cAMP can also 
be involved in gene expression via PKA and phosphorylation of a cAMP-responsive element-
binding protein (CREB). cAMP is converted to noncyclic AMP by intracellular 
phosphodiesterases and the signal thus turns off. 
Based on the genomic structure (sequence homology), signal transduction machinery 
and pharmacological properties DR have been classified into two subgroups: D1-like and D2-
like families (reviewed Civelli et al., 1993; Missale et al., 1998; Sibley and Monsma, 1992). D1 
DR and D5 DR are two forms of the D1-like group receptors, coupled with the Gαs class of G 
proteins, leading to an increase in intracellular cAMP formation. On the other hand, DR D2, 
(DR D2L and DR D2S, see below for more details) D3 and D4 form the D2-like group couple 
with the Gαi class of G proteins, leading to a decrease in intracellular cAMP formation (Sibley 
et al., 1993; Seeman and Van Tol, 1994). 
The genomic organization of the DR supports the concept that they derive from the 
divergence of two gene families that mainly differ in the absence or the presence of introns in 
their coding sequences. D1-like receptors genes do not contain introns in their amino acid 
coding regions, in both D1 and D5 subtypes in mammals (Civelli et al., 1993; O’Dowd, 1993). 
In contrast, the protein coding regions of the D2-like receptors are interrupted by introns and 
different receptor variants (isoforms) have been identified as a result of alternative splicing 
(Civelli et al., 1993; Sibley and Monsma, 1992; Missale et al., 1998). The DR D2 coding region 
contains six introns. So far two alternatively spliced transcripts of the DR D2 gene code are 
identified, for two different DR D2 isoforms known as the “long” and “short” forms, D2(443) and 
D2(414) respectively. When compared, long DR D2 has 29 more amino acids, which are located 
in the putative third intracellular loop of the receptor, a region involved in the coupling of the 
receptor to G-proteins. These two receptor isoforms exhibit largely similar pharmacological 
characteristics but differ in G-protein coupling affinities (Liu et al., 1996). 
The short isoform of the DR D2 is placed pre-synaptically, and has modulatory 
function, while, long DR D2 isoform, is a classic post-synaptic receptor and transmit 
information in an excitatory or an inhibitory fashion. Splice variants of the DR D3 receptor and 
polymorphic variants of the DR D4 receptor have also been identified (Missale et al., 1998). 
The DR D4 gene displays polymorphisms, that has been identified in the length of the third 
intracellular loop, implicated in the interaction with the G-protein (Petronis et al., 1998). 
Sunahara et al. reported the cloning of a gene encoding a protein with strong homology to the 
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cloned DR D1, identify as DR D5, that binds drugs with a pharmacological profile similar to 
that of the DR D1, but displays a 10-fold higher affinity for the endogenous agonist, DA 
(Sunahara et al., 1991). Pharmacologically, DR D1 and DR D5 are indistinguishable by their 
ability to bind the numerous antagonists and can only be discerned by their differing affinity 
for DA and other D1-like agonists. For as yet unknown reasons, the affinity of DR D5 for 
agonists is up to 10 times higher to that of DR D1 (Weinshank et al., 1991). The function of the 
DR D5 remains elusive largely due to the fact that no D5-selective drugs are available. 
 
Figure 3. Dopamine receptors signalling 
(reproduced with permission from Savica and Benarroch, 2014) 
 
Model of DR activation and signalling throughout the sequential activation of G 
proteins and specific enzyme or channel effectors might be too simplistic to explain the 
functional flexibility of DR (Savica and Benarroch, 2014) (Figure 3). Dopamine signalling 
should rather be reconsidered in the way that it is not limited only to activation or inhibition of 
adenylyl cyclase, but that DR regulate multiple signalling pathways by interacting with various 
G proteins and G protein-independent mechanisms (reviewed in Beaulieu and Gainetidinov, 
2011). Recent studies have shown that DR has complex function involving dimers (homo- 
and/or heterodimers) or even higher order of oligomers (Vischer et al., 2011). Some 
antiparkinsonian agents – such as the preferential high-efficacy DR D3 versus DR D2 receptor 
agonists, pramipexole and ropinirole – show amplified potency at D3/D2 heterodimers versus 
constituent monomers, and others in contrast, such as the D3/D2 receptor agonist pergolide, 
show no difference (Maggio et al., 2009). Protein-protein interaction among GPCRs and 
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downstream DA signalling is regulated by specific and finely orchestrated actions of GPCR 
kinases isoforms, playing a critical role in the modulation of receptor pharmacology and 
functions upon activation by an agonist (Gurevich et al., 2016). Those forms have different 
pharmacological, signalling and trafficking properties from their single constituent receptors 
(Fuxe et al., 2008). 
Since heterodimers represent novel receptor entities working as unique functional units, 
heterodimerization increases heterogeneity within DR subtypes, regarding different 
combinatorial possibilities. The discovery of DR heterodimers with atypical properties opens a 
new horizon to the development of promising targets for bifunctional compounds selectively. 
Possible targets could involve action on the: entire complex, allosteric ligands, that could 
interact with one co-receptor, modify the function of other co-receptor, or small molecules that 
can disrupt heterodimeric complexes. For example, the recent discovery of DR D2 signalling 
heterogeneity has led to a reconsideration of the mechanism(s) of action of some antipsychotic 
drugs used in the treatment of schizophrenia (Urs et al., 2012). One of first attempts to develop 
“biased drugs” involved new compounds binding to the DR D2, acting as partial agonists for 
arrestin 3 (β-arrestin2) (Allen et al., 2011). 
Evidence accumulating through the study of DR signalling in the last ten years has 
pointed to a further degree of complexity within these receptor families. This differential 
coupling of DR allows that DA might promote distinct cellular effects in two different kinds of 
cells expressing the same DR. Furthermore, differential expression of DR on different cells 
also contributes to DA exerts distinct effects in those cells. According to this idea and to the 
fact that there are a differential expression and differential coupling of DR in distinct neurons, 
DA may play different roles in the distinct zones of the nervous system (Sidhu, 1998). Taken 
together, complexity and differential coupling of DR might represent a new approach needed to 
be taken into account in the development of innovative drugs for the treatment of a variety of 
DA-related disorders.  
 
1.2.1. Dopaminergic pathways in the central nervous system 
 
Although role of DA as a neurotransmitter in the brain was characterised in 50-ies of 
the last century, a detailed analysis of its neural distribution became possible after developing 
the fluorescence technique based on the formation of fluorescent derivatives of CAs in the 
tissues that were previously treated with formaldehyde (Falck et al., 1962). Detailed maps of 
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dopaminergic pathways were identified in the laboratory animals, and similar basic 
characteristics have been confirmed, later on in the human brain. The central dopaminergic 
neuron system is comprised of three major pathways, identified in the mammalian brain 
(Anden et al., 1964; Dahlstroem and Fuxe, 1964) (Figure 4). 
 
(1) Dorsal (or upper) pathway, also called the nigrostriatal pathway, originates in 
substantia nigra pars compacta (SNpc) (A9 region), projects to the basal ganglia and striatum, 
and is involved in extrapyramidal motor function. Dopaminergic neurons of SNpc projects 
primarily to the striatum, as a major origin of the dopaminergic innervation. The major 
function of the striatum is the regulation of posture and muscle tonus. Under physiological 
conditions, the extrapyramidal system processes information coming from the cortex to the 
striatum and returns it back to the cortex through the thalamus. Nigral cell loss results in the 
depletion of striatal DA, and decreased nigrostriatal input leads to an increase of inhibitory 
output from the globus pallidus interna to the thalamus and, indirectly, to the cortex, thereby 
repressing the initiation of movements and leading to motor manifestations characteristic for 
Parkinson’s disease (Shulman et al., 2011) (Figure 5). 
 
(2) Ventral (lower) pathway, also called the mesolimbic/mesocortical pathway, 
projects from the ventral tegmental area (VTA) (A10 region) to the prefrontal cortex (PFC) 
considered to be crucial for cognitive function and motivation (Willner and Scheel-Kruger, 
1991). The PFC is a crucial target area for the action of antipsychotic drugs such as 
neuroleptics, which impair DA neurotransmission. Mesolimbocortical DA plays role in: i) 
reward and reinforcement mechanisms (shown by the observation that psychostimulants and 
drugs of abuse elicits DA release in the mesolimbic areas); ii) learning and iii) memory. 
 
(3) Tubular- infundibular pathway originates in the hypothalamus (A12 region), 
projects to the hypophysis, and is involved in neuroendocrine regulation. 
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Figure 4. Three major dopaminergic pathways in the brain. 
(reproduced with permission from Cho et al., 2010). 
 
Dopamine is important for the normal function of the nervous system, that is shown by 
several brain impairments and diseases that are shown to be significantly correlated with/to 
abnormalities in DA levels and/or in the expression, function of DR and dopaminergic 
signalling. 
 
1.2.2. Dopamine receptors in the central nervous system 
 
In the CNS, DA receptors are widely expressed and are involved in a range of 
physiological functions. DR subtypes show different topographic segregation within the CNS 
(Strange 1993). DR D1 are abundant in the basal ganglia, nucleus accumbens, and cerebral 
cortex, DR D2 have highest concentrations in the basal ganglia and anterior pituitary, DR D3 in 
the ventral striatum (nucleus accumbens, islands of Calleja, olfactory tubercle), DR D4 show 
the highest density in the frontal cortex, hippocampus and amygdala, and DR D5 are mainly 
located in the hippocampus and thalamus. The precise distribution of diverse DR subtypes in 
the brain is summarised in Table 2. 
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Table 2. Dopamine receptor distribution in the human brain 
Family Receptor Type of receptors 
Transduction 
mechanisms 
(effectors) 
Tissue distribution Physiological functions 
D1 like 
DR D1 Gs-
coupled 
Increase of 
cAMP 
Activating AC 
Basal ganglia, 
striatum, nucleus 
accumbens and 
cerebral cortex, 
retina 
Control of 
locomotor 
activity; 
reward and 
reinforcement 
mechanisms; 
learning and 
memory 
DR D5 Hyppocampus and hypothalamus 
Cognitive 
functions 
 
D2 like 
DR D2 
 
Gi/G0 
coupled 
 
Decrease of 
cAMP  
Inhibiting AC 
Striatum,  
substantia nigra 
(SNpc),  
basal ganglia, 
the anterior pituitary 
gland 
Control of 
locomotor 
activity; 
reward and 
reinforcement 
mechanisms; 
learning and 
memory 
DR D3 
Ventral striatum 
(nucleus accumbens, 
islands of Calleja, 
olfactory tubercle), 
hypothalamus 
Control of 
locomotor 
activity; 
cognitive 
functions 
DR D4 
Frontal cortex, 
hippocampus and 
amygdale, midbrain, 
medula 
Cognitive 
functions 
(based on Beaulieu and Gainetidinov 2011; Cosentino and Marino, 2013) 
 
The DR D1 is the most widespread DR in the brain and is expressed at higher levels 
than any other DR (Dearry et al., 1990). Its mRNA and protein have been found in the striatum, 
the nucleus accumbens, and the olfactory tubercle, but also have been detected in the limbic 
system, hypothalamus, and thalamus. Lesion studies in animal models shown that localisation 
of DR D1 can be primarily presynaptic (in the substantia nigra, on afferent projections), but 
also postsynaptic (in the caudate-putamen) (Joyce and Marshall, 1987). 
The distribution of the DR D2 is similar to that of the DR D1, being localised primarily 
in the mesencephalon, where dopaminergic cells contribute to the innervation of the cerebral 
cortex, striatum, and limbic regions (Weiner et al., 1991). DR D2 are abundant in regions of the 
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hypothalamus that innervate the pituitary, and are located throughout the midbrain, found 
localised on DA neurons themselves (Autelitano et al., 1989; Sesack et al., 1994).  
The DR D2 has nanomolar affinity for DA and is located both pre-synaptically (short 
isoform of the DR D2, mostly involved in autoreceptor functions and has modulatory function) 
and postsynaptically (long DR D2 isoform, that transmit information in an excitatory or an 
inhibitory fashion) (Usiello et al., 2000; De Mei et al., 2009). These splice variants of the DR 
D2 (D2L and D2S) have different neuronal distributions, and therefore, the varying roles (Usiello 
et al., 2000; De Mei et al., 2009). Pharmacological and genetic evidence suggests that DR D3 
exert some relatively minor modulatory influences on D2S autoreceptor’s role, thereby 
complementing the presynaptic regulation phasic release of DA, regulating the neuronal firing 
rate and synthesis of DA (De Mei et al., 2009). Koulchitsky and co-workers suggested that the 
alteration of the main frequency of the rat ventral tegmental area (VTA) rhythm induced by the 
action of quinpirole on D2 autoreceptors disturbs the ability of this region to interact with its 
input or output regions, hence the altered locomotor behaviour (Koulchitsky et al., 2016).  
Enrichment of DR D3 is observed in the nucleus accumbens and islands of Calleja 
(Meador-Woodruff et al., 1994), at moderate levels in the basal ganglia, and at slightly lower 
densities in the substantia nigra, hippocampus, and the amygdaloid (Lahti et al., 1995). The DR 
D4 seems to occur at 10- to 100-fold lower densities than the DR D1 and DR D2 in the striatum 
(Schlachter et al., 1997; Patel et al., 1996). 
In general, these receptors can be differently distributed among neurons and according 
to this they are divided into two groups, referred to as a postsynaptic receptor (locate on 
dendrites or cell body, axons or nerve terminals) and presynaptic autoreceptors locate on the 
same neuron. Autoreceptors are sensitive to the transmitter that is secreted from the neuron on 
which these receptors are located. Terminal autoreceptors are involved in the control of 
transmitter release, and somatodendritic autoreceptors are involved in the control of transmitter 
synthesis. Activation of autoreceptors by released DA is thought to be one of the principal 
mechanisms responsible for regulation of dopaminergic neuronal function. Autoreceptors are 
present on most parts of a DA neuron and are responsive to both terminal and dendritic DA 
release. Stimulation of DA autoreceptors in the somatodendritic region slows the firing rate of 
DA neurons (impulse-regulating autoreceptors) and according to findings, inhibits subsequent 
dendritic DA release (Cragg and Greenfield, 1997), while stimulation of autoreceptors located 
on DA nerve terminals results in an inhibition of DA synthesis and/or release (release and 
synthesis- regulating autoreceptors). Dopamine autoreceptors are more sensitive to the effects 
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of DA than postsynaptic DA receptors. In general, all DA autoreceptors can be classified as 
D2-like receptors. Taking all above mentioned, it might be rational to reconsider autoreceptor-
selective agonist as a useful pharmacological tool. 
 
1.2.3. Behavioural role of dopamine receptors 
 
To date, knowledge of the functional role of specific DR on various functions or 
behaviours varies because of the availability of specific pharmacological tools, DR agonist, and 
antagonist. Generally, agonists increase DA function, thus increasing motor activity, while 
antagonists have the opposite effect. The systemic administration of the DR D1 partial agonist 
(SKF 38393) in rats increases grooming and sniffing but does not significantly increase 
locomotion or other stereotypical behaviour (Jackson and Westlind-Danielsson, 1994). In the 
brain, the biological significance of some specific classes of DA receptors has been well-
documented with the help of transgenic mice deficient in the expression of a specific class of 
DR. Disruption of the DR D1 gene showed locomotor hyperactivity in mice (Xu et al., 1994), 
and inactivation of DR D2 gene produced almost the opposite phenotype. These DR D2 
deficient mice were akinetic and bradykinetic with significantly reduced spontaneous 
movement (Baik et al., 1995). 
A recent study of Moraga-Amaro et al., 2016 indicated that DR D5 deficiency resulted 
in impaired spatial memory without provoking depression-like symptoms. This study 
represents the first genetic evidence pointing the involvement of DR D5 in memory, linking the 
same receptor with hippocampal synaptic plasticity. The same authors also demonstrate a 
selective reduction in the expression of the NMDAR subunit NR2B observed in the 
hippocampus of D5RKO mice, suggesting collaboration between DR D5 and glutamatergic 
pathways, providing a useful tool for future therapies for disorders involving alterations in 
memory and the dopaminergic system (Moraga-Amaro et al., 2016). 
Early studies with a putative selective DR D1 agonist, SKF 38393, including seven 
patients with idiopathic PD, administered orally, alone or in combination with levodopa (L-
DOPA) was not effective in reversing symptoms of PD (Braun et al., 1987). Later on, it has 
been shown, that SKF 38393 is only a partial DR D1 agonist, that has limited penetration 
through the blood-brain barrier and a short duration of action which, at least partially, might 
explain why it did not induce any beneficial effects in patients with PD. First full developed 
DR D1 agonist A-77636 was shown to be a highly potent, long-lasting, and together with 
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dihydrexidine (selective, full DR D1 agonists) have been shown to reverse MPTP-induced 
motor deficits in primates (Schneider et al., 1994). 
Increased dopaminergic transmission in the CNS leads to a behaviourally aroused state, 
referred to as psychomotor activity. This stands for DA, non-selective DA agonists, and also 
for the central stimulants (cocaine and amphetamine). In experimental animals, enhanced 
dopaminergic transmission is observed as an increase in locomotion (Beninger, 1983). 
Treatments that decrease DA signalling cause a specific sedation that is often comparative with 
motor disturbances such as parkinsonism or catalepsy (Johnels, 1982). Regarding the role in 
behaviour and motor stimulation and increased locomotion the best characterised, so far, are 
DR D2 receptors (Missale et al., 1998), while DR D1 function is less understood. Decline in 
DR D1 receptors in the prefrontal cortex as a function of age (Suhara et al., 1991) is 
significant as drugs targeted at this receptor subtype have proven to be beneficial for the 
amelioration of age-related memory deficits. In aged monkeys, acute administration of either 
low doses of a partial DR D1 agonist (SKF 38393) or selective, full DR D1 agonists 
(dihydrexydine, A77636, SKF 81297) has improved spatial working memory performance 
(Arnsten et al., 1994). These cognitive-enhancing effects of DR D1 agonists are believed to 
be due to enhanced signalling via DR D1 receptors in PFC and notably, in all cases, were 
blocked by pretreatment with the DR D1 antagonist SCH 23390. This principle has been used 
to develop a novel treatment regimen targeted to enhance cognitive function in DA-deficient 
states (Castner et al., 2000). Specifically, repeated intermittent low-dose treatment with the 
selective full DR D1 agonist (ABT-431) produced a pronounced and enduring enhancement 
of spatial working memory performance in both endogenous (aging) and pharmacologically 
(chronic haloperidol treatment) induced DA-deficient states (Castner and Goldman-Rakic, 
2004).  
Overall, the findings from the non-human primate models of prefrontal DA deficiency 
and cognitive dysfunction indicate that the DR D1 is a key target for developing novel 
compounds for the alleviation of cognitive deficits in DA dysfunctional states such as 
schizophrenia. The data so far, are suggesting that in monkey repeated, yet intermittent, DR 
D1 agonist treatment produces a robust and sustained enhancement of cognition should prove 
to be a useful therapeutic strategy for the treatment of cognitive dysfunction in conditions 
where DR D1 receptor signalling in PFC is suboptimal, as is likely the case in both PD and 
schizophrenia (Goldman-Rakic et al., 2004). 
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Interest in the DR D3 is related to its selective localisation in limbic areas of the brain. 
Accumulating evidence suggests high comorbidity of depression with PD. Recent data, 
obtained in rodents, has demonstrated that brain dopamine and its mesolimbic projections have 
a role in the induction of depressive-like symptoms (Tye et al., 2013). Pharmacological studies 
performed in both rodents and humans, support antidepressant effects of high-affinity DR D3 
agonist pramipexole, classically used for the treatment of PD symptoms (Breuer et al., 2009; 
Chernoloz et al., 2012). One of the recent studies provided evidence that D3RKO knockout 
mice (lacking DR D3) developed symptoms similar to depression and anxiety, pointing that 
DR D3 itself mediates the antidepressant effect, which deficiency results in chronic depression 
(Moraga-Amaro et al., 2014).  
 
1.3. Endocrine roles of dopamine 
 
1.3.1. Regulation of prolactin release 
Prolactin is formed in the anterior lobe of the pituitary gland and is important hormone 
for the: i) stimulation of growth and differentiation of the mammary gland, ii) inhibition of 
pulsatile, but not the basal, release of the gonadotropins such as luteinising hormone (LH) and 
follicle-stimulating hormone (FSH), iii) induction of the milk production during lactation 
period, iv) inhibition of cellular glucose uptake and interestingly v) inhibition of the cellular 
immune defences. Dopamine inhibits prolactin release. As prolactin increases DA metabolism 
in the hypothalamus, it inhibits its own release (negative feedback regulation mechanism). 
Excess prolactin can be caused by administration of antidopaminergic drugs or hormone-
producing tumours (Torre and Falorni, 2007). 
 
1.3.2. Regulation of female sex hormones release 
A lack of estrogens and progestogens is frequently the result of a decreased GnRH 
(gonadotropin-releasing hormone) release in severe psychological or physical stress. The 
GnRH release can also be reduced through the influence of the neurotransmitters NA, DA, 5-
HT, and endorphins. It is relatively common for a reduction in gonadotropin release to be due 
to raised prolactin secretion, for example, as a result of the absence of inhibition of pituitary 
secretion of prolactin or a prolactin-producing pituitary tumour. Gonadotropin release can be 
inhibited by dopaminergic drugs that cause a rise in prolactin secretion (Ben-Jonathan and 
Hnasko, 2001). 
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1.3.3. Growth hormone release 
Growth hormone (GH) is a stress hormone that inhibits the uptake of glucose in fat and 
muscle cells and like these raises the concentration of glucose and free fatty acids. It also 
stimulates the enteric absorption of calcium and phosphates as well as the renal excretion of 
calcium. This peptide hormone stimulates growth, cell reproduction, and cell regeneration 
promotes T-cell proliferation, interleukin 2 (IL-2) production and the activity of natural killer 
cells, cytotoxic T cells, and macrophages (Jeay et al., 2002). In this way, it strengthens the 
immune defence. Dopamine can stimulate the release of GH (Jaffe and Barkan, 1992). 
 
1.3.4. Dopamine and thyroid gland 
Formation and release of T3 and T4 as well as the growth of the thyroid gland are 
stimulated by thyrotropin (TSH) from the anterior pituitary. Its release is, in turn, stimulated by 
thyroliberin from the hypothalamus. Stress and estrogens increase TSH release, while 
glucocorticoids, somatostatin, and DA inhibit it (Haugen, 2009). 
 
1.3.5. Regulation of kidney function 
Dopamine stimulates the release of the antidiuretic hormone (ADH), which is formed in 
the hypothalamus and is transported to the posterior lobe of the pituitary gland via the axons. 
ADH promotes water reabsorption in the distal tubules and in the collecting duct of the kidney. 
ADH stimulates the tubular absorption of Na+ and urea and high concentration of ADH leads to 
vasoconstriction. An important stimulus for the release of the mineralocorticoid aldosterone is 
angiotensin II, which is formed in increased amounts via the renin–angiotensin system when 
the renal perfusion pressure is reduced. Aldosterone release is decreased by DA and the atrial 
natriuretic factor (Wu et al., 2001). 
 
1.3.6. Dopamine and hematopoiesis 
The direct evidence of the involvement of DA in hematopoietic regulation has been 
proposed. Exogenous administrated DA stimulates erythropoiesis and platelet production in 
both normal and tumour-bearing mice (Lahiri et al., 1990). Significant uptake of DA by bone 
marrow (BM) cells have been shown in vivo and in vitro in murine, and this uptake was found 
to be specific since DA receptor antagonists inhibited this uptake (Basu et al., 1993). Until 
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today, huge advancement has been made in characterising the different cell types that are 
important for maintenance of hematopoetic stem cells (HSC). Anatomical studies have shown 
that sympathoadrenergic innervation has role in BM hematopoiesis that occurs through the 
adrenoceptors (AR) and DR expressed on hematopoietic cells affecting their migration, 
proliferation and survival ability (Lymperi et al., 2010; Wang and Wagers, 2011; Mendelson 
and Frenette, 2014). 
The first record of adrenergic modulation of hematopoiesis in vivo has been shown after 
syngeneic BM transplantation in mice, when chemical sympathectomy mimicked by the α1-
adrenoceptor antagonist prazosin, increases the number of peripheral blood leukocytes 
(Maestroni et al., 1992). The regulation of hematopoietic system is achieved trough three steps: 
i) at the cellular level of bone marrow stroma, ii) at the humoral level by cytokines, and iii) by 
CAs and other neuroendocrine factors. 
It seems that AR agonists, like the sympathetic neurotransmitter NA, inhibit 
myelopoiesis and this effect might be of clinical relevance. An early summary of the facts was 
performed in normal mice (Maestroni and Conti, 1994) showing that prazosin can enhance 
myelopoiesis and platelet formation, while α1-adrenergic agonist, directly inhibits in vitro 
growth of granulocyte/macrophage-colony-forming unit (GM-CFU). In following studies 
Maestroni (1995) emphasised the ability of α-AR antagonists to augment myelopoiesis and 
platelets production while declining lymphopoiesis, in both normal mice as well as after BM 
transplantation. 
The effects of NA and DA in the BM launch the issue regarding their physiological 
relevance, especially when it comes to the origin of these catecholamines at the BM level. It 
was suggested that sympathetic nerve endings and hematopoietic cells are the main source of 
bone marrow NA, as well as DA and A, but also immune cells themselves are a valuable 
source of CAs (Maestroni et al., 1998). By use of a high performance liquid chromatographic 
method (HPLC), Marino et al. (1997) measured endogenous catecholamines in BM from 
normal, 6-OHDA- treated and pargyline-treated mice. Noradrenaline levels were lower after 
sympathetic denervation with 6-OHDA and higher after irreversible MAO inhibition with 
pargyline, while A and DA were not affected under either condition (Marino et al., 1997). 
Thus, it seems that NA in the bone marrow originates mainly from sympathetic nerve endings. 
Among the CAs, a substantial amount of DA was detected in bone marrow, that is only a minor 
part, if any of neurogenic origin, and at the low level present in BM could be considered as a 
biosynthetic precursor of NA (Marino et al., 1997). 
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Interestingly, in murine hosts, NA and DA showed a rhythmicity of levels in BM with 
peak values observed during the night (Maestroni et al., 1998). Scheiermann et al., 2013 
suggested that daily rhythmicity is an important regulator of specific immune system functions 
of BM catecholamines. Marino et al., 1999 have shown endogenous production of CAs by 
immune cells.  
To show DA regulation of bone marrow hematopoiesis, Spiegel et al. (2007) showed, 
by the means of flow cytometry, that human CD34+ cells expressed both DR D3 and DR D5 on 
their surfaces. Amusingly, dopaminergic agonists augmented the polarisation, motility, 
clonogenic progenitor content and engraftment potential of these cells (Spiegel et al., 2007). 
It has been recently established that activation of sympathoadrenergic system is a link 
between chronic stress and inflammatory response (Heidt et al., 2014), so the 
neutrophil/lymphocyte ratio can represent a negative prognostic marker in a numerous critical 
conditions, such as cardiovascular disease (Guasti et al., 2011; Bhat et al., 2013) and even 
cancer (Templeton et al., 2014), offering opportunity for therapeutic intervention. Results 
obtained so far in preclinical models would already support to the various extent the clinical 
evaluation of dopaminergic agonists (Spiegel et al., 2007) for HSC transplantation, as well as 
dopaminergic agonists (Sarkar et al., 2014) to protect against the adverse effects of cytotoxic 
agents on BM. 
 
1.4. Peripheral tissues producing dopamine 
 
Besides of its action in the CNS, DA exerts its function in the periphery, primarily as a 
precursor of NA and A. Dopamine is main and independent transmitter of most autonomic 
sympathetic postganglionic fibers, having an important effect on various physiological 
functions in organs and tissues including: the vascular beds, the heart, the gastrointestinal tract, 
and renal physiology acting as an endocrine hormone, but also in regulation of olfaction and 
retinal processes. Moreover, a number of studies showed DA components in the immune 
system, suggested that DA plays a key role on neural-immune interactions acting as an 
important modulator of peripheral physiologic functions (Basu and Dasgupta, 2000; Besser et 
al., 2005; Ilani et al., 2004; Sarkar et al., 2006; Watanabe et al., 2006). 
Dopamine may arrive into the bloodstream from several different sources. An important 
peripheral source of DA and other neurotransmitters is a peripheral nervous system (PNS) and 
its sympatho-adrenergic termini that can release both DA and/or NA. Noradrenaline is the main 
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neurotransmitter released by the sympathetic nerve system (SNS) and thereby the main 
neurotransmitter responsible for SNS-mediated regulation of immunity. Several lines of 
evidence suggest that DA may be stored in, and release from sympathetic nerve terminals, 
acting as a transmitter at this level, outside the CNS (Bell, 1998; Bencsics et al., 1997). The 
major primary and secondary lymphoid organs (thymus, spleen, lymph nodes and intestinal 
Peyer’s patches) are extensively supplied by dopaminergic terminals, where SNS seems to play 
an important role in the regulation of T cell-mediated responses (Mignini et al, 2009). The 
presence of adrenergic and DR on immune cells provide channels for noradrenergic signalling 
to lymphocytes and macrophages by sympathetic nerves (Madden et al., 1995). Epithelial cells 
in the gut are an important source of a gastrointestinal DA described as an endogenous 
gastroprotective element, acting through DR D1 receptors (Rasheed and Alghasham, 2012). 
 
1.4.1. Role of peripheral dopamine in metabolic control 
 
Dopamine was found to modulate regulation of glucose homeostasis and body weight 
by influencing the endocrine pancreatic hormone levels, in more specific, it inhibits insulin 
secretion in both animals and humans (Quickel et al., 1971; Leblanc et al., 1977). It has been 
recently confirmed that DA and selective DR D2 agonist inhibit insulin exocytosis (Rubí et al., 
2005). Regulating the pancreatic endocrine function, DA also modulates the effects of insulin 
action on adipocytes. Dopamine action in the central DA pathways is a putative additional 
component in mediating metabolic homeostasis in the human body. In the brain, at the basal 
ganglia level, DA participates in the signalling of the rewarding effects of food intake, in a 
similar way described as a mechanism of drug abuse (Volkow et al., 2008). Behavioural 
addiction-like syndrome and compulsive food seeking were shown in a DR D2 striatal 
knockdown rats (Johnson and Kenny, 2010). Briefly, treatment with bromocriptine (D2-like 
receptor agonist) reduces hyperphagia and adiposity in animals with diet-induced obesity 
(Davis et al., 2009). Moreover, antipsychotic antagonists of DR D2-like receptors, such as 
clozapine, have been shown to increase insulin secretion in isolated rat pancreatic islets 
(Melkersson and Jansson, 2007). Consequently, schizophrenic patients are at risk of obesity, 
insulin resistance, impaired glucose tolerance and hypertension (Newcomer, 2007). 
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1.4.2. Dopamine – activates multiple receptors in the periphery 
 
Catecholamines plasma levels are defined by release from autonomic nerve endings and 
through suprarenal glands presenting the main source of CAs. The physiological concentration 
of DA, as an endogenous catecholamine ranges between 10–10 M and 10–11 M. Among this 
physiological range, it is expected that DA acts preferentially on DR, affecting several 
important functions and features of human effector cells. In addition, it is important to consider 
that among DR each receptor displays different affinities for endogenous DA: DR DR3 > DR 
D5 > DR D4 > DR D2 > DR D1 [Ki (nM) = 27, 228, 450, 1705, 2340, respectively] and so 
stimulatory effects of different DR on different cell and tissue may provoke different 
physiological responses (Sunahara et al., 1991; Van Tol et al., 1991). Thus, low levels of DA, 
e.g. 50 nM, would stimulate mainly DR D3, while moderate DA levels, e.g. 300 nM, would 
stimulate DR D5 as well. It is likely that, by stimulating multiple DR, higher DA levels promote 
complex effects in different circulating cells types and tissues expressing this receptor subtype 
(Pacheco et al., 2014). Binding studies have shown that DA also has affinities for different AR 
(Xhaard et al., 2006). Origin of the specificity of binding in adrenergic versus dopamine 
receptors was confirmed by distinct morphological features of the receptors, such as: i) an 
unusually long third intracellular loop (α2 and D2-like receptors), ii) a long carboxyl-terminal 
segment (α1-ARs, β-ARs and D1-like receptors), but also iii) specificity for coupling certain G-
proteins (Gi/0 for α2-ARs and D2-like receptors and Gs for β-ARs and D1-like receptors) 
(Xhaard et al., 2006). This observation suggests that the ligand-based pharmacological 
classification does not reflect the evolutionary history of the ARs and DR. In addition, in vivo 
has shown the interplay between DA and ARs, where DA activated adrenoreceptors in the 
preotic area of Japanese quail (Cornil et al., 2002) and re-uptake of DA has been reported at 
adrenergic neurons in adult male Sprague-Dawley rats (Pan et al., 2004).  
Structure-activity relationship study, comparing DA with A and NA, reveals that by 
removing the hydroxyl group from the side chain of NA, DA molecule has less affinity for α- 
and β- adrenergic receptor, and higher affinity for dopaminergic receptors. The β-hydroxyl 
group is found only in NA and not in DA, thus is expected to form unique interactions with 
ARs (Xhaard et al., 2006). Since S-enantiomer of NA binds to the ARs with an affinity similar 
to DA in contrast to the tight binding of the R-enantiomer, it might be assumed that chirality of 
this group is key to NA selectivity (Nyrӧnen et al., 2001). So far, no amino acid has been 
identified that could account for specific interactions of β-hydroxyl of NA with α1-ARs or α2-
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ARs. In the β-ARs, the main candidate for interaction with the β-hydroxyl group on ligands is 
asparagine at the position N6.55 (Wieland et al., 1996), but asparagine is also found at the 
equivalent position in the D1-like type receptors activated by DA lacking the β-hydroxyl 
group. Adrenaline, having a methyl group attached to the positively charged nitrogen, binds 
with a higher affinity to the ARs in comparison to NA (Nyrӧnen et al., 2001). 
Knowledge of peripheral DR function is mainly derived from observations of DA 
hydrochloride administered intravenously, widely used in the treatment of various shock states 
and congestive heart failure. In congestive heart failure, decrease in cardiac output triggers a 
series of compensatory actions: fluid retention, vasoconstriction, an increase in peripheral 
vascular resistance, tissue hypoxia and an increase in the levels of circulating CAs. The state of 
shock leads to a strong activation of the SNS resulting in a massive increase of circulating CAs. 
When endogenous CA release fails to stabilise cardiovascular parameters, therapeutic CAs are 
frequently administered (Flierl et al., 2008). Administration of CAs becomes the choice of last 
resort to stabilise cardiovascular functions in the critically ill patient (Annane et al., 2005). 
The pharmacological low dose of DA stimulates mainly DR, while higher doses 
stimulate both β1-adrenergic and DR as well (Table 3). High therapeutic doses stimulate also α 
-adrenergic receptors (α1, α2) (Smit, 1989). 
Both D1-like and D2-like receptors are located at various sites within the cardiac, 
vascular, and renal vascular bed (Lokhandwala and Amenta, 1991). Low doses of DA are 
widely used for its specific effects on renal function, suggested to be beneficial. Dopamine is 
able to improve negative circulatory events by renal vasodilatation (via DR D1), the decrease of 
renal vascular resistance and to improve urine output trough the increase of the kidney blood 
flow. However, a meta-analysis of multiple studies fails to demonstrate that DA can prevent 
acute renal failure or reduce mortality (Kellum and Decker, 2001; Friedrich et al., 2005). At 
low concentrations, the primary cardiovascular effect of DA is stimulation of vascular DR D1 
leading to vasodilatation. Therefore, DA is particularly useful in the management of states of 
low cardiac output associated with a compromised renal function such as cardiogenic shock. At 
higher, moderate concentrations, the β1-adrenergic-mediated response occurs and a selective 
increase of force of myocardial contraction without a significant effect on heart rate. High 
doses of DA, like all CAs (which activate the β1-AR), can induce rhythm disturbances. In 
addition, at high concentrations, DA stimulates α1-AR, leading to vasoconstriction. 
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Table 3. Degree of different receptor stimulation and major effects mediated by DA 
based on different dosing rate 
Dopamine 
infusion rate 
(clinically 
relevant 
doses) 
Receptor 
subtype 
Location 
 
Contribution to 
therapeutic effect 
Theoretical 
concentrations of 
DA in plasma in 
steady state (nM) 
Lower DA 
infusion rates 
(0,5-4 
μg/min/kg) 
D1–like 
receptors 
(DR D1) 
Kidney  
Vascular smooth 
muscle in renal, 
mesenteric, and 
coronary arteries 
Increased renal blood 
flow, natriuresis, urine 
output and a decrease 
of fluid retention 
(edema). 
Relaxation of vascular 
smooth muscle. 
 
 
 
 
2 - 522* 
D2–like 
receptors 
Neurons 
Kidney  
 
Inhibited release of 
NA and aldosterone 
secretion, 
vasodilatation and 
sodium excretion 
(Smit, 1989; Girbes et 
al., 1992) 
Intermediate 
DA doses (4-
10 μg/min/kg) 
β1 - AR 
Heart  
 
 
Positive inotropic 
effect, increased heart 
rate, cardiac output, all 
beneficial in 
congestive heart 
failure 
(Amenta et al., 1993). 
 
 
16 -1300* 
Infusion rates 
10-20 
μg/min/kg 
α1/α2 - AR 
Smooth muscle 
Blood vessels 
Gastrointestinal 
tract  
Liver  
Systemic 
vasoconstriction and 
increase in blood 
pressure (Girbes & 
Hoogenberg, 1998). 
 
 
 
40- 2600* 
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Pancreatic islets  
Nerve terminals 
 
May increase risk of 
tachyarrhythmias 
 The decrease of 
insulin secretion. 
Relaxation of GIT. 
Glycogenolysis. 
Adrenergic and 
cholinergic      
decrease release 
Notes: * Theoretical DA concentrations in the human plasma in the steady state (Css, nM) 
during prolonged continuous infusion were estimated from the equation Css = υinf/CLtot (where υinf 
represents the infusion rate (μg ∙kg-1 ∙min-1), and CLtot represents DA total clearance, expressed in units 
(ml ∙kg-1 ∙min-1) used from DA pharmacokinetics parameters presented in Table 4. 
 
Of note is, that plasma DA concentrations in patients receiving DA infusion at identical 
rates, despite a homogeneous population of healthy male subjects (n = 9) and weight-based 
dosing, may vary profoundly (MacGregor et al., 2000). Variability in plasma DA 
concentrations was 10- to 75-fold intersubject, thus DA dosing based on body weight does not 
yield predictable blood concentrations, but rather shows marked intraindividual and 
interindividual variability in DA distribution and/or metabolism (MacGregor et al., 2000). 
In cardiology, DA is the drug commonly used to prevent renal failure and treat 
moderate hypotension in the critically ill patients (Oberbeck, 2006). Dopamine is approved by 
Food and drug administration (FDA) since 1974 and is in use for more than 40 years with a 
favourable therapeutic index. On the basis of inter-individual variation in pharmacodynamics 
(Table 4), DA requires careful monitoring of the achievement of the desired hemodynamic 
profile. For this reason, the use of DA infusion is often restricted to intensive care units and 
operating rooms that are equipped with appropriate hemodynamic surveillance. Summary of 
established clinical use of DA in hospital cardiovascular unit is: to correct hemodynamic 
imbalances present in shock syndrome due to myocardial infarction, endotoxic septicemias, 
renal failure, open heart surgery and chronic cardiac decompensation. 
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Table 4. Pharmacokinetics parameters of the clinically used intravenous DA 
Absorption 
Usual dosage: 5-10 μg/min/kg 
Onset: 5 min (adults) 
Distribution Vd: 0.8-2.45 L/kg 
Metabolism 
Metabolised in liver, kidney, and plasma by MAO and COMT 
Metabolites: NA (active), inactive metabolites 
Elimination 
Half-life: 2 -20min 
Total body clearance: 50 – 1600 mL/kg/min 
Excretion: Urine (80%) 
(data from Johnston et al., 2004; Lehtonen et., 2004) 
 
1.5.Dopaminergic pathways involvement in pathological conditions 
 
Dopamine is particularly important in relation to neuropharmacology, because it is 
involved in several common disorders of brain function, with a number of neurological or 
psychiatric disorders such as: Parkinson's disease, schizophrenia (Hoenicka et al., 2007; 
Strange, 1993), migraine, drug dependence, mania, depression, and Gilles de la Tourette 
syndrome, ADHD, as well as in certain endocrine disorders (Table 5). Many of the drugs used 
clinically to treat these conditions work by influencing DA transmission. Due to the extensive 
and important role that DA plays in the nervous system, the imbalance on the capture/release of 
DA and/or DR expression have been extensively studied. 
 
Table 5. Role of DA in certain pathophysiological conditions 
Dysfunction of the dopaminergic system might be expressed by: 
Impaired DA levels in CNS and/or at the periphery 
Expression of dopaminergic receptors  
Impaired dopaminergic signalling 
Autoimmune disease 
Multiple sclerosis (MS), systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA), inflammatory bowel diseases (IBD) 
Neurological/neuropsychi
atric disorders 
Parkinson’s disease, Huntington's disease Alzheimer’s disease, 
schizophrenia, bipolar disorder, mania, hypersexuality, 
depression, social phobia, anxiety disorder, obsessive-
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compulsive disorder, drug abuse/use/addiction, alcohol 
dependence, migraine, attention deficit hyperactive disorder, 
Gilles de laTourette syndrome  
Cancer 
breast and colon cancer (Sarkar et al., 2008), gastric cancer 
(Chakroborty et al., 2008) 
 
Dopamine–DR interaction is responsible for different cellular responses depending on 
the target cell and subtype of the receptor. Abnormalities of intracellular response can occur if 
the number of receptors is reduced (e.g. down-regulation in persistently high concentrations of 
DA), or the receptor’s affinity for DA is reduced, or coupling to the intracellular signalling 
cascade is impaired. 
 
1.5.1. Neurological and neuropsychiatric disorders 
 
Dysfunction of dopaminergic neurotransmission in the CNS has been shown in a 
variety of neurological and neuropsychiatric disorders. These include PD, schizophrenia, 
ADHD, drug abuse, addiction, alcohol dependence, social phobia, obsessive-compulsive 
disorder (OCD) and Tourette’s syndrome. Some disorders, such as hypersociality, bipolar 
disorder, mania and hypersexuality are related to an increase in DA, but also in the conditions, 
as cancer and stress are found increased levels of circulating DA are found (Table 5). 
Interestingly, in some disease, there have been shown impaired DA levels/receptors/signalling 
and abnormalities in DR expression on lymphocytes, and some other important immune 
functions are, sometimes in significant correlation with the severity of the disease. So far, no 
define evidence exists supporting primary dysfunction of dopaminergic pathways in psychiatric 
conditions. Neuroleptic drugs, which are used in psychosis and schizophrenia are mainly (but 
not only) DR antagonists. Neurolepsis is "an altered state of consciousness, as induced by a 
neuroleptic agent, characterised by quiescence, reduced motor activity, decreased anxiety, and 
indifference to the surroundings" (http://medical-dictionary.thefreedictionary.com/neurolepsis). 
 
1.5.1.1.Parkinson’s disease 
 
In 1960, a ground-breaking study of Ehringer and Hornykiewicz discovered significant 
reduction of DA levels in the striatum of idiopathic Parkinson’s patients (Ehringer and 
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Hornykiewicz, 1960). Today, PD is considered to be an aging-related neurodegenerative 
disorder mainly characterised by loss of dopaminergic neurons in SN in the locus coeruleus. 
Unfortunately the main course of disease onset still remains ill defined. So far, defined risk 
factors are age, hereditary disposition, trauma (e.g., in boxers), inflammation (encephalitis), 
impaired circulation (atherosclerosis), tumours and poisoning (especially by CO, manganese, 
and MPTP). Parkinson’s disease symptoms become manifest when about 50-60 % of the DA-
containing neurons in the SN and 70-80 % of striatal DA are lost. Disease-related symptoms 
are suppression of voluntary movements becoming slow and rigid, muscle tremor, hypokinesia 
(difficulty initiating movement), resting tremor, rigid facial expression, micrographia 
(abnormally small handwriting). Many other disturbances occur, such as increased salivation, 
depression, and dementia, due to additional lesions and death of neurons in the nucleus of the 
median raphe of the locus coeruleus, or lesions of the vagus nerve.  
In the mammalian brain, DA is present at the highest levels within the striatum, which 
major function is regulation of posture and muscle tonus. The striatal neurons are partly 
activated and partly inhibited by DA from the SNpc, and also activated via cholinergic 
neurons. An imbalance between inhibitory and activating influences has a harmful effect on 
motor functions: too strong an inhibition of the thalamic nuclei has a hypokinetic, too little has 
a hyperkinetic effect. When dopaminergic neurons degenerate in the nigro-striatal 
dopaminergic tract, and the inhibitory influence of DA on the striatum is diminished, the 
consequence is an increased activity of excitatory cholinergic neurons (Figure 5). 
Molecular mechanisms leading to degeneration of SNpc neurons are not fully 
understood. A number of evidence indicate some factors important for the final degeneration, 
but relationships among them are not well characterised. Major factors have been identified as 
mitochondrial impairment, ubiquitin-proteasome dysfunction, altered calcium homeostasis and 
oxidative stress (Banerjee et al., 2009; Surmeier et al., 2010). 
Degeneration of nigrostriatal pathway and ensuing deficit in brain DA remains at 
present the most prominent alteration in PD (Dauer and Przedborski, 2003). The appearance of 
intracytoplasmic inclusions, Lewy bodies (LB) is another pathological hallmark of disease 
(Shults, 2006). Lewy bodies consist mainly of ?-synuclein protein, which is encoded by the 
causative gene of fPD/PARK1 in familial Parkinson’s disease. 
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Figure 5. Anatomy and physiology of Parkinson’s disease (PD) motor manifestations. A simplified 
schematic of the neuronal circuits involving the basal ganglia, thalamus, and cortex and their 
derangement in PD. For simplicity, only the direct pathway is shown. It normally functions to 
facilitate movements (left), but in PD the output is attenuated (right). The midbrain substantia nigra 
pars compacta (SNpc) provides dopaminergic input to the putamen, which is excitatory to the direct 
pathway. The putamen inhibits (red) the globus pallidus interna, which subsequently inhibits the 
thalamus. The thalamus projects excitatory input (green) to the motor cortex. In PD, degeneration 
within the SNc leads to net increased inhibition of the thalamocortical projection. The indirect 
pathway (not shown), including the globus pallidus externa and subthalamic nucleus, is inhibited by 
SNc dopaminergic input and normally functions to repress movements, but its activity is enhanced in 
PD. (Reproduced with permission from Shulman et al., 2011) 
 
Whatever insult initially provokes neurodegeneration, studies of toxic PD models 
suggest that one of the major hypotheses regarding the pathogenesis of the disease is 
misfolding and aggregation of proteins as instrumental in the death of SNpc dopaminergic 
neurons (Auluck et al., 2002; Luk et al., 2012). The abnormal deposition of protein in brain 
tissue is a feature of several age-related neurodegenerative diseases such as dementia with 
Lewy bodies (DLB). Neurodegenerative diseases with LB are generally referred as 
synucleinopathies. Although the composition and location (i.e., intra- or extracellular) of 
protein aggregates differ from disease to disease, this common feature suggests that protein 
deposition per se is toxic to neurons. Little is known about the factors that might affect the 
propagation of α-syn pathology. Recent research suggests that neuroinflammation plays an 
important role in promoting of the prion-like behaviour of misfolded α-syn and that the same 
mechanisms contribute to inflammation in the olfactory bulb and gastrointestinal tract and 
promote the initial misfolding and aggregation of α-syn that lead to PD neuropathology (Lema 
Tomé et al., 2013). The same group propose that neuroinflammation and α-syn propagation 
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may be targeting mechanism for a novel antiinflammatory therapies that could slow disease 
progression (Lema Tomé et al., 2013). 
Nigral dopaminergic neurons are particularly susceptible to oxidative stress because of 
their exposure to a high oxidative load: first of all, the metabolism of DA gives rise to various 
molecules that can act as endogenous toxins and start the formation of oxygen reactive species 
(ROS). Normally, these species are eliminated by intracellular antioxidant systems, which 
might be impaired by aging or by specific alterations owing to the PD pathogenesis (Alberio 
and Fasano, 2011). 
Recent evidence increasingly points to another prominent neuropathological feature in 
PD patients’ brains, the presence of a glial response (Sanchez-Guajardo et al., 2013) in all areas 
of the brain where signs of neurodegeneration can be found (Przedborski, 2010). The initial 
observation that activated microglia were detectable in brains of PD patients at autopsy came 
25 years ago (McGeer et al., 1988). Since then, numerous studies, both in humans and animal 
models of parkinsonism, have implicated inflammatory processes in the development and 
progression of nigral dopaminergic neuron death. Several reviews of the subject of 
neuroinflammation have clearly demonstrated glial reaction in pathological situations of the 
CNS can play either a beneficial or detrimental role (Wyss-Coray and Mucke, 2002; McGeer 
and McGeer, 2004; Przedborski 2007). Microglia cells contribution to chronic inflammation in 
PD and their toxicity towards dopaminergic neurons is confirmed in vitro studies, but also in 
animal models of PD (McGeer and McGeer, 2008). 
In recent years serious attention has been given to the potential impact of the immune 
system in pathogenesis of PD. Attention has been dedicated to changes in cellular immune 
responses in the peripheral immune system of PD patients, since there is a growing body of 
evidence that immune cells infiltrate the brain from peripheral compartment and that these cells 
are responsible for consequent changes of levels of neuroprotective or neurotoxic substances 
such as cytokines and reactive molecules (Nagatsu and Sawada, 2006). 
Mounting evidence supports the fact that the peripheral immune system actively patrols 
the CNS and contributes to the functional integrity (Ransohoff et al., 2003). Under 
physiological conditions, the entry of immune system cells in the CNS parenchyma is restricted 
primariily by the brain blood barrier (BBB). Importantly, some immune cells involved in 
immunosurveillance may infiltrate into the cerebro spinal fluid (CSF) and patrol CNS. CSF 
flows into the subarachnoid space and drains into cervical lymph nodes, enabling peripheral 
immune cells to recognise and respond to CNS Ags in the absence or presence of inflammation 
45 
 
(Hatterer et al., 2008; Laman and Weller, 2013). Recently proposed, possible mechanisms, that 
lead to the development of the disease are neuroinflammatory processes in the brain of PD 
patients (reviewed in Hirsch and Hunot, 2009; Tansey and Goldberg, 2010). Recently, it has 
been shown that CD4+ T cells infiltrate brain and mediated dopaminergic toxicity in murine 
models of PD, as well as, human brain specimens examined post mortem (Benner et al., 2008; 
Brochard et al., 2009). In a recent immunohistochemical analysis of several leukocyte markers 
in the SN, Brochard and co-workers reported no B cells or natural killer cells and higher 
densities of CD8+ and CD4+ T cells in the brains of patients with PD than in healthy 
individuals. These cells were in close contact with blood vessels (suggesting migration from 
the bloodstream) and near to melanised dopaminergic neurons (suggesting an interaction 
between the lymphocytes and the dopaminergic neurons) (Brochard et al., 2009). Recent 
studies have shown that peripheral T cells that infiltrate into the brain play a fundamental role 
in neurodegeneration in PD (Reynolds et al., 2010). T cells with a pro-inflammatory phenotype 
(Th1, Th17) contribute to the destruction of dopaminergic neurons. Conversely, other T cell 
subsets, such as Treg and Th2 cells, could contribute to microglial switch towards M2-like 
anti-inflammatory phenotype (releasing neurotrophic factors e.g., insulin-like growth factor-1, 
IGF-1) promoting neuronal protection (Appel, 2009; Reynolds et al., 2010). 
Infiltrating T cells can control the neurodegenerative process by the production of 
different molecules, acting on microglia cells and modulating their phenotype and function. 
The crosstalk of diverse population and phenotypes of CD4+ cells and activated microglial 
cells depends on activation status of infiltrating T lymphocytes that are able to promote 
neuroprotection or neurotoxicity, suggesting that an immunologic mechanism may be 
important in the development of PD, but it is uncertain whether immunological changes are 
primary or secondary events (Baba et al., 2005). During MPTP-induced PD, CD4+ T cells that 
infiltrate in the SN produce high levels of cytokines that synergistically act to promote 
microglia inflammatory M1-like phenotype (Barcia et al., 2012). This pro-inflammatory 
phenotype is characterised by the secretion of inflammatory factors mediating neurotoxicity, 
such as TNF-α, IL-1β, superoxide anions, and other neurotoxins and cytokines (Appel, 2009; 
Klegeris and McGeer, 2000).  
Several researchers have demonstrated that pathological features of PD can also be 
detected outside CNS, increasing the possibility that PD may, in fact, be a generalised disease 
(Lema Tomé et al, 2013). One direct consequence of this concept has been to prompt scientists 
to scrutinise non-CNS tissues, including blood and other body fluids, from PD patients for 
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hints of problems in oxidative metabolism. Several of these studies have reported significant 
alterations in the measured parameters in PD blood and CSF (Buhmann et al, 2004; Prigione et 
al, 2006). 
Since inflammation and inflammatory mediators significantly contribute to the 
neurodegenerative process of PD, strategies targeted towards central and peripheral 
inflammation may, therefore, result in significant neuroprotective effects with unanticipated 
therapeutic relevance (Przedborski, 2010). In the case of PD, epidemiological studies have 
shown that the use of nonsteroidal anti-inflammatory drugs decreased the risk of developing 
PD (Chen et al, 2003). Involvement of peripheral adaptive immunity in neurodegeneration 
might provide novel perspectives in the pathogenesis of PD as well as in innovative therapeutic 
strategies.  
 
1.5.1.2.Parkinson’s disease therapy 
 
Since the pathological process in neurodegenerative diseases causes irreversible 
neuronal death, it appears very unpromising territory for pharmacological intervention and 
drug therapy has rather little to offer. So far, no treatment has been shown to slow or stop the 
progression of PD. Therefore, the treatment is symptomatic. 
Dopamine replacement therapy with L-DOPA (dopamine precursor) in PD has shown 
need to the clinical utility of several other dopamine ergot agonists including: bromocriptine, 
lysuride, piribedil, pergolide, cabergoline and also some non-ergoline, newer generation DA 
agonist: pramipexole, ropinirole, rotigotine, and other similar compounds (Millan, 2010), but 
also apomorphine that act by direct stimulation of DR. Dopamine agonists bind to postsynaptic 
DR and mimic the action of DA in the synaptic cleft (Deleu et al., 2002). 
They exert their action by directly activating DR, bypassing the presynaptic synthesis of 
DA. The activation of D2-like receptors (especially DR D3) is important for antiparkinsonian 
effects of DA agonists, although concurrent D1-like and D2-like stimulation is required to 
produce optimal physiological and behavioural effects (Jankovic and Aguilar, 2008). Some 
commonly used DA agonists in the clinical practice are ropinirole, pramipexole, and rotigotine. 
Pharmacological modulation of dopaminergic pathways can be obtained also by 
targeting: DA synthesis, storage, release, uptake, and metabolism with indirectly acting drugs 
(Table 6).  
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Although currently available PD therapies both delay disability and prolong life 
expectancy, none has been proven to significantly alter the ongoing neurodegenerative process 
(Shulman et al., 2011). 
 
Table 6. Pharmacological targets and examples for the modulation of dopaminergic 
pathways by indirectly acting agents 
Dopaminergic 
pathway: 
Target Example of drug Main effect/indication 
DA synthesis 
enzymes 
TH α-methyl-p-tyrosine Enzyme inhibitor; treatment 
of pheochromocytoma and 
treatment-resistant 
hypertension 
DOPA 
decarboxylase 
benserazide, carbidopa Enzyme inhibitors, unable to 
cross the blood–brain barrier; 
treatment of PD in association 
with L-DOPA 
Dopamine-β-
hydroxylase 
disulfiram Enzyme inhibitor; treatment 
of chronic alcohol 
dependence 
Storage and 
release 
VMAT reserpine Transporter inhibitor; 
treatment of hypertension and 
psychosis 
tetrabenazine Transporter inhibitor; 
treatment of hyperkinetic 
movement disorders 
Reuptake DAT benztropine Transporter inhibitor; 
treatment of PD 
NET tricyclic antidepressants 
(desipramine, 
imipramine, 
amitriptyline) 
Transporter inhibitors; 
Treatment of depression 
noradrenaline reuptake 
inhibitors (atomoxetine, 
Transporter inhibitors; 
treatment of depression and 
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reboxetine) other psychiatric syndromes 
serotonin-noradrenaline 
reuptake inhibitors 
(venlafaxine, duloxetine, 
sibutramine) 
Transporter inhibitors; 
treatment of  depression, 
anxiety disorder, chronic pain 
syndromes 
noradrenaline-dopamine 
reuptake inhibitors 
(amineptine, bupropion, 
methylphenidate) 
Treatment of depression and 
other psychiatric syndromes 
Metabolism MAO nonselective MAO 
inhibitors (nialamide, 
tranylcypromine) 
Treatment of depression and 
anxiety 
selective MAO-A 
inhibitors (moclobemide, 
toloxatone) 
 Treatment of depression and 
anxiety  
selective MAO-B 
inhibitors (selegiline, 
rasagiline) 
Treatment of PD 
COMT tolcapone entacapone Treatment of PD 
(data adapted from Cosentino and Marino, 2013) 
 
1.5.1.2.1. Levodopa in PD therapy 
 
Although PD is characterised by a loss of neurons that contain and release DA, oral or 
intravenous DA is not effective because it presents charged amino acid that does not pass the 
BBB. L-DOPA, as a precursor of DA, passes through the BBB and it is metabolised to DA in 
dopaminergic neurons hence supplying a source of DA to the brain (Olanow et al., 2001). L-
DOPA is the cornerstone of  PD therapy, sometimes also called “golden standard” and the most 
efficacious antiparkinsonian medication in moderate and advanced disease, as it provides 
relatively rapid symptomatic benefits and significantly improves patient quality of life. 
L-DOPA is generally well tolerated with few initial side effects. Unfortunately, the 
therapeutic benefit of L-DOPA (maximal benefit usually lasts 3–5 years) is diminished by the 
unacceptable motor and psychological side effects that occur in many patients after several 
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years of treatment. In the severe stage of PD, very few nerve terminals remain where occurs 
conversion of L-DOPA to DA, and the effects of treatment consequently diminish. L-DOPA 
treatment over years leads to variability and fluctuation in response that patients sense like "on" 
and "off" periods. The causes of these fluctuations still are not defined. Most likely, 
postsynaptic DR changes are important, however variable pharmacokinetic of L-DOPA are 
equally involved. Another form of motor fluctuation is uncontrolled abnormal movements 
called dyskinesias. Some clinical and experimental data had concerned DR D1 receptor subtype 
stimulation in the genesis of L-DOPA-induced dyskinesias, but experimental findings obtained 
with selective DR D1 and DR D2 high-efficacy agonists showed that neither dyskinesias nor 
antiparkinsonian effects could be ascribed solely to activity at DR D1 or DR D2 receptors 
(Boyce et al., 1990). Probably a synergistic effect between the two receptors appears to mediate 
these responses (Grondin et al., 1999). Controlled-release L-DOPA preparations provide fewer 
fluctuations in plasma than standard preparations. In this way, a smoother therapeutic response 
is achieved, although the onset of action is slower. For most individuals, treatment with L-
DOPA reduces the symptoms of slowness, stiffness, and tremor. 
Further on, L-DOPA and DA autoxidation gives rise to quinones, semiquinones and 
H2O2, which can be easily reduced in the presence of ferrous iron to hydroxyl radicals 
(Asanuma et al., 2003). Since it has been shown that L-DOPA is potentially neurotoxic, it was 
difficult to evaluate whether motor complications and dyskinesias are caused by the 
progression of the disease or exposure to L-DOPA. The controversy stems from the 
observation that L-DOPA increases DA metabolism, augmenting production of free radical 
species. It has been also shown that DA initiate apoptosis of neurons in vitro and exert toxic 
effects on various cultured cell lines (Offen et al., 1996), hence it seemed justified to speculate 
that the treatment with L-DOPA, as a DA precursor may, augment neuronal damage and 
provoke inflammatory changes in the SNpc and striatum by formation of free radical as well. 
However, it has been shown, that long-term L-DOPA treatment, at large, cumulative 
doses, is not toxic to human SNpc neurons and does not lead to the development of the 
symptoms of PD (Rajput et al., 1997). In vitro experiments showed that L-DOPA generates 
oxyradicals and the formation of unnatural neurotoxic metabolites, such as 6-OHDA as other 
possible mechanisms for causing neuronal degeneration (Maharaj et al, 2005) or could lead to 
the excess formation of naturally-occurring, however neurotoxic intermediaries in the dopa-
quinone-melanin pathway. Recent reports suggest that peripheral neuropathy is more common 
in patients with PD than age-matched controls (Toth et al., 2010). Possible reasons for this 
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association include peripheral nerve involvement by the pathology of PD or L-DOPA-induced 
metabolic derangements. The latter may include cobalamin deficiency and/or elevation of 
methylmalonic acid and homocysteine, which may be neurotoxic (Toth et al., 2010). 
Nonetheless, the evidence is lacking for L-DOPA toxicity in the treatment of PD patients 
(Olanow et al., 2004). 
In vitro assays have demonstrated both toxic and protective effects of L-DOPA on 
dopaminergic cells, while in vivo studies have not provided convincing data. Colamartino et 
al., have demonstrated the protective effect of both L-DOPA and carbidopa on neuroblastoma 
cells in vitro. They have evaluated in vitro: i) modulation of DNA damage in the presence of 
oxidative stress, ii) direct scavenging activity of L-DOPA and carbidopa and iii) the expression 
of genes that were involved in cellular oxidative metabolism in the PBLs of healthy donors 
affected by different concentrations of L-DOPA and carbidopa confirming the antioxidant 
capacity of L-DOPA and carbidopa and their ability to protect DNA against oxidative-induced 
damage (Colamartino et al., 2015). 
Because L-DOPA has antioxidant effects in the striatum (Camp et al., 2000), there has 
also been a rationale to explore a beneficial effect in vivo. Another interesting study aimed to 
examine in vivo effect of chronic treatment with L-DOPA and DA on murine lymphocyte 
proliferation and cytokine production/release, such as IFN-y and IL-4 (designate Th1/Th2 cell 
subsets) and to ascertain whether these effects were mediated through direct stimulation of DR 
(Carr et al., 2003). In vivo treatment with L-DOPA for 5 days resulted in an increase in the 
proliferative response to ConA of splenic lymphocytes while cell supernatant concentrations of 
IL-4 and IFN-? were not significantly altered (Carr et al., 2003). However, the number of IFN-
?, but not IL-4 producing cells was significantly reduced by L-DOPA and this effect was 
replicated by infusion of DA, suggesting that DA may have a direct role in regulating immune 
responses through down-regulation of IFN-? (Carr et al., 2003). In conclusion, peripheral in 
vivo administration of DA or L-DOPA, has regulatory effects on T lymphocyte function since 
it augment the proliferative capacity of T lymphocytes in response to mitogenic stimuli and the 
reduction of numbers of IFN-γ-producing cells in the spleen, through stimulation of DR D2, 
since concomitant administration of DR D2 antagonist reversed these effect (Carr et al., 2003). 
To investigate if treatment with L-DOPA/benserazide exerts immunomodulatory 
potential of T-cell accumulated in the post-ischemic brain, Kuric and Ruscher subjected male 
Sprague–Dawley rats to transient occlusion of the middle cerebral artery and initiated with 
treatment on day 2 post-stroke. One week after intervention, distribution of T-cell populations 
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was analysed and it have been shown that treatment had significantly reduced CD3+CD8+ 
cytotoxic T-cells in the ischemic hemisphere together with reduced levels of T-cell-associated 
cytokine IL-5, while other T cell populations (CD3+, CD3+CD4+, CD3+CD4+CD25+) were 
unchanged compared with vehicle-treated rats (Kuric and Ruscher, 2014). Post-stroke 
treatment with L-DOPA/benserazide significantly downregulated the expression ICAM-1 
levels on endothelial cells, which correlated with a reduced number of infiltrating cytotoxic T 
cells, suggesting that DA might act as a potential immunomodulator by attenuating 
inflammation in the post-ischemic brain (Kuric and Ruscher, 2014). 
 
1.5.1.2.2. Catechol-O-methyl transferase inhibitors  
 
To prevent the peripheral metabolic breakdown of most of an administered dose of L-
DOPA, it is frequently combined with DOPA-decarboxylase inhibitors (DDIs) and COMT 
inhibitors. In the US, the licensed DOPA-decarboxylase inhibitor is carbidopa, whereas in 
Europe benserazide is used. This drug combination allows more L-DOPA to reach the brain, 
prolong the duration of action of L-DOPA and prevents the peripheral accumulation of L-
DOPA metabolites (Olanow et al., 2001).  
COMT inhibitors, dose-dependently inhibit the formation of the major metabolite of L-
DOPA (3-O-methyldopa). They are added to the therapy, as adjuncts to L-DOPA in patients 
with end-of-dose fluctuations and when DA agonists are not tolerated. Main representatives, 
entacapone, and tolcapone cause potent, selective and reversible inhibition of soluble COMT in 
the liver, kidney, small intestine and red blood cells (Kaakkola, 2000). While, entacapone is a 
peripherally-acting COMT inhibitor with no effect on central enzyme activity, tolcapone also 
inhibits O-methylation in the brain (Nissinen et al., 1992). Tolcapone causes severe hepatic 
failure, therefore its use has been restricted and is indicated only for patients whose symptoms 
are not adequately controlled, with appropriate monitoring of liver function (Borges, 2003). 
 
1.5.1.2.3. Monoamine oxidase B inhibitors 
 
MAO-B inhibitors increase DA availability by inhibiting the degradation of DA by 
MAO-B (Youdim and Bakhle, 2006). When it is inhibited, the action of DA is prolonged in the 
brain, and the symptoms of PD are improved. Selegiline, MAO-B inhibitor, appears to have 
neuroprotective properties as it slows progression of PD, however, there is no firm evidence for 
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these now. It is effective as monotherapy for symptomatic relief or as an adjunctive agent. 
Inhibition of MAO-B prevents DA metabolism and the subsequent formation of oxygen 
species. These drugs also have a mild antidepressant effect. Side effects include heartburn, 
nausea, dry mouth, insomnia, and dizziness, as well as: confusion, nightmares, hallucinations, 
and headache that occur less frequently. 
 
1.5.1.2.4. Ergot dopamine agonists 
 
The first generation of DA agonists were ergot derivatives with a different 
pharmacological profile from L-DOPA. Ergot derivatives had a longer half-life than L-DOPA 
and a differential affinity primarily to D1-like and D2-like DR. The ergolines, including 
bromocriptine, lysuride, cabergoline, and pergolide, are commonly available DA agonists 
which are structurally similar semisynthetic ergoline derivatives, and are generally considered 
to be full agonists.  
Bromocriptine is an agonist of DR D2 receptors (De Leeuw Van Weenen et al., 2010) 
and various types of serotonergic receptors. Both bromocriptine and cabergoline, acting as a 
DR D2 agonists, have shown efficacy in the treatment of pituitary tumours, hyperprolactinemia, 
and related conditions (Colao et al., 2006). Bromocriptine has been used in the treatment of 
type 2 diabetes (Scranton and Cincotta, 2010).  
Bromocriptine and the recently withdrawn pergolide may rarely cause retroperitoneal, 
pulmonary and pericardial fibrosis, but also cardiac valvulopathies (Elangbam, 2010). 
 
 
1.5.1.2.5. Non-ergoline dopamine agonist 
 
After the remarkable success of the use of the DA precursor and indirect DR agonist in 
patients with PD (Birkmayer and Hornykiewicz, 1961), a number of highly effective 
compounds that activate DR have been developed. Nevertheless, it should be noted that none 
of these DA agonists can be compared in efficacy to L-DOPA as the first choice in PD 
treatment. 
The most of the currently used non-ergot DA agonists have entered the clinic more 
recently and include pramipexole, ropinirole, rotigotine, naxagolide, and piribedil. Besides two 
orally prescribed DA agonist, pramipexole and ropinirole, rotigotine is used as a transdermal 
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patch, containing an active ingredient that is released gradually when is applied to the skin. 
Initially, they were introduced as an adjunct to L-DOPA chronic treatment in patients 
exhibiting motor complications and dyskinesias (Oertel and Quinn, 1997). Introduce of DA 
agonist reduce around a 20-30% of the L-DOPA dose, leading to significant improvement of L-
DOPA treatment complications. There is evidence that DA agonists may provide symptomatic 
benefit but also be a neuroprotective and thereby slow progression of PD (Whone et al., 2003). 
Although DA agonists treatment causes motor fluctuations less frequently than L-
DOPA, it is more likely that this drugs will cause a number of other side effects: nausea, 
vomiting, dry mouth, dizziness, hallucinations, somnolence, orthostatic hypotension and lower 
extremity oedema. These particularly occur in patients over 70 and those with baseline 
cognitive deficits. In some individuals, DA agonists cause confusion, hallucinations, or even 
psychosis. Sleep attacks, drowsiness, or sedation is sometimes a significant side effect that may 
occur with all of the DA agonists. Behavioural side effects occur in 5-10% of patients and often 
reflect a disorder of “impulse control”. These behavioural changes are often compulsive and 
include gambling, shopping, and binge eating, as well as increased sexual behaviours and can 
be resolve once the dose of the DA agonist is reduced or discontinued (Weintraub, 2008). 
 
1.5.1.2.5.1. Pramipexole 
 
Pramipexole has high selectivity for interacting with dopamine D2-like subfamily 
receptors, in particular, DR D3 and a very low affinity for adrenergic or serotonergic receptors 
(5-HT2A and 5-HT2B receptors), as well as no affinity for D1-like receptors. Preferential affinity 
for the DR D3 receptor subtype, according to preclinical studies, could contribute additional 
efficacy for treatment of both motor and psychiatric syndromes in PD (Piercey, 1998). High 
selectivity for DR D3 provides safe drug profile, so pramipexole does not carry increased risk 
for valvular heart disease or pulmonary and retroperitoneal fibrosis, usually seen with long-
term use of the ergot-derived DA agonists. Immediate-release pramipexole dihydrochloride is 
indicated for the treatment of signs and symptoms of idiopathic PD. It is administered alone or 
in combination with L-DOPA, during the entire progress of the disease, up to an advanced 
stage. 
The first clues suggestive of beneficial effects of DA agonists on neurons came from a 
study in animal models. Whole-animal and cell culture studies suggest that pramipexole might 
provide neuroprotective effects through the decrease of DA metabolism, antioxidant effects, 
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and stimulation of trophic activity. In fact, all DA agonists are shown to have antioxidant 
properties in vivo and in vitro and these effects might be mediated by direct action on 
mitochondrial membrane potential and the inhibition of apoptosis (Schapira, 2002). However, a 
therapeutic benefit is not sustained, and it is possible to treat patients for only several years 
with DA agonists alone. Rather is considered preferable to use a combination of DA agonists 
and L-DOPA.  
Studies with pramipexole have demonstrated a number of potentially protective actions 
against oxidative stress and the influence on dopaminergic neurons of various experimental 
toxins, including 6-OHDA and MPTP (Ferger et al., 2000). The mechanisms contributing to 
the protective actions of pramipexole have not been defined, although activation of the DR D3 
was suggested and blocking the cascade of apoptosis (Deigner et al., 2000). These effects 
appeared to be derived from the enhanced expression of Bcl-2 protein in neuronal dendritic 
processes or to other actions unrelated to the dopaminergic actions of the drug (Ferger et al., 
2000; Deigner et al., 2000). 
 
1.5.1.2.6. Other medications 
 
Other medications used in antiparkinsonian treatment can act by modulation of ganglia 
neurotransmission or affect receptors other than dopaminergic. Commonly used are 
apomorphine, amantadine, and anticholinergic medications. 
 
1.5.1.2.6.1. Apomorphine 
 
Subcutaneous apomorphine is currently the only non-oral formulation of a DA agonist 
available. Apomorphine is a liposoluble molecule, moderately soluble in water and rapidly 
oxidised by light and air. Oral intake of the drug leads to nephrotoxicity since the high 
therapeutic doses are needed to overcome the extensive first-pass hepatic metabolism. 
Subcutaneous administration of apomorphine avoids first-pass metabolism and allows low 
dosages which are free of renal toxicity (Gancher et al., 1991). It acts as a potent nonselective 
DR D1 and DR D2 receptor agonist. Structurally it is a non-narcotic, synthetic morphine 
derivative, structurally related to DA. Apomorphine has been reported as a strong 
antiparkinsonian drug (Antonini and Tolosa, 2009; Garcia Ruiz et al., 2008). It is used as add-
on rescue therapy for patients who have advanced PD and a wide spectrum of complications 
55 
 
not controlled by optimal oral dopaminergic therapy (Riley and Lang, 1993). Common side 
effects are gastrointestinal, including severe nausea and vomiting at the recommended doses. 
Psychiatric side effects include hallucinations and confusion and slowing down of cognitive 
performance has been reported as well (Schellekens et al., 2010). Cardiovascular side effects 
have included syncope, and have been reported in very rare cases. 
 
1.5.1.2.6.2. Amantadine  
 
Amantadine is an antiviral drug, originally licensed for the prophylactic or symptomatic 
treatment of influenza A (Dolin et al., 1982). It has been used for decades as an 
antiparkinsonian agent, in particular for idiopathic PD (Lang and Blair, 1989), but also to treat 
extrapyramidal reactions, in particular, uncontrolled muscle movements caused by some 
medicines and for post-therapeutic neuralgia. Although most PD patients experience 
symptomatic improvement upon treatment, the exact mechanism of action remains elusive. The 
mechanism of action of the drug is probably a reflection of an increase dopaminergic 
transmission by augmentation of synthesis and release of DA, with possible inhibition of DA 
uptake and in addition it has mild antimuscarinic activity (Kulisevsky and Tolosa, 1990). It is 
well absorbed and widely distributed. In practice, amantadine may be used as a monotherapy or 
as an add-on to L-DOPA/peripheral decarboxylase inhibitor combination or DA receptor 
agonists in early and advanced PD. 
Amantadine is used to reduce symptoms of fatigue and tremor in patients with early 
PD, but benefits are short-lived. Side effects include difficulty concentrating, confusion, 
insomnia, nightmares, agitation, headache and hallucinations. 
 
1.5.1.3. Psychosis 
 
The term psychosis is very broad and includes state from relatively normal aberrant 
experiences through to the complex and catatonic expressions of schizophrenia and bipolar 
disorder. Clinical research has focused on applying brain research to understand the etiology, 
as well as to improve treatment, prognosis, and progression. Although direct evidence is 
lacking, it seems that when DA levels increase in the thinking areas of the brain, hallucinations 
start to occur in hearing, sensing, tasting and smell, but also delusions, disordered thinking, 
unusual speech or behaviour can occur. At the more extreme, this results in schizophrenia, 
56 
 
characterised by the loss of contact with reality and social dysfunction. The symptoms of 
schizophrenia are classified in categories as positive (delusions, hallucinations, thought 
disorder), negative (flat affect, poverty of thought, amotivation, social withdrawal), cognitive 
(distractibility, impaired working memory, impaired executive function), and mood (mania, 
depression) sensations (Wallwork et al., 2012). 
Since the mechanism of pathogenesis is not very well understood, schizophrenia is a 
model of disease that relies on the basis of responsiveness to the treatment of known drugs. In 
fact, pharmacological studies indicate a strong correlation between the potency of antipsychotic 
drugs and blockade of the DR D2 (Kapur et al., 2000; Seeman, 2010). Notably, all clinically 
approved antipsychotics are DR D2 antagonist. 
Originally described as neuroleptics, antipsychotics are effective in treating “positive” 
symptoms (particularly hallucinations and delusions). Unfortunately, the drugs may not be as 
helpful with other symptoms, such as reduced motivation and emotional expressiveness. 
“Positive” symptoms are linked to increased DA, especially in basal forebrain areas and are 
known for the presence of abnormal experiences and behaviour, disordered thought and 
speech, hallucinations (usually auditory) and delusions (often paranoid). “Negative” symptoms 
are linked to reduced DA, especially in the frontal and prefrontal cortex, the absence of normal 
experiences and behaviour, emotional blunting, anhedonia, apathy, social withdrawal and 
poverty of speech. Thus, antagonist drugs that act directly on DR D2 and reduce DA activity in 
the brain are effective in the treatment of positive symptoms. 
Antipsychotics are divided into first-generation or typical antipsychotics and second-
generation or atypical antipsychotics:  
1) typical antipsychotics are potent DR D2 and D3 antagonists  
2) atypical antipsychotics target DR D4 receptors (Van Tol et al., 1991) and cause a 
blockade of 5HT2A/5HT2C/5HT1A serotonin receptors. 
First antipsychotics (haloperidol and chlorpromazine) also known as neuroleptics have 
some side-effects that patients may experience as short-term side-effects including drowsiness, 
restlessness, muscle spasms, dry mouth, tremor, and blurred vision, but the also important 
long-term side effect is described as tardive dyskinesia. Neuroleptic antipsychotics can cause 
Parkinson-like side-effects, which are referred to as “motor side-effects” or extrapyramidal 
symptoms linked to reduced DA in the dorsal system (Tandon and Jibson, 2002). In some 
patients occur unpleasant subjective reactions to medication: feelings of restlessness 
(akathisia), emptiness, anhedonia, and apathy referred to as “mental side-effects” or 
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“neuroleptic-induced dysphoria” linked to reduced DA in the ventral system (Gerlach and 
Larsen, 1999). 
The second generation of antipsychotics, target receptors other than DR D2, such as the 
serotonin 5-HT2A, but also 5HT2C/5HT1A having a lower incidence of side effects, but still 
possessing antagonistic activity at DR D2 (Nord and Farde, 2011). Clinically, atypical 
antipsychotics evoke less severe extrapyramidal side effects because of the lower blockade of 
DR in the basal ganglia. Recent studies indicate that atypical forms are more likely to cause 
metabolic alterations, but a drug-associated obesity and type 2 diabetes are observed with both 
typical and atypical antipsychotics (Lindenmayer et al., 2003). This observation suggests that 
DR D4 or serotonin receptor antagonism might be a contributing factor(s) in metabolic 
syndrome since it has been shown that DR D4 are expressed in human pancreatic islets (Rubí et 
al., 2005). 
In view of the role of prefrontal dopamine DR D1 in cognition, cognitive symptoms, in 
particular, might respond well to treatment with DR D1 agonist (Castner et al., 2000; Goldman-
Rakic et al., 2004). Also, negative symptoms such as emotional indifference and social 
withdrawal may be amenable to treatment with DR D1 agonist, as such symptoms might be the 
result of the hypodopaminergic function in the brain (Fink-Jensen, 2000). 
Neuroanatomical, physiological and behaviour data suggest that DA agonist, ropinirole, 
and pramipexole, exhibit high affinity for cerebral DR D3 receptor subtype. Use of these 
medications in PD has been complicated by the side effects characterised as pathologic 
behavioural patterns (gambling, hyperphagia, excessive hobbying, hypersexuality) shown in 
patients having no history of such disorders (Kelley et al., 2012). This receptor specificity may 
have relevance to increase rates of described pathological behaviours, since DR D3 is 
particularly expressed in limbic areas, where the DA levels have shown to be increased by use 
of addictive drugs. Pathological behaviour has not been generally observed in patients taking 
bromocriptine, likely reflecting bromocriptine lacking affinity for DR D3 (Montastruc et al., 
2003), suggesting that DR D3 receptor might represent a therapeutic target for new atypical 
antipsychotic drugs and OCDs. Various observations also suggest that DR D3 might be 
implicated in schizophrenia (Schwartz et al., 2000). Behavioural abnormalities are shown to be 
mediated by DR D3 (locomotor hyperactivity in mice mediated by glutamate/NMDA receptor 
blockade), and since glutamate/NMDA transmission is deficient in schizophrenia, DR D3 
receptor-selective antagonist may be useful as a novel antipsychotic drug (Sokoloff et al., 
2006). 
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1.5.1.4. Drug abuse/use/addiction 
 
A large number of drugs act by altering the synthesis, storage, release, transport, or 
metabolism of endogenous ligands such as neurotransmitters. For instance, there are many 
examples of drugs that act on neuroeffector junctions by altering neurotransmitter synthesis, 
storage, release into the synaptic cleft, and subsequent removal. Cocaine blocks reuptake of 
DA, leading to increased concentration in the synaptic cleft. Mechanisms of cocaine 
dependence were described by Dackis and O’Brien (2001) by positive reinforcement where 
acute subjective effects of cocaine are intensely pleasurable and negative reinforcement, 
described as unpleasant rebound effects due to DA depletion (depressed mood, anhedonia, 
apathy, lethargy) are reversed by further drug use. Drugs that increase DA levels in the brain 
(acting indirectly on different components of dopaminergic pathways) are i) L-DOPA - used to 
treat symptoms of PD, ii) MAO inhibitors - prevent the breakdown of DA (and other 
monoamines, noradrenaline, and serotonin) and iii) psychostimulants - amphetamine and 
cocaine.  
 
1.5.2. Autoimmune diseases 
 
In autoimmune diseases, DA levels are altered and this change also affects deregulation 
of dopaminergic components expressed in immune cells association in inflamed tissues of 
patients in the different stages of the development and progression diseases (reviewed by 
Pacheco et al., 2014). 
 
1.5.2.1. Multiple Sclerosis 
 
Multiple sclerosis is one of the most common autoimmune diseases that represents a 
major cause of disability in both young and older populations (Frohman et al., 2006; Nylander 
and Hafler, 2012). Genetic and environmental factors have been proposed to be involved in the 
pathophysiology of the disease. Key pathological features of MS include: progressive loss of 
neurological function, increased BBB permeability and infiltrated lymphocytes into the CNS, 
crhonic glial activation and destruction of the axonal myelin sheath in several areas of the brain 
and spinal cord (Chastain et al., 2011). 
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Until recently, the contribution of T cells to the CNS function was largely ignored, 
since only a few cells were found in CNS parenchyma in healthy individuals (Smolders et al., 
2013). However, evidence of an interactive communication between the CNS and peripheral 
immune system cells are accumulating (Zipp and Aktas, 2006; Ferrari and Tarelli 2011). 
Human CD4+ T cells that patrol the CSF and perivascular space for detrimental Ags are shown 
to have central memory phenotype: CCR7+, L-selectin+, CD27+ and activation marker CD69+ 
(Kivisakk et al., 2003). In MS or in infectious encephalitis, upon severe immune attack (by 
self- of non-self-reactive T cells, respectively), damage takes place locally, leading to 
conclusion that CNS is primarily damaged by the immune system (Ellwardt and Zipp, 2014). 
Multiple sclerosis is regarded as an autoimmune process mediated by myelin-specific 
CD4+ T helper cells. In MS, myelin-reactive CD4+ T effector cells cross the BBB, enter the 
CNS and interact with resident cells to promote inflammation and promote further 
demyelination, leading to neurodegeneration (Kasper and Shoemaker, 2010). In the 
pathogenesis of MS, Th1 cells secrete the proinflammatory cytokines TNF-? and IFN-γ 
(Hemmer et al., 2006), while Th17 cells produce IL-17 (Tzartos et al., 2008). Self-reactive T 
cells differentiation toward inflammatory Th17 phenotype, recently described as a novel subset 
(Harrington et al., 2006), distinct from Th1 and Th2 cells, have been shown to contribute to the 
development of autoimmunity (Bailey et al., 2007). 
A recent report shows that DA can decrease IL-17 and IFN-γ production by PBMCs 
both in patients with relapsing–remitting MS and in healthy controls (Melnikov et al., 2016). 
According to their work: i) the number of circulating Th17 cells was augmented during MS 
relapses, ii) cultured PBMCs from patients in relapse release more IFN-γ and TNF-? than cells 
from patients in remission or cells from healthy controls and iii) in vitro treatment of PBMCs 
with DA reduced the production of both proinflammatory cytokines in all groups (Melnikov et 
al., 2016). Further, strengthening evidence for a potential benefit of dopaminergic agents in MS 
is summarised in recent reviews, briefly: i) in untreated patients, the expression and activity of 
D1-like DR (possibly not D2-like DR) on circulating PBMCs is reduced, and ii) in treated 
patients, immunomodulatory drugs, such as IFN-β, restore the functional responsiveness of DR 
on lymphocytes and shift the balance of DR in lymphocytes from predominantly D2-like (in 
cells of untreated patients) towards mostly D1-like. Since D1-like DR mediate most DA-
dependent inhibition of human T cell proliferation and cytotoxicity, whereas D2-like DR can 
induce T cell proliferation and adhesion, increased expression of D1-like DR would, therefore, 
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be expected to be beneficial in MS (Cosentino and Marino, 2013; Marino and Cosentino, 
2016). 
 
 
Figure 6. The putative mechanism of pathogenesis and progression in MS. T cells with adopted pro-
inflammatory phenotype after activation are infiltrating to CNS from the periphery and passing BBB 
mediated by adhesion molecules and chemokines. In the CNS these cells are once again activated by 
microglial cells bearing the same Ags. This way activated T cells start to produce and secrete pro-
inflammatory cytokines IFN-γ or IL-2, which induce inflammation by consequent activation of 
macrophages, B cells, and other T cells. Macrophages and T cells attack the myelin sheath of 
oligodendrocytes by cytotoxic molecules that they produce, mainly by TNF-α, O2 and NO. Upon 
differentiation into plasma cells, B cells produce demyelinating antibodies that can activate 
macrophages, and initiate the complement cascade, that forms membrane attack complex and causes 
pore formation in myelin membranes, finally leading to demyelination which occurs by four different 
pathological. Reproduced with permission from Neuhaus et al., (2003). 
 
 
1.5.2.2. Studies supporting modulation of dopaminergic pathways in multiple 
sclerosis 
 
So far, there is no cure for MS and treatment aim at slowing disease progression and 
reduce relapse rates. It relies mainly on immunosuppressive therapeutics, such as IFN-β 
(Kremenchutzky et al., 2007), although the mechanism of its action awaits clarification.  
Evidence in humans and animal model of MS support the relevance of both 
sympathoadrenergic and dopaminergic pathways, therefore both systems could be considered 
in a common, integrated context to understand and exploit better the therapeutic potential of 
drugs acting on both systems at the same time. 
Bromocriptine, a dopaminergic D2-like receptor agonist, showed improvement of 
clinical course in experimental autoimmune encephalomyelitis (EAE, animals model of MS 
disease) (Dijkstra et al., 1994). In MS patients study, the same dopaminergic agent was tested 
in in a pilot study, where the majority of patients complete the study showed disease  
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progression (Bissay et al., 1994). Mechanism of bromocriptine action may be explained in 
terms of the ability of this drug to reduce pituitary secretion of prolactin (Riskind et al., 1991). 
Prolactin has been reported to have a stimulatory role on immune function and is shown to be 
elevated in MS (Kira et al., 1991). Indeed prolactin might promote autoimmunity, and also 
hyperprolactinemia has been recorded in several autoimmune diseases (Orbach and Shoenfeld, 
2007). 
Besides bromocriptine, amantadine is the only drug that directly affects dopaminergic 
pathways and has been used for exhaustion in MS. Amantadine is not a pure dopaminergic 
agent, as it affects also noradrenergic and serotonergic pathways, blocks MAO-A and NMDA 
receptors, and may also increase beta-endorphin/beta-lipotropin levels (Huber et al., 1999). 
Evidence for the clinical effectiveness of amantadine suggests that the improvements in fatigue 
MS were small, while the impact on patients’ functioning and quality of life remained 
undetermined (Pucci et al., 2007). 
Although the clinical experience with dopaminergic drugs in MS are very limited, 
emerging evidence point to dopaminergic pathways in immune cells as potential therapeutic 
targets. 
 
1.5.2.3. Rheumatoid arthritis 
 
Accumulating evidence concerning aetiology of RA involves a complex interplay 
among environmental triggers and suggests that the disease develops in genetically predisposed 
individuals. Rheumatoid arthritis is characterised by certain clinical features: synovial 
inflammation and hyperplasia (“swelling”), autoantibody production (rheumatoid factor and 
anti–citrullinated protein antibody), cartilage and bone destruction (“deformity”), and systemic 
features, including cardiovascular, pulmonary, psychological, and skeletal disorders. 
The SNS has been proposed to be involved in the pathogenesis of RA since it has been 
shown in experimental animals that developed collagen-induced arthritis (CIA) is less severe in 
sympathectomised mice than in animals with intact SNS (Härle et al., 2008), suggesting a pro-
inflammatory role of SNS. Further, an adoptive transfer of Treg in this animals revealed that 
this cells might have a significant impact on disease severity (Härle et al., 2008). 
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Importantly, during RA synovial TH+ leukocytes, that have been found in RA patients 
but not in healthy controls, produce DA and NA, independently of SNS function (Capellino et 
al., 2010). By production of CAs that have strong anti-inflammatory effects, those TH+ 
leukocytes obtained from synovial tissues of RA patients showed in vitro and in vivo that these 
cells start to replace sympathetic nerve fibers around the onset of disease (Capellino et al., 
2010). 
Nakano et al., found that DA present in DCs in the synovial tissue of RA patients, and 
significantly increased in RA synovial fluid (Nakano et al., 2011). In the human RA 
synovial/SCID mouse chimera model, the selective D2-like receptor antagonist significantly 
induced accumulation of IL-6+ and IL-17+ T cells, and exacerbated cartilage destruction. 
Treatment with SCH-23390, selective DR D1 antagonist, strongly suppressed these responses 
and diseases severity. These findings suggest that DA released by DCs may act, via D1-like 
receptors, to elevate the IL-6–dependent Th-17 production by CD4+ T cells and causes 
aggravation of RA synovial inflammation (Nakano et al., 2011).  
A study in DBA/1 mice, immunised with type II collagen develop CIA showed that 
treatment of arthritic mice with the SCH-23390 suppressed CIA severity (Nakashioya et al., 
2011). Nevertheless, the treatment did not affect serum levels of antibodies to type II collagen 
or the splenic Th1/Th17 differentiation in the treated animals. Co-administration of other 
selective DR D1 agonist A68930 abrogated the in vivo anti-arthritic effect and has shown 
suppression of osteoclastogenesis when macrophages were isolated from the bone marrow and 
stimulated in vitro. 
Taken together, elevated DA levels in RA synovial fluid play an important role in RA, 
and blocking of D1-like receptors could represent a potentially novel approach that can be of 
benefit in RA treatment. 
 
1.5.2.4. Studies supporting modulation of dopaminergic pathways in rheumatoid 
arthritis 
 
Observations gained from animal models, together with the preclinical studies of DR 
antagonists implied studies in patients. Several clinical trials evaluated the effect of 
bromocriptine on RA disease activity. Clinical therapeutic trials using bromocriptine have 
shown efficacy in RA treatment (McMurray, 2001) inducing immunosuppression and 
improvement in morning stiffness and swollen/painful joints. These clinical observations give 
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support to the use of bromocriptine, as a non-standard primary or adjunctive therapy to 
traditional approaches, in the treatment of RA. Cabergoline exhibits a higher affinity for D2 –
like receptors, with less severe side effects and more convenient dosing schedule, and has 
much less tendency to cause nausea than bromocriptine. In summary, treatment of active RA 
by administration of bromocriptine (McMurray, 2001) or cabergoline (Mobini et al., 2011), 
both well known as a DR D2 and DR D3 agonists, suppress immune parameters and 
significantly reduces RA disease activity. 
 
1.5.3. Role of dopamine in cancer 
 
At present, very few studies deal with the role of DA in cancer, mainly are studies that 
are concerned about the role of DA in angiogenesis in tumour tissue. Angiogenesis is essential 
for the development of the embryo, tissue repair, and reproductive functions in the adult, but 
also this is a process of new blood vessel formation that is critical for the growth and 
progression of malignant tumours (Dvorak, 2005). Although angiogenesis is a balanced 
phenomenon between proangiogenic and antiangiogenic factors in normal physiological 
processes, in pathological conditions like cancer this balance is lost, thereby leading to the 
formation of abnormal blood vessels with increased permeability (Dvorak, 2005). Nowadays it 
is established that antiangiogenic therapy can slow down the growth and progression of 
malignant tumours (Dvorak, 2005). 
Accordingly, there is considerable interest in identifying antiangiogenic molecules and 
their mechanism of actions so that newer therapies can be designed to effectively target tumour 
angiogenesis.  
More than two decades ago DA was suggested as a novel anti-tumour agent against e.g. 
melanoma (Wick, 1982), however, its possible mechanism(s) of action remained not so clearly 
defined (FitzGerald and Wick, 1983). Dopamine possibly controls cell survival and 
proliferation, in a cell-type specific manner and exerts a paradoxical two-way outcome: i) in 
nontransformed cells, DA promotes cell proliferation and survival, and in tumour cell lines DA 
exhibits predominantly antiproliferative effects (Rubi and Maechler, 2010). In addition, DA 
might also protect against apoptosis (Nair and Olanow, 2008). 
Adjunctive therapy of DA enhances the efficacy of anticancer drugs on breast and colon 
tumours in mice animal models (Sarkar et al., 2008), which is probably a consequence of an 
inhibitory role on tumour neo-vessel formation through the control of endothelial progenitor 
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mobilisation from bone marrow (Chakroborty et al., 2008). The inhibitory effect on cancer 
growth is confirmed by both DA and SKF-38393 (selective DR D1 and DR D5 receptor partial 
agonist) inhibiting the growth of human meningioma cells in vitro (Schrell et al., 1990). 
Fascinatingly, it was recently shown that DA also inhibits tumour angiogenesis and growth of 
human colon cancer, not causing hypertension, hematological, renal and hepatic toxicities in 
normal and tumour bearing animals (Sarkar et al., 2015). Also, D2-like receptor agonist, 
bromocriptine inhibited proliferation of human small lung cancer cells (Ishibashi et al., 1994). 
Collectively, the important role of DA in the regulation of metabolic effects (decrease of 
insulin release (Rubí et al., 2005) and immunomodulatory effect (by increase migration and 
proliferation from bone marrow (Chakroborty et al., 2008) may underlie tumour-protective 
effects of DA. 
It has been documented that DA by acting upon DR D2 inhibits angiogenesis by 
suppressing the action of vascular permeability factor/vascular endothelial growth factor-A 
(VPF/VEGF) (Basu et al., 2001; Chakroborty et al., 2008). In view of these findings, 
endogenous DA in lymphocytes provides in principle these malignant tumour cells with a 
source of antiangiogenic mediators which could be released upon appropriate pharmacological 
treatment, e.g. with type I IFNs (Cosentino et al., 2005) or with reserpine-like drugs (Cosentino 
et al., 2007). It cannot be excluded that DA as an antitumour agent may also act through 
downregulation of Treg, which maintain tolerance towards tumour cells (Hiura et al., 2005). 
Interestingly, it was reported that activation of IFN-Type I receptors effectively induces DA 
release from activated lymphocytes (Cosentino et al., 2005), an effect which occurs also in 
vivo, in humans (Zaffaroni et al., 2008). Treg play a key role in immune evasion mechanisms 
employed by cancer. Treg are actively recruited and induced by tumours to block immune 
priming, effector function and memory response, which can inhibit the efficacy of therapeutic 
cancer vaccines. It is therefore highly provocative that DA can effectively inhibit human Treg 
function, at least in vitro (Cosentino et al., 2007). Treg are critical for the maintenance of 
immune homeostasis and are often found at elevated frequencies in blood and tumours of 
patients, and for many cancers, a high density of Treg correlates with poor disease outcome 
(De Leeuw et al., 2013). 
An improved understanding of the fundamentals and complexities of Treg – DA 
interplay may enable the selective modulation of this cells and valuable pharmacological target 
for the cancer treatment. 
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1.6. Use of dopamine agonists as a “tool” to modulate dopaminergic system  
1.6.1. Pharmacological properties of dopamine agonists in clinical use 
 
Table 7 summarises the potency of some DR agonists with current marketing approval 
for PD to inhibit DR D1, D2, or D3 binding in human putaminal tissue (Gerlach et al., 2003). 
Dopamine exhibited a low affinity for the D1 receptor. The second generation of non-ergot DR 
agonists, pramipexole, and ropinirole, displayed no affinity for D1 receptors even at high 
concentrations (up to 104 M). 
 
Table 7. Pharmacological properties of DA agonists with current marketing approval 
for PD 
 D2/D3 
receptor 
affinity 
D1 receptor 
affinity 
NA 
receptor 
affinity 
5-HT2B 
receptor 
affinity 
Half-
life (h) 
Dopamine D3>D2 low + - 2 min 
Ergot agonists      
α-
dihydroergocriptine 
D2> D3 + n.d. n.d. n.d. 
Bromocriptine D2> D3 + + +/- 3-6 
Cabergoline D3>D2 low + + 65 
Lisuride D2 = D3 + + + (antagonist) 2-3 
Pergolide D3>D2 + + + 15-20 
Non-ergot agonists      
(-)Apomorphine D2>D3 + - - 0,5 
Piribedil D3>D2 - +/- - 20 
Pramipexole D3>>D2 - +/- - 10 
Ropinirole D3>>D2 - - - 6 
Rotigotine D3>D2 + - - 5-7 * 
Quinpirole 
D2 low 
D3 – n.d. 
n.d. n.d. n.d. n.d. 
Notes: *(transdermal application), n.d. not determined  
(data modified from Antonini et al., 2009; Gerlach et al., 2003) 
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DA itself shows actions on DR D1 and D2 receptors but appears to have the greatest 
affinity for the DR D3 receptor subtype.  
Apomorphine is active on DR D1 and D2 and to some extent on DR D3 receptors.  
Lisuride is used as an antiparkinson drug, and has been described as an agonist of DR 
D5 receptors, a partial agonist of all other DR, and also is an antagonist at α2-AR and 5HT-2B 
receptors.  
Cabergoline is a primary agonist at DR D1 and D5 receptors, a partial agonist at D2-like 
receptors, and also an antagonist at α2-AR.  
Bromocriptine has multi-receptor and complex action among them, acting as a full 
agonist at DR D2, a partial agonist at DR D3, an antagonist at DR D4, also a full/partial agonist 
at D1-like DR and antagonist at α2-AR.  
Pergolide is a full agonist at DR D2, and a partial agonist at DR D3 and D4 (Cosentino 
and Marino, 2013).  
Receptor profiles of DA agonists corresponding to their clinical actions are not clear 
since none of these compounds are specific for only one receptor subtype. Consequently, DR 
agonist overall, can be at least considered as either D1-like (D1 and D5 receptors) and D2-like 
(D2, D3, and D4 receptors) specific. 
DR agonists are currently used in the treatment of restless leg syndrome, 
hyperprolactinemia, and PD, while antagonists are mainly used as antipsychotics and 
antiemetics (Table 8). 
 
Table 8. Dopamine receptor agonists that have been used clinically 
Dopamine 
agonist 
Major Clinical Application References 
Apomorphine PD, erectile dysfunction 
Carson, 2007; Garcia et al., 2008; 
Antonini and Tolosa, 2009 
Bromocriptine 
PD, pituitary tumours, 
hyperprolactinemia, 
type 2 diabetes 
De Leeuw Van Weenen et al., 2010; 
Shirasaki et al., 2010; Colao et al., 2006; 
Scranton and Cincotta, 2010 
Cabergoline 
Pituitary tumours, 
hyperprolactinemia 
Colao et al., 2003; Freda et al., 2004 
Fenoldopam Hypertension Murphy et al., 2001; Sarafidis et al., 2012 
Pramipexole PD, restless legs syndrome, Zintzaras et al., 2010; Aiken, 2007 
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bipolar disorder, depression 
Piribedil PD Rascol et al., 2006 
Pergolide PD Elangbam, 2010 
Ropinirole PD, restless legs syndrome Zintzaras et al., 2010; Aiken, 2007 
Rotigotine 
PD, bipolar disorder and 
depression 
Aiken, 2007 
(data adapted from Beaulieu and Gainetidinov, 2011) 
 
1.6.2. Therapeutic potential of drugs acting on dopaminergic system 
 
According to available literature, there are some abnormalities in DA levels in the brain 
and in the periphery associated several neurological/neuropsychiatric, autoimmune and cancer 
diseases (Table 5). Recent papers stress that in these pathologies, abnormalities in expression 
of DR in lymphocytes, and/or in immune functions might also be alerted. Based on these 
relatively small number of publications, it can be hypothesised that when the DA levels in the 
brain and periphery are changed, the immune system is also influenced. 
A range of DA agonists is in various stages of preclinical and clinical development and 
the reports of their efficacy await confirmation. The overall activity of these drugs is governed 
by their affinity, efficacy, and selectivity with respect to different types of DR, and intensive 
research has been devoted to developing drugs with the most desirable properties for specific 
clinical indications. 
The pharmacological targeting of DR has proven to be a very effective approach to 
affect deficient functions in above-mentioned pathological conditions (Table 8). Several DA 
agents are already in clinical use for non-immune/non-oncological/non-autoimmune 
indications and have a usually favorable risk-benefit. DR agonists are currently used mainly in 
the treatment of PD, restless leg syndrome, and hyperprolactinemia, while antagonists are 
mainly used as antipsychotics and antiemetics. 
Pharmacological modulation of DA pathways can be gain also by use of indirectly 
acting agents. All the steps involved in DA synthesis, storage, and release, uptake and 
metabolism represent the target of several drugs already in use for non-immune indications 
(e.g. cardiovascular, neurologic, neuropsychiatric) (Cosentino and Marino, 2013). The 
established use of such DA drugs and the extensive available clinical experience would allow 
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the straightforward translation of the present results "from bench to bedside", through the 
development of well-designed clinical trial protocols. 
Upon this background, new mounting evidence should be documented through in vitro 
experimental approach using DA agents to potentiate the beneficial immune response through 
the action on specific DR (D1-like and/or D2-like family) and to pave the way to further 
clinical trials of DA agents as add-on medications in conventional treatments. The most 
appropriate agent among the many that are currently available should be chosen in the way to 
achieve modulation of targeted, specific immune cell function, which have been shown to hold 
a key function in defining pathological diseases. So far developed research direction(s), may 
help in the repurposing of established drugs for the novel, original and critical indications, with 
the potential to significantly increase the therapeutic efficacy of current conventional, already 
established and in use, treatments. 
The immunoregulatory effects of DA are becoming more evident, but the actual role of 
DA and DR in the regulation of pathologic conditions, as well as in specific immune responses, 
demands further studies. From a pharmacologic standpoint, the availability of several DA 
agonists coupled to their potential application in vitro, in stimulation/inhibition of functional 
activities of immune cells, appears provocative. Nonetheless, a clear understanding of the 
pharmacology, in vivo effects and potential side effects of these agents requires careful 
interpretation and clarification. 
 
Table 9. Arguments for taking in account DA agonist, and not DA antagonist 
Focus of presented work is on DA agonists for several strong reasons: 
1. Preliminary evidence (in vitro/animal models/clinical trials) have shown specific 
modulation of functional immune response among key immune cells involved in certain 
pathological conditions. 
2. Dopamine agonists are usually with a very complex binding properties for either D1-
like or D2-like family receptors and so far obtained pharmacological agonist and antagonist 
effects on physiological cell function(s) represent a useful tool to clarify the extent of DA 
modulation involvement in important immunological response(s). 
3. The molecular and pharmacological heterogeneity of DR potentially represents an 
opportunity to develop targeted immunomodulating strategies, towards D1-like or D2-like 
receptors-specific agonist, targeting DR in the brain or in the periphery, and consequently 
leading to a pharmacological challenge in producing selective drugs that may be of use in the 
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DA-related pathologies. 
4. The range of different DA agonists already in clinical use represent a good starting 
point for a further understanding of potential ways of immunomodulatory response and 
possibly drug repurposing. 
5. Antagonist are not part of our focus, since this pharmacological drug group (in the first 
line D2-like antagonist, used like neuroleptics/antipsyhotics) has a lot of side effects, in 
comparison to DA agonist that have safer pharmacological profiles, display a greater 
therapeutical index and usually favorable risk-benefit ratio. 
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Dopaminergic modulation of CD4+ T cells 
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1.7.1. Introduction to immunity 
 
The physiological function of immune system is to protect the host from foreign 
infection, but also from injury. The collective and coordinated response of the cells and 
molecules elicited by foreign substances is called immune response. A wide range of 
mechanisms is involved in the normal protection of the human body from infection and foreign 
substances, which are capable of causing tissue injury and eventually disease. Studies of the 
response to infectious agents, inflammation process (such as occur in autoimmune or 
neuroinflammatory diseases), transplanted organs and tumour immunology, helped shape 
modern immunology and the study of the immune system as a model system in molecular cell 
biology have yielded dramatic advances in our understanding of the mechanisms of immunity. 
Immune system comprehends two types of responses: early response, known as innate 
immunity, and late, adaptive or acquired immunity. Adaptive immunity is specific, specialised 
and has prodigious memory cells, which increase future responses. It is divided into two types 
of responses, humoral and cell-mediate immune response. The humoral immune response is the 
main defence mechanism against extracellular microbes and their toxins. Most recognisable 
cells of humoral immune response are B lymphocytes, that after the encounter of foreign Ag 
transform into plasma cells and produce specific Ab. The cell-mediated immune response is 
defending human organism against viruses and some bacteria. Hallmark cells are T 
lymphocytes, that are able to recognise intracellular Ags of microbes and destroy these 
microbes or all infected cell (Abbas et al., 2005). 
 
1.7.2. Biology of the T lymphocyte immune response 
 
T lymphocytes originate from stem cells in the bone marrow, mature in the thymus 
through complex stages of developmental selection upon maturation and finally acquire 
phenotype and functional characteristics of mature cells, upon which leave the thymus, enter 
the bloodstream and populated the peripheral lymphoid organs as naïve T cells ready to be 
activated after the recognition of an Ag. T cells have restricted specificity for Ag; they 
recognise only peptide Ag that are attached to host proteins that are encoded by genes of major 
histocompatibility complex (MHC) and that are expressed on the surface of other cells, hence, 
T cells respond to cell surface-associated but not soluble Ag. T cell-mediated immunity is an 
adaptive process of developing Ag-specific T lymphocytes to eliminate pathogenic treat or 
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development of malignant cells. T cell-mediated immunity can also involve abnormal 
recognition of self-Ag, leading to autoimmune inflammatory diseases.  
The most important marker of T cells is a unique, surface T cells receptor (TCR), and 
invariant proteins CD3 and ζ chain, that together shape the TCR complex. Antigen presentation 
consist of coordinated reaction between TCR and MHC molecules expressed on APCs (so-
called “signal 1”) and co-stimulation mediated by CD28 and CTLA 4 (cytotoxic T-
lymphocyte-associated protein 4) molecules expressed on T cells and B7 family of molecules 
(CD80 and CD86) expressed on APCs (“signal 2”), during which T cell becomes activated. 
Recognition of Ag by the immune system evokes a coordinate number of changes in 
lymphocyte subsets allow them (i) to eliminate or neutralise potential harmful agents and (ii) to 
respond more rapidly and appropriately after renewed Ag encounter, a process referred to as 
immunological memory.  
Naïve T cells (that have not yet encountered foreign Ag), circulate through the blood 
and the lymphatic system and reside in secondary lymphoid organs. Presentation of Ag to naïve 
T lymphocytes lead to activation and subsequent complicated patterns of differentiation and 
clonal expansion of Ag-specific lymphocyte pool that will give rise towards short-lived 
effector T cells that will combat the infection. At the end of the immune response, most of the 
effector cells die by apoptosis, and an eventually small portion of these cells will become 
memory T lymphocytes (Zhu et al., 2010). In response to the activation, T cells start to produce 
and secrete diverse cytokines to promote further proliferation and differentiation and to 
potentiate effector function of other immune cells, such as macrophages, DC, and NK cells 
(Levite, 2012). 
To conclude, pursuant to their activation, T lymphocytes can be discriminated into three 
subsets: unprimed, naïve T cells (which have not yet encountered Ag), effector T cells (with 
specialised functions), and memory T cells (long-lived cell capable of being reactivated in a 
case if an infection is reoccurred). 
 
1.7.3. Polarisation of naïve T cells 
 
Upon activation, signals from the TCR and co-receptors alter the pattern of gene 
transcription for proliferation and differentiation into effector T helper cells (Th1, Th2, or Th17 
cells). The effector activity of the T cell is accomplished through the cytokines produced by 
surounding cells. TCR binding to Ag and initial T-cell activation involves a cascade of 
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signalling events that include the transcription factors NF kB, nuclear factor of activated T cells 
(NFAT), and activator protein 1 (AP-1). The production of IL-2 in response to T-cell activation 
is important for the initial proliferation and differentiation of the T cell.  
All Th subsets are produced from a non-committed population of precursor T-cells 
which are polarised upon contact with APC. Besides the presence of specific cytokines 
produced by the innate immune system responding to microbial and parasitic Ag, or allergens, 
the differentiation of naïve CD4+ T cells into effector T helper cells requires the engagement of 
TCR and costimulatory molecules. Depending on the signal brought by APCs and surrounding 
microenvironment naïve CD4+ T cells can differentiate into various effectors cell populations 
with specialised functions: Th1, Th2, and Th17 cells. These Th subsets secrete a defined, and 
largely non-overlapping, subset of cytokines acting on distinct target cell populations. 
Non-polarised, naïve Th0 precursor can differentiate into Th1 after activation in the 
presence of IL-12 (Moser and Murphy, 2000) and IL-18 (Rodriguez-Galan et al., 2005), both 
derived from DCs or by IFN-γ derived from NK. Importantly, recent studies using IL-12-/- 
knockout mice have shown that stimulation of T cells with IL-18 and anti-CD3 failed to 
provoke IFN-γ producing cells, but markedly upregulated IL-12Rβ2 expression, suggest that 
IL-18 cannot drive Th1 cells alone, but it is an important cytokine to enhance IL-12 signalling 
and to promote Th1 development (Chang et al., 2000). Although IL- 12 appears to be a key 
player in Th1 development, Th1 cell polarisation shown to occur in IL12-/- mice indicates that 
also other mechanisms and pathways exist. DC recognising DNA, RNA, or bacterial structures, 
such as lipopolysaccharide (LPS), but also viruses as intracellular parasites, have been shown 
to promote differentiation towards Th1 phenotype (Amsen et al., 2004). Th1 cells thus direct 
cell-mediated inflammatory reactions to control intracellular pathogen infections effectively 
(Figure 7). 
Differentiation of T cells towards strong Th2 phenotype occurs in answer to parasitic 
helminths, fungal products, toxins such as cholera and allergens, which cause chronic T cell 
stimulation, often without any innate immune response or macrophage activation, in the 
presence of IL-4 derived from B cells or lymphoid DC (Kapsenberg, 2003). Further, while IL-4 
is an important differentiation factor for Th2 cells, IL-4 production by non-T cells is not 
absolutely required for Th2 cell differentiation (Schmitz et al., 1994). Recently, other cytokines 
such as IL-33 (Schmitz et al., 2005) and IL-21 (Wurster et al., 2002) have been shown to 
potently induce Th2 cytokine production and downregulate Th1 responses. Thus, investigators 
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seek to identify alternative mechanisms that can direct differentiation of CD4+ T cells into Th1 
and Th2 lineages (Reizis and Leder, 2002). 
Recent evidence showed that former dogma that IL-12-driven Th1 response as a critical 
contributor to inflammation has to be revised since it has been found that IL-23 induced 
production of CD4+ T cells that secrete proinflammatory cytokine IL-17A (Palmer and 
Weaver, 2010). These cells were characterised as a separate Th subset called Th17. Initially, it 
has been described that result of Ag stimulation of DC results in IL-23 secretion, which 
induces T cell production of IL-17 in a T cell receptor-independent manner (Kolls and Lindén, 
2004). Bettelli et al., demonstrated in transgenic mice, that IL-23 is not the differentiation 
factor for the generation of Th17 cells since the IL-23 receptor is not expressed on naïve T 
cells, and it was not possible to generate de novo IL-17-producing T cells from sorted naïve T 
cells. Instead, IL-6 and TGF-β together induce the differentiation of pathogenic Th17 cells 
from naïve T cells (Bettelli et al., 2006). However, IL-23 stabilises differentiating Th17 cells 
and leads to the further maturation of Th17 cells (Zhou et al., 2007) further supporting its 
importance for full and sustained differentiation of Th17 cells. 
It seems that TGF-β is absolutely required to induce RORγt, but its function is inhibited 
by high concentration of TGF-β, suggesting a biphasic effect of this cytokine. TGF-β is 
required to induce expression of IL-23R, since it is not present originally on naïve T cells. Only 
when additional cytokines: IL-6, IL-23 or IL- 21 are present, RORγt is relieved from inhibition 
and naïve T cells can begin transcribing IL-17 (Manel et al., 2008). At a molecular level, it 
seems that the differentiation conditions of mouse and human Th17 cells do not appear to be 
different (Korn et al., 2009). Interestingly, IL-17 cannot amplify Th17 cells because IL-17 does 
not act as a growth or differentiation factor for the Th17 lineage (Korn et al., 2009). 
The effector cytokines that are subsequently produced by Th1 and Th2 cells (such as 
key cytokines IFN-γ and IL-4, respectively) can potentially feed back to amplify or Th1 or Th2 
cells and further enhance differentiation of the respective T cell subset. 
Th17 cells have been recognised as a lineage separate from Th1 and Th2 cells, and also 
differentiation of Th17 cells is inhibited by factors, both IFN-γ and IL-4, that support Th1/Th2 
differentiation (Harrington et al., 2005; Park et al., 2005). 
To conclude, since it has been shown that INF-γ produced by Th17 inhibits Th2 
developmental pathway, IL-4 produced by Th2 inhibits Th1 development, both INF-γ and IL-4 
inhibit Th17 polarisation ruth, and also IL-17 inhibits Th1, appear that all effector CD4+ T 
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cells exert certain suppressive activities holding the balance in immune system homeostasis 
(Corthay, 2009). 
 
1.7.4. Maturate and developed T helper subsets 
 
Th1 cells mainly produce IFN-γ, and to a lesser extent IL-2 and IL-12, TNF-α, 
lymphotoxine α (LTα) and lymphotoxin, that are all involved in enhanced pro-inflammatory 
cell-mediated immunity (Zhu and Paul, 2008). Th1 cells stimulate anti-microbicidal and 
cytotoxic effector functions, activate macrophages and recruit and activate NK cells, CD8+ T 
lymphocytes, and stimulated B cells to differentiate into plasma cells. Th1 cells drive a cellular 
immune response to fight viruses and other intracellular pathogens, but also to eliminate 
cancerous cells. 
 
 
Figure 7. Differentiation of naïve CD4+ T cells into diverse subset of effector cells, their characteristic 
cytokines production and specific transcription factors. 
 
Th2 cells basically promote non-inflammatory immediate immune responses through 
the production of cytokines that include IL-4, IL-5, IL-6, IL-10 and IL-13 (Mosmann and 
Coffman, 1989; Fiorentino et al., 1989; Le Gros et al., 1990). Th2 cells drive a “humoral 
immunity” pathway and up-regulate Ab production to fight extracellular organisms. This type 
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of response is particularly important for host defence or resistance against parasitic infections. 
Overactive Th2 cells recruit eosinophils and maintain their function, but also cause 
macrophages to become alternatively activated. In contrast to Th1 cells, Th2 cells direct and 
enhance B cell activation and Ab production (particularly IgE) to promote allergic reactions 
and eosinophilic inflammation important in the induction of asthma.  
Mature Th17 cells produce mainly IL-17, which is best known for its participation in 
the recruitment and survival of polymorphonuclear neutrophils (PMN) (Schwarzenberger et al., 
2000; Kolls and Lindén, 2004; Yu and Gaffen, 2008). Once secreted, IL-17 in the bone marrow 
seem to induce stromal/ fibroblast expression of both G-CSF and stem cell factor, an effect that 
increases neutrophils differentiation and production, and by directly blocking neutrophil 
apoptosis promotes greater circulating PMN numbers (Schwarzenberger et al., 2000). In 
macrophages, IL-17 induces TNF-α, IL-1β and IL-6 production (Jovanovic et al., 1998). IL-17 
further contributes to PMN influx by inducing endothelial cells CXC chemokine release and 
NO production, which may increase vascular permeability (Kolls and Lindén, 2004; Miljkovic 
et al., 2003). Th17 cells mediate responses against extracellular bacteria, which cause acute 
inflammation such as Streptococcus, and fungi (Weaver et al., 2006). It has been confirmed 
that patients lacking these cells have frequent Candida and Staphylococcus infections, and in 
additionally, they are implicated in the induction of many organ-specific autoimmune diseases 
(Zhu and Paul, 2008). 
The differentiation of naïve Th cells towards Th1, Th2, and Th17 cells is regulated by 
the master transcriptional regulator factors T-box expressed in T-cells (T-bet), GATA-binding 
protein-3 (GATA-3) and orphan nuclear receptor RORγt (RORγt) (Korn et al., 2009), 
respectively (Table 10). The loss of the IL-12Rβ chain is thought to be a marker for Th2 
commitment, while the transcription factor GATA-3 is lost in Th1 cells. These functionally 
distinct cytokine-producing T cell lineages can be also distinguished by expression of master 
transcription factors. Evidence suggests that signal transducer and activator of transcription 4 
(STAT4) regulated IL-12Rβ expression and T-bet expression are associated with the 
development of Th1 cells (Nishikomori et al., 2002) while GATA-3, STAT5, and c-Maf are 
associated with the development of Th2 responses (Mathew et al., 2001; Zhu et al., 2006; 
Chakir et al., 2003). Recent experimental data suggests that naïve T cells tend toward a Th2-
like development through GATA-3 (which down-regulates the STAT4/ IL-12Rβ pathway) 
unless T-bet is activated (Usui et al., 2006). Once T-bet is activated, GATA-3 is downregulated 
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suggesting that the role of T-bet is to control GATA-3 levels rather than to positively regulate 
the IFN?γ gene as originally proposed (Usui et al., 2006). 
 
Table 10. Signature characteristic molecules of different CD4+ T cell subsets 
CD4+ Th 
designation 
Cytokines 
produced 
Cellular 
targets 
Transcription 
factor 
Proximal 
regulators 
Homing 
receptors 
Th1 IL-2, IL-3, 
IL-15, IFN-
γ, TNF-α, 
TNF-β, 
GM-CFS 
B cells, 
macrophages, 
NK cells 
T-bet, STAT4 IL-12, IFN-γ  
CXCR3, 
CCR5 
Th2 
IL-4, IL-5, 
IL-6, IL-
13, IL-21, 
TNF-β, 
GM-CFS 
B cells, mast 
cells, 
eosinophils 
GATA-3, 
STAT5 
IL-4, IL-25, 
IL-33 
CCR4, 
CCR3 
Th17 
IL-17A, IL-
22, IL-21 
Neutrophils, 
macrophages, 
endothelial 
cells 
RORγt, STAT3 IL-6, IL-1β, 
TGF-β, IL-21, 
IL-23 
CCR6, 
CCR4 
(Data adapted from Sallusto et al, 2012; Miossec and Kolls, 2012) 
 
The driving factors that dictate the quality of the immune response are recognised as  
quantitative events that affect the specification, differentiation and commitment of Th cells. In 
vitro approaches have been of essential importance in the elucidation of the different 
quantitative factors determining the development and commitment of Th cells. New 
discoveries in terms of previously unknown cytokines, expanded numbers of potential helper T 
cell subsets and the influence of identified factors and pathways triggered by different 
pathogens. 
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1.7.5. Phenotypical and functional charactherisation of different T cell subsets 
 
It was originally believed that chemokine receptor expression could reliably distinguish 
the different subsets, and although there is some functional division, it is becoming clear that in 
vivo this association is less well defined. So far, there are only a few cell surface markers that 
can reliably differentiate between Th1 Th2 and Th17 cell populations (Table 11).  
 
Table 11. T helper cells related chemokine markers and transcriptional factors 
 Receptor  Description/Function References 
 
 
 
 
 
 
Th1 
CXCR3 
(CD183) 
Receptor for IP-10, Mig, and I-Tac Bonecchi et al., 1998 
CCR5 
(CD195) 
Receptor for RANTES, MIP-1α, β Bonecchi et al., 1998 
STAT-4 
Transcription factor that regulates IL?12Rβ 
expression and drives Th1 development  
Nishikomori et al., 
2002 
T-bet 
Transcription factor overexpressed in Th1 cell 
populations may inhibit GATA-3 
levels to promote Th1 development 
Usui et al., 2006; 
Chakir et al., 2003 
 
 
Th2 
CXCR4 
(CD184) 
Receptor for CXCL12, co-receptor for HIV-1 Galli et al., 1998 
CCR3 
Chemokine receptor for MIP-1α, MIP-1β, 
RANTES, MCP-2, 3, and 4, and eotaxin 1, 2, 
and 3 
Sallusto et al., 1998; 
Bonecchi et al., 1998 
STAT6 
Transcription factor was shown to regulate Th2 
recruitment and effector function as well as 
eosinophilia 
Mathew et al., 2001 
GATA-3 
Transcription factor upregulated in developing 
Th2 cells, enhances IL-4, IL-5, and IL-13 
production. Downregulates IFN-γ production 
Zhu et al., 2006; 
Chakir et al., 2003 
 
 
 
CCR4 
(CD194) 
Receptor expressed on Th2 cells, skin-homing T 
cells and IL-17-producing cells 
Acosta-Rodriguez et 
al., 2007 
CCR6 Receptor expressed on T cells (regulatory and Acosta-Rodriguez et 
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Th17 memory), B cells and DC, shown to be involved in 
mucosal humoral immunity, allergic asthma and 
intestinal T-cell homing, particularly at epithelial 
sites 
al., 2007; Cook et 
al., 2000; Singh et 
al., 2008 
RORγt 
Transcription factor that (together with Runx1) 
regulates IL-17 transcription 
Zhang et al., 2008; 
Korn et al., 2009 
(The table was drawn based on the compilation of findings revealed by several research groups 
worldwide) 
 
1.7.6. Plasticity and commitment of helper T cells 
 
Although once thought to be permanently polarised and committed stable lineages, 
nowadays it is apparent that conversion between these cellular phenotypes can occur depending 
on a range of altering genetic factors and micro-environmental signals that are able to promote 
flexibility in the programmes of this cells, so these effector T cell subsets can rapidly react in 
order to promote the most effective type of immune response and to allow flexibility in T cell 
programmes. Even though the cytokine profile may initially not be entirely polarised, with 
differentiating T cells producing a combination of both Th1 and Th2 cytokines, chronic 
stimulation leads to unequivocal, terminally differentiated phenotypes. In fact, a large body of 
evidence suggests that there is a conversion between Th1, Th2 and Th17 populations under 
defined activation conditions (Abbas et al., 1996; Zhu and Paul, 2008; O’Garra et al., 2011). In 
vitro has been demonstrated that Th17 cells are very unstable and that they are able to change 
their cytokine production from IL-17 to INF-γ in chronic immune responses (Annunziato et al., 
2007; Hirota et al., 2011). 
In cases where the immune response is strongly fixed towards one phenotype, the 
prevalent cytokine imbalance has been associated with disease pathogenesis. For example, a 
dominant Th2 response has been associated with atopic dermatitis, asthma, and the outgrowth 
of a number of cancers (Pellegrini et al., 1996; Nakazawa et al., 1997), a dominant Th1 
response has been described for sarcoidosis, tuberculosis, and CIA (Mauri et al., 1996), while a 
Th17 response is shown to be important in chronic inflammatory diseases such as psoriasis, 
RA, ankylosing spondylitis, Crohn’s disease, MS, chronic obstructive pulmonary disease 
(COPD) and other conditions (Miossec and Kolls, 2012). 
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1.7.7. T helper subsets role in disease pathology 
 
Inappropriate or poorly controlled effector T cells can cause host pathology and are 
particularly deleterious when directed against self or ubiquitous environmental or commensal 
Ags, which cannot be effectively cleared. In this setting, persistent effector T cell responses 
drive chronic inflammatory disorders such as autoimmunity and allergy. Effector T cell 
responses are therefore normally under stringent regulatory control.  
An overactive Th1 pathway is aggressive and can generate organ-specific autoimmune 
disease. The overactivation of Th2 pathway leads to allergy and IgE-related disorders. It has 
been recently reviewed that specific Th17 subpopulation might, along with Th1, contribute to 
neurotoxicity, possibly through the secretion of IL-17 and/or release of a cytolytic enzyme 
(granzyme B) and directly injure DA neurons by signalling through the Fas/FasL system 
(Appel et al, 2009). Increasing evidence shows that IL-17 family members play an active role 
in inflammatory diseases, autoimmune diseases, and cancer. 
 
1.7.8. T regulatory cells subset 
 
CD4+CD25+ regulatory T lymphocytes are specialised T cells that play a crucial role in 
the control of immune homeostasis, contributing to the maintenance of immune homeostasis 
and immune responses to foreign and self-antigens setting up and maintenance immune 
tolerance (Sakaguchi 2004; Sakaguchi et al. 1995). The role of Treg implies critical 
involvement in immunologic diseases, tumour immunity, and transplantation tolerance. Mice in 
which Treg cells are absent or depleted are more prone to development of several autoimmune 
and inflammatory diseases (Ochs et al., 2007; Brunkow et al., 2001) and numerous studies in 
animal models of autoimmunity showed that the disease could be reversed by the adoptive 
transfer of Treg cells (reviewed in Sakaguchi et al., 2006). 
Treg suppress the function of other T effector cells by the employment of several 
mechanisms: (i) cell-cell contact (Shevach, 2006), and/or (ii) production of their specific 
cytokines, including TGF-β and IL-10 (Zhu et al., 2008). Activated Treg produce IL-10 and 
TGF-β, powerful immunosuppressants that are able to inhibit Th1 cellular immunity and Th2 
mediated antibody production and therefore induce tolerance, hence, Treg have been identified 
as important mediators in the Th1/Th2 balance. 
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So far, several types of Treg cells have been defined; such as “naturally occurring” ones 
that originate directly from the thymus in contrast to other types of T regulatory cells such as 
Tr1 and Th3, which likely develop from conventional CD4+CD25- T lymphocytes (Teffs) in 
the periphery (Table 12) (Rutella and Lemoli, 2004; Thompson and Powrie, 2004; Piccirillo 
and Thornton, 2004; Milojevic et al., 2008). 
Table 12. Key characteristics of Treg subsets. 
 
Phenotype 
Associated 
markers 
Role 
Mechanism of 
suppression 
Natural 
Treg 
CD4+CD25high 
CD127low 
CTLA4+, 
GIRT+FoxP3+ 
CD127low 
Suppression of 
autoreactive T cells 
Contact-dependent, 
granzyme B-
dependent, produce 
TGF-β 
Tr1 CD4+CD25- CD45RBlow, 
FoxP3- 
Mucosal immunity, 
inflammatory 
response 
Through IL-10 
cytokine production 
Th3 CD4+CD25+ CD45RBlow, 
FoxP3+ 
Mucosal immunity, 
inflammatory 
response 
Through TGF-β 
cytokine production 
(data adapted from Milojevic et al., 2008) 
 
A characteristic marker of Treg cells is the transcription factor FoxP3. In humans, the 
Treg are a heterogeneous population, in which not all CD25+ cells are Treg (Baecher-Allan et 
al., 2005; Taams et al., 2001). Studies revealed that only those CD4+ cells that expressed very 
high levels of CD25, representing approximately 2–3% of total CD4 T cells, demonstrate the in 
vitro suppressive activity similar to that described in murine cells, while those who are 
expressing low-to-intermediate levels of CD25 do not exhibit suppressive activity directly in 
the in vitro experiments (Baecher-Allan et al., 2005). 
Treg express a high level of IL-2Rα (CD25) constitutively, and this notion highlights 
the crucial role of IL-2 in the development, survival and homeostasis (Fontenot et al., 2005; 
Malek and Castro, 2010), since it has been shown that deficiency of IL-2 or IL-2R may result 
in defects in Treg. IL-2 is able to activate STAT5, a transcription factor that binds to the Foxp3 
promoter, induce Foxp3 expression and hence contribute to Treg development (Yao et al., 
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2007; Burchill et al., 2007). Since Treg cells cannot produce significant amounts of IL-2, 
unlike activated effector CD4+ T cells, they are fully dependent on the IL-2 production by 
other cells in vivo, or exogenously added IL-2 in vitro conditions (Rubtsov et al., 2010). 
Nonetheless, Treg express several other surface markers of activation, including 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and glucocorticoid-induced tumour 
necrosis factor receptor (GITR) (reviewed in Piccirillo and Thornton, 2004). It is very difficult 
to distinguish activated CD4+ T cells from Treg on the basis of expression of surface 
molecules, since those molecules are not constitutively expressed in peripheral, naïve T eff 
cells but their expression is induced after activation. 
Recently, it has been described that CD127 expression is down-regulated in the Treg 
cells, inversely correlating with the expression of FoxP3 marker (Liu et al., 2006). CD127 is 
part of the heterodimeric IL-7 receptor that is composed of CD127 and the common γ chain, 
which is also shared by other cytokine receptors (IL-2R, IL-4R, IL-9R, IL-15R, and IL-21R). 
Studies have shown that IL-7R plays an important role in the proliferation and differentiation 
of mature T cells, and in vitro experiments show that the expression of CD127 is down-
regulated following T cell activation (Hofmeister et al., 1999; Fitzgerald et al., 2001). It has 
been shown that FoxP3 interacts with the CD127 promoter and might contribute to reduced 
expression of CD127 in Treg (Liu et al., 2006).  
To conclude, a population of Treg cells with a highly suppressive function can be 
identified based on a combination of surface markers such as CD4, CD25, and CD127. 
Based on the appropriate phenotypes (e.g. expression of CD25, CD127, CD45RA and 
FoxP3 markers), proliferation status in the physiological state, cytokine secreting capacity and 
in vitro suppressive activity, CD4+ Treg cells were divided into 3 distinct subsets: resting 
(naïve) Treg cells (nTreg, CD45RA+FoxP3lo), activated Treg (aTreg, CD45RA-FoxP3lo) and 
third subtype of cytokine-secreting CD45RA-FoxP3lo non-Treg cells (Miyara et al., 2009). 
Both nTreg and aTreg were suppressive in vitro, and the third subset has shown cytokine 
production without suppressive activity in vitro, suggesting that functional analysis of FoxP3+ 
subsets is essential for assessing immunological state in a variety of physiological and 
pathological immune responses (Miyara et al., 2009). 
The microenvironment plays a crucial role in the differentiation of classical Treg cells, 
but also in their expansion and function. The cytokines that have a major role in promoting the 
activities of Treg include TGF-β, as a critical differentiation factor for the generation of Treg 
cells (Chen et al., 2003) and IL-2 as a critical factor for induction and expansion of Foxp3+ 
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Treg (La Cava, 2008). Cytokines that promote Th17 responses significantly counteract the 
activation and functionality of the Treg (La Cava, 2008). 
1.7.9. Therapeutic approach using T regulatory cells 
Since the discovery of Treg cells, intense investigation has been conducted aimed at 
determining how they protect an organism and whether defects in their number and/or function 
contribute to the development of various pathologies.  
Deficiencies in Treg number and function lead to exacerbated lesions or accelerated 
disease progression in animal models of multiple sclerosis, inflammatory bowel disease, and 
rheumatoid arthritis (Atassi and Casali, 2008; Cosentino et al., 2012).  
A new study, in a mouse model of multiple sclerosis, shows that widely used IFN-β 
treatment induces upregulation of transcription factor FoxA1 and a new population of FoxA1+ 
regulatory T cells (Delgoffe and Vignali, 2014), which suppress conventional T cells via cell 
surface expression of programmed cell death 1 ligand (PD-L1). CNS-infiltrating autoreactive T 
cells are suppressed by FoxA1+ Treg cells upon activation in the presence of neurons and/or 
IFN-β treatment and inflammatory milieu via PD-L1–PD-1 interaction, which limits 
proliferation by inhibiting Akt and p38 phosphorylation or promotes cell death by inducing 
active caspase-3. The induction and function of FoxA1+ Treg cells results in ameliorated 
disease in animals (Delgoffe and Vignali, 2014). FoxA1+ Treg subset was found in patients with 
MS who responded to IFN-β therapy (Liu et al., 2014). 
Treg seem to be key neuroprotective immunomodulators in acute experimental stroke 
(Kuric and Ruscher, 2014) as well as in animal models of neuronal injury, possibly through 
modulation of microglial oxidative stress and inflammation (Reynolds et al., 2007). 
Comprehensive evaluation of the relevance of the dopaminergic modulation of CD4+ T cells, 
in particular, Treg subset in PD is burning concern. Preliminary evidence in patients with 
neurodegenerative disease indicates the occurrence of specific functional alterations affecting 
the Treg subset (Saunders et al., 2012). Kuric and Ruscher, 2014 provide evidence data that 
DA can act as a potential immunomodulator by attenuating inflammation in the post-ischemic 
brain (Kuric and Ruscher, 2014). Since Treg function has been reported to profoundly affect 
neurodegenerative processes and dopaminergic pathways are identified in Treg cells, Treg cell 
subset should be reconsidered as a potential target for novel and selective neuroprotective 
strategies. 
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Despite their essential role in maintaining the integrity of the host, Treg may act as 
detrimental players in the process of cancer development and progression in some types of 
malignancies. Treg cells act to diminish anti-tumour immunity by suppressing the effector 
functions of a variety of immune cells, including Th1 cells, CD8+ T cells, NK cells and 
tumour-infiltrating DCs. High levels of Treg have been found in many malignant disorders 
including lung, pancreas, and breast cancers. Treg may also prevent anti-tumour immune 
responses, leading to the increase in mortality. So far employed immunotherapies of cancer 
include (i) antibody blockade of inhibitory molecules (Hodi and Dranoff, 2010), (ii) adoptive T 
cell transfer (Galluzzi, et al., 2012), and (iii) autologous cell-based vaccines (Kantoff et al., 
2010). The majority of current cancer immunotherapies predominantly rely on the ability of 
CD8+ T cells to fight against tumours, but it should be noticed that Treg cells as well could be 
a potential target. 
As understanding of regulatory T cell populations is constantly growing, convincing 
evidence does support the hope that in vitro expanded Treg, with the potential to be modulated 
and then, as an adoptive cell transferred, could serve as a therapy and improvement of the 
certain diseases (neuroinflammatory, autoimmune or cancer progression). 
 
1.7.10. T naïve/memory cell subset 
 
Naïve T cells, are the most homogenous representatives of CD4+ subsets, circulating in 
the blood, expressing CCR7, a chemokine receptor involved in T-cell homing into lymphoid 
tissue, L-selectin (CD62L) and LFA-1 (leukocyte function antigen-1), that are mediating the 
rolling, adhesion and extravasation of the cells in peripheral lymph nodes and mucosal 
lymphoid organs. Naïve T cells are characterised by CD45RA molecule expression. 
Unlike naïve T cells that live for few months or effector cells that disappear at the end 
of the immune response, memory T cells may survive in lymphoid organs and peripheral 
tissues for years. In order to understand the memory T cells function, efforts have made to 
define the properties that distinguish the naïve, effector and memory T cells, including their 
phenotype, distribution, and lifespan. It has been also shown that not all memory cells have the 
equal life span. The short-lived activated memory cells mediate early memory response, while 
later memory is controlled by long-lived resting cells (Tough and Sprent, 1995). 
The memory lymphocytes CD4+ T cell subset is easily activated and capable of being 
reactivated if the same Ag is reoccurred, performing immediate effector functions in peripheral 
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tissues or undergo activation and clonal expansion in lymphoid organs to mount a secondary 
immune response. Almost two decades ago Sallusto et al., have proposed division of memory 
cells into two distinct yet interconnetcted subsets, T central memory and T effector memory 
cells (Sallusto et al., 1999). Initially, division into TCM and TEM was based on two diverse 
criteria: absence/presence of immediate effector function and the expression of peculiar 
homing capacity dictated by specific receptors allowing cells to migrate to secondary lymphoid 
organs or into non-lymphoid tissues (Sallusto et al., 1999). In the human peripheral blood, the 
expression pattern of the lymph node–homing receptors, CD62L and CCR7 is linked to the 
functional status of memory CD4+. Reactive memory is mediated by TCM cells that home to 
secondary lymphoid organs, have little or no effector function, but are able to readily 
proliferate and differentiate into effector cells in response to Ag stimulation. On the other hand, 
protective memory is mediated by TEM that has the ability to migrate to non-lymphoid organs, 
such as inflamed peripheral tissues and exhibit immediate effector function. 
The T effector memory cells express CCR7 and CD62L, residing in lymphoid organs 
and producing IL-2 upon stimulation. Some of these have been found to migrate into certain 
inflammation sites, depending on the expression of chemokine receptors such as CCR4, CCR6 
and CXCR3. TEM cells that lack CCR7 and have low CD62L expression have intensive effector 
functions. Upon stimulation, they produce IFN-γ and IL-4 (Sallusto et al., 1999). So far, data 
support the notion that the two subsets are located in distinct tissues, with TCM cells in lymph 
node, spleen and blood, and TEM cells in spleen, blood and nonlymphoid tissues (Reinhardt et 
al., 2001). 
Generation of memory cells is still intriguing issue. So far, the classical view of the 
generation of memory cells (“linear” pathway) and revised model for memory generation 
called, the “intersecting” pathway model has been described. 
Following Ag stimulation, naïve T cells become activated, begin to proliferate and 
differentiate into Teff cells, which ultimately undergo activation-induced cell death. After Ag 
clearance, a proportion of Ag-primed T cells persists as a long-lived memory T cells. So, 
memory T cells are assumed to arise sequentially from Teff cells, through a so-called “linear” 
pathway. 
On the other hand, Moulton and Farber (2006) have proposed a revised model for 
memory generation called, the “intersecting” pathway model. This model takes into account 
proliferative turnover, acquisition of effector function and survival. In the Ag-dependent 
pathway, Ag-stimulated naïve CD4+ T cells upregulate CD25 and downregulate IL-7 receptor 
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expression, resulting in rapid IL-2-driven proliferation and the acquisition of effector function 
that increases with Ag exposure. In the Ag-independent pathway, naïve T cells (CD25lowIL-
7Rhigh) undergo slow proliferative turnover driven by host factors such as IL-7, with increased 
turnover driving differentiation to memory-phenotype cells with effector capacity. The 
intersection of the effector differentiation (Ag-dependent) and memory differentiation (Ag-
independent) pathways occurs by Ag removal, resulting in the rapid down-regulation of CD25 
and upregulation of IL-7 receptor, forming “pre-memory” T cells. These cells respond to 
homeostatic survival factors and differentiate into a stable memory T-cell population (Moulton 
and Farber, 2006). 
Subsets of TCM and TEM with distinct functional programs can be identified according to 
the expression of surface molecules. The first markers used to separate memory T cells into 
diverse subpopulations were co-stimulatory molecules CD27 and CD28. Further, it has been 
discovered that human TCM cells are CD45R0+ memory cells that constitutively express CCR7 
and CD62L, receptors required for cell extravasation through high endothelial venules (HEV) 
and migration to secondary lymphoid organs (Forster et al., 1999). But it was shown that T 
naïve cells also express CCR7 and CD62L, so functional test have shown that TCM cells have 
higher sensitivity to Ag stimulation, are less dependent on co-stimulation, and up-regulate 
CD40L to a greater extent, and following TCR triggering, produce mainly IL-2. After the phase 
of initial proliferation, they efficiently differentiate into Teff cells that produce large amounts 
of characteristic cytokines such as, IFN-γ or IL-4. On the other hand, human TEM lost the 
constitutive expression of CCR7, and display characteristic sets of chemokine receptors and 
adhesion molecules, required for homing to inflamed tissues. Further, TEM cells are 
characterised by fast effector function, following Ag stimulation, mirrored in the production of 
IFN-γ, IL-4, and IL-5 cytokines (Sallusto et al., 2004). Within the tissues, however, TCM and 
TEM show typical patterns of distributions. TCM are augmented in lymph nodes and tonsils, 
whereas lung, liver, and gut contain greater proportions of TEM (Campbell et al., 2001).  
More recent studies demonstrated that TCM cells differentiate to Teff cells expressing 
receptors for inflammatory chemokines and producing large amounts of cytokines in response 
to homeostatic cytokines (Geginat et al., 2001). In response to IL-7 and IL-15, CXCR3+ TCM 
will differentiate to Th1, whereas most CCR4+ TCM will differentiate to Th2, consistent with 
the notion that these subsets are pre-committed. 
Combined expression of adhesion molecules and chemokine receptors on TCM or TEM 
will allow tissue-specific migration. Thus, for example, the simultaneous expression of CLA 
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and CCR4 identifies skin homing T cells (Campbell et al., 1999), whereas the expression of 
α4β7 and CCR9 is characteristic of gut-homing T cells (Zabel et al., 1999).  
There has been disagreement about what happens to CD4+ T memory cells upon 
stimulation in vitro. According to some authors when stimulated in vitro, memory T cells show 
low-activation threshold and vigorous proliferation (Sallusto et al., 2004), while some other 
authors claim that CD8+ T cells require only a short period (6–24 h) of interaction with Ag to 
undergo an Ag-independent period of programmed expansion and differentiation, and CD4+ T 
cells may require several days of interaction with Ag for optimal activation and expansion 
(Ravkov and Williams, 2009). Though both TCM and TEM have a high responsiveness to Ag 
stimulation, the expansion potential decreases from TCM to TEM (Geginat et al., 2003). The 
reduced proliferative capacity correlates with a decrease in telomere length and with an 
increased propensity to undergo apoptosis. 
It has been shown that percentage distribution of each of memory subsets within the 
CD4+ T cells can vary depending on previous experience. Hence, in Ag-primed individuals, 
tetanus toxoid (TTd)-specific CD4+ T cells can be detected in circulating TCM and TEM up to 
10 years after Ag stimulation, and in the case of booster immunisation their frequencies 
increase in both subsets (Sallusto et al., 1999). Further, HIV- specific T cells largely belong to 
the TEM subset, whereas CMV-specific T cells are predominantly found in a subset called 
TEMRA (terminally differentiated central memory subset) (Champagne et al., 2001). 
 
1.7.11. Dopaminergic modulation of peripheral CD4+ T lymphocytes 
Although it is well established that sympathoadrenergic system plays an active role in 
the cross-talk between the nervous and the immune system (Friedman and Irwin, 1997; 
Elenkov et al., 2000), up to several years ago, it was generally accepted that CAs were 
produced exclusively by adrenal gland and neurons. Catecholaminergic modulation of the 
immune response was assumed to be mediated by CAs released by nerve terminals directly in 
lymphoid tissues and/or by adrenal cells in the bloodstream to act on immunocompetent cells 
expressing dopaminergic (Ricci and Amenta, 1994) and adrenergic receptors (Khan et al., 
1986). Interactions between the nervous and immune systems occur through the hypothalamic–
pituitary axis and through sympathetic/parasympathetic innervations of primary and secondary 
lymphoid organs. Immune system cells activity is regulated by interactions of the receptors on 
their surface and appropriate endogenous mediators, such as neurotransmitters, neuropeptides, 
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hormones, and cytokines. These “messengers” molecules produced by immune cells are 
actually functioning as mediators of the neuro-endocrine-immune network. The ability of 
CD4+ cells of the immune system, to receive signals from the nervous as well as the endocrine 
system is dependent on the expression of receptors for neurotransmitters and neurohormones. 
In the past 20 years, DA has been increasingly acknowledged as a key transmitter in 
mediating bidirectional communication between the nervous system and the immune system. 
Numerous studies support the immunomodulating role of DA, wich is a key molecule bridging 
this two systems (Basu and Dasgupta, 2000; Sarkar et al., 2010). DA induces direct and potent 
effects on immune cells depending on i) concentration, ii) different state of cell activation and 
specific immune cell type/subtype, and iii) specific DR subtype/s and level of expressed on 
immune cell surface but also at the level of mRNA for these receptor proteins (Levite, 2016). 
Besides its action on the nervous system, DA plays a role in immune cell interactions. It 
has been shown that T cells synthesize DA through the tyrosine-hydroxylase/DOPA-
decarboxylase pathway, and express DR and DA transporter (DAT) on their plasma membrane 
(Cosentino et al., 2007; Sarkar et al., 2010). Latest studies have shown that immune system 
cells can be regulated by DA acting on DR present on the surface of T and B cells, eosinophils, 
monocytes, macrophages and microglia, DC and NK cells, and also neutrophils (Pacheco et al., 
2009). The presence of DR on immune cells and dopaminergic pathways demonstrated to 
regulate crucial human immune cells functions, support the importance of dopaminergic 
regulations in the immune response in physiological and pathological conditions. 
A) Expression of dopamine receptors on different T cell subsets 
 
Dopamine receptors have been found in cells of the innate and adaptive immune 
response, such as DCs, NK cells, macrophages/monocytes, granulocytes (Prado et al., 2012) 
and also B cells, CD4+ and CD8+ T cells (Besser et al., 2005; Sarkar et al., 2006; Watanabe et 
al., 2006; Nakano et al., 2009, Kustrimovic et al., 2014). So far, studies performed with human 
T cells suggested that both D1-like (DR D1, DR D5) and D2-like (DR D2, DR D3 and DR D4) 
receptor types contribute to the regulation of T cell functions (Sarkar et al., 2006; Levite, 
2016). Various CD4+ T cell subsets have shown to express different arrangements of DR 
(Levite et al., 2001; McKenna et al., 2002; Ilani et al., 2004; Besser at al., 2005; Sarkar et al., 
2006; Watanabe et al., 2006; Cosentino et al., 2007; Nakano et al., 2009; Pacheco et al., 2009; 
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Prado et al., 2013; Kustrimovic et al., 2014; Kustrimovic et al., 2016) offering different 
possibilities for modulation and manipulation of dopaminergic pathways on these cells. Both, 
human Teff and Treg expressed D1-like and D2-like receptors on their surface (Cosentino et 
al., 2007).  
Kustrimovic et al., 2014 recently demonstrated the cell surface expression of all the 5 
DR types in human CD4+ T cell subsets, namely: naïve, TCM and TEM cells with a different 
expression patterns showing that naïve T cells express more D1-like than D2-like receptors, 
which on the contrary were higher expressed in TCM and TEM cells. The same group of authors 
investigate also the changes in DR expression during the in vitro activation and shown that 
expression of D1-like and receptors increased D2-like receptors was markedly elevated by 71-
84% and 55-97%, respectively. Another interesting finding of this study was that DR 
expression is higher in apoptotic than in resting viable cells, suggesting DR involvement in the 
apoptotic process of T cells (Kustrimovic et al., 2014). 
B) Dopamine and dopamine analogues-induced effects on T cell function  
Dopaminergic receptors expressed on various subsets of T cells can be activated by 
either DA or selective agonist, leading to a potent DA-induced effect on T cell function.  
Studies showing pro-apoptotic effects of DA typically used concentrations of 10–500 
μM (Bergquist et al., 1997) or even 1 mM (Del Rio and Velez-Pardo, 2000). In agreement with 
those findings, in previous studies DA at concentration 100–500 μM induced a concentration-
dependent increase in the percentage of apoptotic cells (Cosentino et al., 2004). On the other 
hand, it was reported that in human PBMC DA decreases oxidative metabolism and apoptosis, 
possibly through activation of D1-like DR-dependent mechanisms, which results in a reduction 
of intracellular ROS levels and subsequent inhibition of apoptosis (Cosentino et al., 2004). 
Bergquist et al., 1997 claimed that B cells, but not T cells are sensitive to DA 
concentration 10 nM, which is in disagreement with later studies conducted by Besser et al., 
2005 and Levite, 2012 claiming that DA induce direct and very potent effects on T cells at low 
concentration of 10 nM, such as triggering beta1 integrin-mediated T cell adhesion to 
fibronectin, important and critical function for trafficking and extravasation of T cells across 
blood vessels and tissue barriers.  
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Further, it have been shown that DA at the very high concentration 10 - 100 μM 
significantly inhibited the proliferation and production of cytokines (IFN-γ and IL-4) by PBMC 
in response to mitogens Concanavalin A (Con A) and PWM (Pokeweed Mitogen), pointing 
that at this high concentration DA is having negative effects on these cells by elevating the 
synthesis of the apoptotic markers Bcl-2/Bax and Fas/FasL by elevating the level of apoptosis 
(by ~ 2.8-fold) (Bergquist et al., 1997). In 2000, the same group confirmed that this high 
concentration of DA (10 - 100 μM) also inhibited the LPS-induced binding of NF-ĸB to the 
promoter of TNF-α, inhibiting production of this pro-inflammatory cytokine, and proving that 
lower concentration of DA (1 μM – 1 nM) did not induce such inhibitory effects (Bergquist et 
al., 2000). 
Levite et al., 2001 have shown T cell increased adhesion to fibronectin (via DR D2 or 
DR D3 selective agonists).  
Ghosh et al., 2003 revealed that human T cells in vitro stimulated with anti-CD3 and 
treated with 3-5 ng/mL DA significantly inhibited proliferation of these cells but also cytokine 
production of IL-2, IL-4, and IFN-γ. Pharmacological study with antagonists revealed that DA 
inhibited T cells activated with anti-CD3 Ab, through the DR D2 and DR D3. 
Besser et al., 2005 demonstrated that in T cells obtained from healthy individuals, DA 
or selective DR D2 and DR D3 agonist may induce T cell selective cytokine production: IL-10 
and TNF-α, respectively via DR D2 and DR D3. These findings suggested that DA has the 
ability to trigger selective secretion of either IL-10 (anti-inflammatory) or either TNF-α (pro-
inflammatory) cytokine, without affecting the secretion of IFN-γ and IL-4. 
Kipnis et al., 2004 revealed that Treg cell exposure to DA in vitro, before their systemic 
injection into mice (an animal model of neuronal survival), reduced their suppressive activity 
in vivo. The same authors found that mouse Treg express functional D1-like receptors and that 
DA binding can suppress the suppressive activity of Treg on Teff cells (Kipnis et al., 2004). In 
consecutive studies was shown D1-like receptor-dependent activation on Treg leads to 
suppression of their suppressive function, and their ability to suppress Teff cells, and finally, 
Teff remained activated (Cosentino et al., 2007). This way DA can indirectly affect Teff cells 
activation status and functional response. Pharmacological studies performed with the different 
antagonist, shown that reserpine-induced suppression of Treg function was due to DR D1, and 
not DR D5 stimulation. Nakano et al., 2008 studied the effects of dopaminergic analogues on 
the interaction between monocyte-derived DCs (MO-DCs) and allogeneic CD4+ T cells from 
91 
 
healthy volunteers and revealed that D1-like receptor blockade reduced, and D2-like receptor 
blockade increased IL-17 secretion by the T cells. The same group revealed that interaction 
between MO-DCs and naïve CD4+ T cells induces the release of DA from MO-DCs, which 
causes Th2 differentiation and polarisation. They also reported that this effect was completely 
blocked by the pre-treatment with selective D1-like receptor antagonist (Nakano et al., 2009). 
Collectively, they concluded that MO-DCs contain DA that can release upon Ag-specific 
interaction with naïve CD4+ T cells, and that released DA can induce Th2 polarisation. 
Furthermore, it has been revealed that in DCs from DR D5 knockout mice, was 
impaired LPS-induced IL-23 and IL-12 cytokines production, and consequently, activation and 
proliferation of Ag-specific CD4+ T cells was attenuated (Prado et al., 2012). In vivo studies, 
revealed the role of DR D5 in a murine model of MS by transfer of DR D5-deficient DCs into 
wild-type recipients showing significant reduction of the percentage of Th17 cells infiltrating 
the CNS, no effects on Th1 cell subsets (Prado et al., 2012; Pacheco et al., 2014). 
Another interesting in vivo study addressing role of DA and its D1-like receptor in 
cutaneous immune response in Th subsets polarisation, was conducted by Mori et al., 2013. 
They showed by the administration of SCH 23390 (D1-like receptor antagonist) into a murine 
model of Th1-type contact hypersensitivity and of Th2-type atopic dermatitis, that Th2 
response was suppressed, and that treatment did not affect Th1 contact hypersensitivity (Mori 
et al., 2013). This data was also confirmed by real-time RT-PCR method that revealed that 
mice treated with the same antagonist had higher levels of IFN-γ and lower IL-4 mRNA in the 
skin (Mori et al., 2013). On the contrary, DA promoted Th2 cell differentiation and mast cell 
degranulation, without affecting Th1 cell function (Mori et al., 2013). 
C) Clinical relevance for dopaminergic modulation of CD4+ T cells in immune-
mediated diseases 
The presence of DR on CD4+ T cells membrane contributes to modulation, 
development, and initiation of immune responses under physiological conditions and in 
pathologies such as autoimmunity, neuroinflammation and cancer (Pacheco et al, 2009; 
Pacheco et al., 2010; Pacheco et al., 2014; Levite, 2016). The emerging role of DA as a 
regulator of CD4+ T cells physiology and its consequent involvement, in the regulation of 
immune response is important since the alterations in the DA-mediated regulation of immunity 
could contribute to the onset and development of immune-related disorders. It has been shown 
that in some autoimmune and neurological diseases, T cells have abnormal expression of DR 
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and/or response/production of DA. It is important to have in mind issue that alterations in the 
DA-mediated immune regulatory mechanisms could contribute to the onset and progression of 
immune-related disorders, since the DA agents could serve as new therapies in this conditions 
or an old one, with a safe pharmacological profile can be repurposed.  
Recent studies have shown that peripheral T cells are recruited to the CNS parenchyma, 
and are having a fundamental role in Parkinson’s disease pathology (Brochard et al., 2009; 
González et al., 2013; Reynolds et al., 2010). In the process of neuroinflammation, endothelial 
cells up-regulate expression of adhesion molecules and allow peripherally activated T cells to 
penetrate into the CNS parenchyma, where infiltrated CD4+ T cells interact with microglia and 
cause switch towards pro-inflammatory M1-like phenotype (Barcia et al., 2012). In parallel, 
activated microglia increase IFN-γ production by Th1 effector T cells, which coordinate 
pathogen killing. Collectively, this evidence indicate dysregulation of adaptive immunity, 
greatly contributes to neurodegenerative disease pathogenesis by modulating microglial 
responses and may provide an attractive therapeutic target for immunomodulatory 
interventions. 
Several other studies described the occurrence of peculiar modifications of peripheral 
immunity in PD, such as fewer CD4+CD25+ T cells, increased ratios of IFN-γ-producing to 
IL-4-producing T cells and decreased CD4+/CD8+ T-cell ratios (Baba et al., 2005), and also 
decreased CD4+ T lymphocytes (Bas et al., 2001; Stevens et al., 2012). Total numbers of 
lymphocytes in PD cohorts have been shown to be diminished by 17%, and CD3+ T cells were 
diminished by 22% (Bas et al., 2001). Among CD3+ T cells, numbers of CD4+ T cells were 
diminished by 31% whereas numbers of CD8+ T cells were not significantly changed. A 
greater loss of naïve CD4+ T cells (CD45RA+) was observed (Bas et al., 2001). A selective 
loss of CD4+CD45RA+ cells was also observed in diseases such as MS, suggesting a common 
immunological abnormality in such neurological disorder (Fiszer et al., 1994; Crucian et al., 
1995). CD4+ T cells were also identified in the brain in both, human PD patients and MPTP 
treated mice. Data obtained in the animal model shown that CD4+ T cells are key players in the 
detrimential process of dopaminergic cell death (Brochard et al., 2009). Saunders et al., 
recently reported that PD patients have increased effector/memory CD4+ T cells and decreased 
CD31+ and α4β7+ CD4+ T cells, which are associated with progressive motor dysfunction, 
suggesting a direct relationship between chronic immune stimulation and PD neuropathology 
and disease severity, strengthening the idea that in PD the lead actors among adaptive immune 
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system cells are CD4+ T lymphocytes (Saunders et al., 2012). The same group has also shown 
impaired abilities of Treg from PD to suppress effector T cell function, suggesting that Treg 
dysfunction is linked to PD pathobiology (Saunders et al., 2012). 
Our most recent study examined effects of dopaminergic substitution therapy and DA 
on CD4+ T naïve and memory lymphocytes in PD patients and in healthy subjects, showing 
that there is an excessive association between DR expression on T lymphocytes and motor 
dysfunction, assessed by UPDRS Part III score (Kustrimovic et al., 2016). Collectively, in total 
and CD4+ T naïve cells, expression of D1-like DR decreased, while in T memory cells D2-like 
increase with increasing UPDRS Part III score (Kustrimovic et al., 2016). In second part, in 
vitro effects of α-syn were assessed on both CD4+ naïve and memory cells, showing an 
increased CD4+ T memory cells, to a possibly different extent in PD patients in comparison to 
healthy subjects (HS), and also expression of DR was affected by the presence of α-syn 
(Kustrimovic et al., 2016). This finding further support involvement of peripheral adaptive 
immunity in PD. 
Evidence from both animal studies and clinical trials studies suggest that manipulation 
of various cell components of the adaptive immune response may provide considerable 
neuronal protection. 
Saussez et al., 2014 have shown, based on a pioneering study, that in vitro addition of 
DA (10 nM) increases spontaneous, chemotactic and towards autologous cancer migration of T 
cells of new patients with head and neck cancer. Such DA-induced effect on T cells from 
cancer patients should give hope for the future beneficial effects that should be examined in 
other types of cancer as well. Basu et al., 2001 showed that normal human T cells and human 
Jurkat T leukaemia cells expressed both D1-like and D2-like receptors, but with a different 
function. They have shown that activation of DR expressed on normal activated T cells leads to 
inhibition of proliferation, but not of the proliferation of malignant T cells. 
Treg are critical for the maintenance of immune homeostasis and are often found at 
elevated frequencies in blood and tumours of patients, and for many cancers, a high density of 
Treg correlates with poor disease outcome (DeLeeuw et al., 2013). Treg are actively recruited 
and induced by tumours to block immune priming, effector function and memory response, 
which can inhibit the efficacy of therapeutic cancer vaccines. It has been show that DA can 
effectively inhibit human Treg function, in vitro (Cosentino et al., 2007), so it can be highly 
provocative to hypothesise the role of DA as anti tumour-agent (Hiura et al., 2005). 
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An improved understanding of the fundamentals and complexities of Treg – DA 
interplay may enable the selective modulation of this cells and valuable pharmacological target 
for the cancer treatment. 
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II. AIMS OF THE EXPERIMENTAL PROGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
General aims 
 
The principal aim of the study was to develop and validate in vitro methods devised to 
investigate the effects of dopaminergic agents, currently used in the pharmacotherapy, on the 
functional responses of CD4+ T lymphocyte subsets. The specific responses were investigated 
in relation to functional conditions and to the expression and functional responsiveness of 
intrinsic dopaminergic pathways. The molecular and pharmacological heterogeneity of DR 
potentially represents an opportunity to develop targeted immunomodulating strategies. 
The aim of the present work was to use in vitro models to investigate the role of DA 
pathways in CD4+ T lymphocytes, namely: (i) CD4+ T naïve, T central memory and T effector 
memory cells, and their responses to recall Ag; (ii) Treg, and their suppressive effects on Teff 
and (iii) CD4+ T naïve cells, and their ability to differentiate towards different T helper 
lineages (Th1/Th2/Th17). 
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III. MATERIAL, METHODS AND RESULTS 
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3.1. Introduction 
 
Having in mind available literature data and hence observing the lack of data regarding 
the expression of DR on specific subsets of CD4+ T cells, the first goal set was to develop 
reliable cytometric methods in order to investigate DR expression on various subsets of CD4+ 
T cells (Figure 8). 
In the first part of our experiments we have shown expression of all five DR on 
CD3+CD4+ circulating T lymphocytes isolated from the venous blood of healthy subjects, 
followed by detailed examination of expression of each DR on Tn, TCM, TEM, Treg, 
Th1/Th2/Th17 (section 3.2., 3.6., 3.7. and 3.8., respectively). 
The most basic approach demanded introduction of apoptosis assay, which allowed us 
to define DR expression on CD4+ T cells undergoing apoptotic process in vitro culture 
conditions. The effects of different concentrations of dopaminergic agents, namely: DA, L-
DOPA and pramipexole were examined in the context of the CD4+ T cell susceptibility to 
apoptotic process (section 3.3.). 
Since the function of proliferation of CD4+ T cells is shown to be an important process 
in the homeostasis of T cells, and also in some pathogenic processes (such as cancer 
development and progression), we have developed and validated a method to examine DR 
expression on proliferating cells. The next step was to examine the effects of dopaminergic 
agents (DA, L-DOPA and pramipexole) on the proliferative capacity of these cells (section 
3.4.). 
Functional responses of CD4+ T naïve and memory subsets were investigated by the in 
vitro model that showed a change in frequencies of Tn, TCM and TEM, evoked by the common 
recall Ag tetanus toxoid (TTd) (section 3.5.). 
The in vitro method was set up to examine Treg-induced inhibition of Teff proliferation 
that was developed and validated both in buffy coat samples and healthy controls. Furthermore, 
the secretion of cytokines (IL-10 and TGF-?) by Treg alone, and Treg cells induced 
suppression of production of cytokines IFN-γ and TNF-α by Teff cells was characterised, and 
additionally, effects of SKF 38393 and pramipexole on cytokine production was examined. 
Finally, the relevance of the in vitro dopaminergic modulation of DA and L-DOPA was 
examined on function of CD4+CD25+ enriched population of T cells alone or co-cultivated 
with Teff cells obtained from healthy subject, and in a small sample group of patients suffering 
from Parkinson’s disease group that was divided into: (i) patients who have never been treated 
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with antiparkinson drugs and (ii) patients that are on dopaminergic replacement therapy 
(section 3.6.). The Parkinson’s disease group was used as a convenient model of the disease 
where DA and peripheral immune system interplay is strongly implicated.  
Lastly, the final aim proposed was developing and validation of in vitro method for 
examination the regulation of Th differentiation process and exploitation of the role of 
dopaminergic modulation on polarisation and differentiation process of Th1, Th2 and Th17 
subset in healthy subjects (section 3.7.). 
 
Figure 8. Schematic picture summarising the experimental models that were used and cell population 
obtained by different methods and approaches. 
 
3.1.1. Chemicals, reagents and antibodies 
 
Rabbit polyclonal antibodies (ab) IgG anti-human DR D1 (cod. 324390), DR D3 (cod. 
324402) and DR D5 (cod. 324408) were from Calbiochem-Inalco, Italy. Rabbit polyclonal ab 
anti-human DR D2 (cod. LS-C22924) and DR D4 (cod. LS-C22938) were obtained from 
LifeSpan-Space Import Exp, Italy. Goat anti-rabbit ab IgG conjugated with phycoerythrin (PE) 
was obtained from R&D System, Space Import Exp, Italy. PerCPCy5.5-conjugated mouse IgG 
anti-human CD3 (CD3 PerCPCy5.5) (cod. 317336, clone OKT3; mouse IgG2a, k) and FITC-
conjugated mouse IgG anti-human CD45RA (CD45RA FITC, cod. 304106, clone HI100; 
Mouse IgG2b, k) were obtained from Biolegend– Campoverde, Italy. APC-Cy7-conjugated 
mouse IgG anti- human CD4 (CD4 APCCy7, cod. 557871, clone RPA-T4; mouse IgG1, k), PE 
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Cy7 conjugated mouse IgG anti-human CD4 (CD4 PECy7, cod. 557852, clone SK3), Alexa 
Fluor 647-conjugated rat IgG anti- human CCR7 (CD197) (CCR7 AF647, cod. 557736, clone 
3D12; rat IgG2a, k), APC conjugated mouse IgG anti human CD3 (CD3-APC, cod. 555342, 
clone HIT3a), PE Cy7 conjugated mouse IgG anti-human CD25 (CD25 PECy7, cod. 557742, 
clone 2A3), AlexaFluor647 conjugated mouse IgG anti-human CD127 (CD127 AlexaFluor647, 
cod. 558598, clone HIL-7R-M21), AlexaFluor448 conjugated mouse IgG anti-human CD183 
or CXCR3 (CD183 AlexaFluor448, cod. 558047, clone 1C6/CXCR3), PE Cy7 conjugated 
mouse IgG anti-human CD194 or CCR4 (CD194 PECy7, cod. 561034, clone 1G1) and 7-AAD 
(7-amino-actinomycin) were all purchased from Becton Dickinson, Pharmingen, Italy. 
PerCPCy5.5-conjugated mouse IgG anti-human CCR6 (CD196 PerCPCy5.5) (cod. 353405, 
clone G034E3) was purchased from Biolegend– Campoverde, Italy. 
Purified mouse ab anti-human CD3 (cod. 555330, clone UCHT1) and purified mouse 
ab anti-human CD28 (cod. 555726, clone CD28.2) were obtained from Becton Dickinson, 
Italy. Bovine serum albumin (BSA) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) were purchased from Sigma, Italy. RPMI 1640, heat-inactivated foetal bovine serum 
(FBS), glutamine, and penicillin/streptomycin were obtained from Euroclone, Italy. Ficoll-
Paque Plus was from Pharmacia Biotech (Uppsala, Sweden). Cell Proliferation Dye eFluor670 
(CPD670) (cod. 65-0840) was purchased from eBioscience-Prodotti Gianni. Dopamine 
hydrochloride (cod. H8502), L-DOPA (3,4-dihydroxy-L-phenylalanine, cod. D9628), (±)-SKF-
38393 hydrochloride (cod. D047), pramipexole dihydrochloride (cod. A1237), mitogen 
phytohemaglutinin (PHA) and recombinant IL-2 (cod. 0208AF12) were all purchased from 
Sigma Aldrich, Saint Louis, MO, USA. Human anti-INF-γ antibody (cod. 130-095-743), anti-
IL-4 antibody (cod. 130-095-753), IL-1β (cod. 130-093-895), IL-4 (cod. 130-095-373), IL-6 
(cod. 130-095-365), TGF-β (cod. 130-095-067) and IL-12 (cod. 130-096-704) were all 
purchased from Miltenyi Biotec, Bergisch Gladbach, Germany. 
Dynalbeads CD4 Positive Isolation Kit (cod. 11331D) and TGF-β (KAC1688) ELISA 
kit were obtained from Invitrogen, Life Technologies AS, Norway. Human INF-γ (cod. 
EHIFNG), TNF-α (EH3THFA), and IL-10 (EHIL10) ELISA kits were all purchased from 
Thermo Scientific, Rockford, USA. Human CD4+CD25+ Regulatory T cell Isolation Kit (cod. 
130-091-301) and human naïve CD4+ T cell Isolation Kit (cod.130-094-131) were purchased 
from Miltenyi Biotec, Bergisch Gladbach, Germany. Human Th1/Th2/Th17 Phenotyping Kit 
(cod. 560751) containing: Th1/Th2/Th17 cocktail (CD4PerCP-Cy5.5 clone SK3; IL-17A PE 
clone N49-653; IFN-? FITC clone B27 and IL-4 APC clone MP4-25D2), BD Cytofix Buffer, 
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BD Perm/Wash buffer and BD GolgiStop Protein Transport Inhibitor was purchased from 
Becton Dickinson, Italy. PMA (phorbol 12-myristate 13-acetate, cod. P8139), ionomycine 
(Calcium Ionophore, cat.nub. I3909) and tetanus toxin, from Clostridium tetani (TTd, cod. 
T3194) were all purchased from Sigma Aldrich, Saint Louis, MO, USA. 
 
3.1.2. Subjects enrolled in the study 
 
The present study is part of a project ”Dopaminergic modulation of CD4+ T cells: 
relevance for neurodegeneration and neuroprotection in Parkinson’s disease – the 
dopaminergic neuro-immune connection” which is aimed at assessing the pattern of expression 
and the functional role of DR on circulating lymphocytes in healthy subjects and in patients 
with Parkinson’s disease. PD patients were enrolled among patients attending the Centre for 
PD and Movement Disorders of the Neurological Service at the Ospedale di Circolo, Varese, 
the Interdepartmental Research Center for Parkinson’s Disease of the Neurological Institute 
“C. Mondino”, Pavia and Divisione di Neurologia, Ospedale Maggiore, Novara, Italy. The 
healthy subjects were mainly spouses and caregivers of the enrolled PD patients. PD was 
diagnosed according to the UKPDS Brain Bank Criteria. Any patients and controls with a 
history of autoimmune or inflammatory disorders and/or receiving chronic immunosuppressive 
treatment were excluded. All enrolled subjects were submitted to a complete examination. 
The study protocol was approved by the Ethics Committee of the Ospedale di Circolo, 
Fondazione Macchi, Varese and Neurological Institute “C. Mondino”, Pavia. All the 
participants signed a written informed consent form before enrolment. The study was 
performed according to the Declaration of Helsinki, and to the relevant ethical guidelines for 
research on humans. 
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3.2. Expression of DR in CD4+ T lymphocytes in whole blood 
 
To our best knowledge, so far only a few studies dealing with DR expression on human 
immune cells were undertaken. McKenna et al., 2002 have identified DR on human 
lymphocytes by flow cytometry, showing that T lymphocytes and monocytes had low 
expression of DR (frequency was on average 1–5 %). DR D3 and DR D5 were found in most 
individuals, DR D2 and D4 had a more variable expression, and DR D1 was not detected. 
Subsequently, Besser et al., 2005 reported the occurrence of D2-like DR on human T cells by 
usage of flow cytometry, showing expression of DR D2 and D3 on 9–10% of these cells. Sarkar 
et al., 2006 documented the membrane expression of DR D4 by means of western blot analysis, 
while Brito-Melo et al., 2012 analysed the expression of DR D2 (2–10 %) and DR D4 (2–16 %) 
on CD4+ T cells. 
 
Aim 
 
The aim of study was to develop and validate reliable flow cytometric protocol to 
examine the expression of DR on circulating CD4+ T lymphocytes in whole blood. 
 
Subjects enrolled in the study 
 
Peripheral venous blood samples were collected from healthy volunteers (n=30) 
between 8:00 a.m. and 10 a.m. and placed in universal tubes containing preservative-free 
heparin (215IU/mL). 
 
3.2.1. DR staining in whole blood  
 
The DR staining protocol consisted of two steps of an indirect immune fluorescence 
labelling procedure (primary Ab + secondary Ab labelled with PE). Briefly, in the first step, 
each aliquot was stained for one of the five membrane DR by using rabbit polyclonal IgG 
directed against human D1-like (D1 and D5) and D2-like (D3, D4, and D5) DR. In the second 
step, a cocktail of the following Abs was added to each aliquot, according to manufactures 
recommendations: pre-titrated PerCPCy5.5-conjugated mouse anti-human CD3 and APC-Cy7- 
conjugated mouse anti-human CD4. 
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? Each sample was prepared as 100 μL of a whole blood added to BD tube. 
? In order to remove the erythrocytes, 3 mL of a lysis buffer (containing NH4Cl 
8.248 g/L, KHCO3 1.0 g/L and EDTA 0.0368 g/L) were added to each sample. 
? Incubation was performed at room temperature (RT) for 5 min, during which 
samples were gently vortexed. 
? Samples were then centrifuged at 1200 g for 5 min at RT, supernatants were 
removed and cells were washed with 1 mL of PBS (pH 7.4) supplemented with 1 % BSA 
(PBS/BSA). 
? Finally, pellets were resuspended in 50 μL PBS/BSA. 
? From each subject 7 aliquots were prepared as follow: 5 were used for DR 
staining, 1 was used as control for the secondary PE-goat anti-rabbit (PEGAR) Ab, and 1 was 
used as a negative control (no Ab). 
? Samples was added with the primary anti-DR Ab (final dilution 1:100). 
? Samples were incubated for 30 minutes on ice in the dark.  
? Cells were washed once with PBS/BSA at 1200 g for 5 min at RT. 
? Pellets were resuspended in 200 μl of PBS/BSA and 10 μl of PEGAR Ab was 
added, following incubation for 30 min on ice in the dark. 
? After incubation, samples were washed with 1 mL of PBS/BSA (1200 g for 5 
min at RT) and resuspended in 50 μL PBS/BSA. 
? A cocktail of anti-human CD3 and anti-human CD4 were added to all samples 
according to manufacturer’s recommendation, and incubated for 30 min in dark at RT. 
? Washing was performed with 1 mL of PBS/BSA (1200 g for 5 min at RT). 
? Finally, samples were resuspended in 350 μL PBS and kept on ice until analysis. 
Acquisition was performed on a BD FACSCanto II flowcytometer (BectonDickinson 
Italy, Milan, Italy) with BD FACSDiva software (version 6.1.3). Lymphocytes were identified 
by their classical forward scatter (FSC), side scatter (SSC) signals and a minimum of 20.000 
lymphocytes from each sample were collected in the gate. Data were analysed with FlowJo 
software (version 8.3.2.). The results were finally expressed as a percentage of positive cells 
(%) (Kustrimovic et al., 2014). 
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3.2.2. Analysis of obtained results 
 
CD3+CD4+ T lymphocytes expressing DR were identified by means of the following 
gating strategy: first, lymphocytes were gated on the scatter dot plot in the typical region of low 
SSC and FSC, CD3 and CD4 double positive cells were then identified among gated 
lymphocytes, and DR+ cells were finally enumerated (Fig. 9). 
 
 
Figure 9. Gating strategy employed to identify DR+CD3+CD4+ T lymphocytes. Total lymphocytes 
were identified on a biparametric dot plot SSC vs FSC (upper panel, region 1 [R1]), to exclude 
monocytes, granulocytes and debris. From the cells in R1, CD3+CD4+ T cells were selected by using 
the CD3 vs CD4 dot plot (middle panel, R2). Finally, DR expression was assessed by a single-
parameter histogram (lower panel), where the black line represents DR+ cells and the gray line 
represents the negative control (cells stained with only the secondary PEGAR ab). 
 
The obtained results showed that CD3+CD4+ T lymphocytes expressed all the five DR 
(Fig. 10), with subsequent frequency: D1-like DR D1 were expressed by 8.3±0.6% of 
CD3+CD4+ T cells and D5 by 11.9±1.0%, while the D2-like DR D2 by 4.8±0.5%, D3 by 5.7 
±0.5 %, and D4 by 6.8±0.8 %. D1-like DR D1 and D5 frequencies were significantly higher 
than those of the D2-like DR D2, DR D3 and D4. Frequency of the CD3+CD4+ cells that are 
expressing DR D1 and D5 were significantly different among themselves (Fig. 10). 
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Figure 10. Expression of DR on CD3+CD4+ T cells. DR expression is presented as percentage of 
total CD3+CD4+ T cells. Results are presented as mean±SEM of 30 subjects. *, P<0.05 vs. DR D5 
and DR D4, P<0.01 vs. DR D3, P<0.001 vs. DR D2; #, P<0.001 vs. DR D2, DR D3 and DR D4. 
 
Conclusions, implications and future perspectives 
The results of this study have shown the expression of all the five DR on human 
CD3+CD4+ T lymphocytes to a different extent, thus opening the possibility of exploring in 
more detail the patterns of DR expression among different CD4+ T cell subsets, as well as the 
relationship with the functional status of these cells, ex vivo and in vitro.  
Given the obtained results, it seems feasible that the relative prevalence of D1-like over 
D2-like DR in CD3+CD4+ T cells may imply that effects of DA on these cells are mediated 
mainly through D1-like DR. 
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3.3. Effect of dopamine and dopaminergic agonists on T cell susceptibility to 
apoptosis 
 
Apoptotic mechanism has an important role in the fine-tuning of the immune response. 
Dopamine itself can exert toxic or protective effects on lymphocytes under specific conditions, 
by modulating their death or survival. 
Studies showing pro-apoptotic effects of DA typically used concentrations of 10–500 
μM (Bergquist et al., 1997) or even 1 mM (Del Rio and Velez-Pardo, 2001). In agreement with 
those findings, in previous studies DA at concentration 100–500 μM induced a concentration-
dependent increase in the percentage of apoptotic cells (Cosentino et al., 2004). On the other 
hand, it was reported that in human PBMC, DA decreases oxidative metabolism and apoptosis, 
possibly through activation of D1-like DR-dependent mechanisms, which results in the 
reduction of intracellular ROS levels, and the subsequent inhibition of apoptosis (Cosentino et 
al., 2004). 
 
Aim 
 
For this part of the study, two specific aims were set: 
(i) define the level of expression of DR on CD4+ T cells that are undergoing 
apoptotic process 
(ii)  validate and develop an in vitro experimental model to obtain the effects of 
different concentrations of DA, L-DOPA and pramipexole on CD4+ T cells and their 
susceptibility to apoptosis. 
 
Subjects enrolled in the study 
 
PBMC were isolated either from Buffy coat samples (n=6) or from venous blood from 
healthy volunteers (n=13). 
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3.3.1. Method of PBMC cultivation and evaluation of effects of DA, L-DOPA and 
pramipexole on apoptosis 
 
Flow cytometry method with usage of 7-aminoactinomycin (7-AAD) colour allowed 
evaluation of DR expression on live, early and late apoptotic cells after 48 h of PBMC 
cultivation. 
 
3.3.1.1. Separation and purification of PBMC by Ficoll-Hypaque method 
 
PBMC isolation was performed from 20-25 mL of whole blood samples by using 
Ficoll-Paque Plus density (1.077 g/mL) gradient centrifugation for purifying lymphocytes. 
Isolation of PBMC by Ficoll-Plaque gradient (Boyum, 1974) resulted in enrichment of 
mononuclear cells with less than 5% contamination of neutrophil granulocytes. 
? All solutions used in this procedure were gradually equilibrated to RT before 
being used in the assay. 
? Fresh heparinised blood samples were placed into 50 mL conical tubes and 
mixed with an equal volume of PBS. 
? 3 mL of Ficoll-Hypaque solution was placed in 15 mL conical tube and 12 mL 
of diluted blood samples were carefully layered on the Ficoll-Hypaque. 
? Samples were centrifuged for 40 min, 400 g, at RT (without a break). 
? After careful centrifugation, the mononuclear lymphocyte cell layer (that 
appears as a white, cloudy band between the plasma and the Ficoll-Hypaque layers) was 
collected and transferred to a new tube. 
? Isolated PBMC were washed with 10 mL of 2% FBS/PBS (600 g, 10 min, RT). 
? After centrifugation supernatants were removed, 3 mL of lysis buffer 
(NH4Cl/KHCO3/EDTA) was added in order to remove any residual erythrocytes.  
? Samples were centrifuged at 100 g, in order to remove remaining platelets, for 5 
min at the RT. 
? Supernatant was removed and pellet was washed in 10 mL of 2% FBS/PBS 
(600 g, 10 min, RT). 
? Supernatants were removed and obtained pellets were resuspended in 10 mL of 
10% FBS/RPMI 1640 and prepared for counting. 
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? Preparation of cell suspension for cell counting: 
? Identical volumes of Turk solution and cell suspension (10 μL + 10 μL) were 
placed in tubes, mixed well and left for 10 seconds to allow colour to penetrate inside the cells. 
? 10 μL of mixture was placed into Burker chamber and number of cells were 
counted on microscope. 
For counting cells, the following formula was used: N cells x 2 x V x 104, where: 
N = mean of 3 quadrants of counted cells, 
2 = dilution factor of Turk solution, 
V = volume of sample, 
104 = volume of Burker chamber. 
The typical PBMC suspension preparation obtained by this method always contained at 
least 80% of lymphocytes, as confirmed by flow cytometry (Fig. 11). Cell viability, assessed 
by the trypan blue exclusion test, was always >99 %. 
 
Figure 11. Purity of separated PBMC 
 
3.3.1.2. PBMC culture and staining of DR on viable and apoptotic cells 
 
? After PBMC isolation, cells were washed and resuspended at the final 
concentration of 1 x 106 cells in 1 mL of RPMI/10%FBS for subsequent culture for 48 h at 
37°C in a moist atmosphere of 5 % CO2, alone, or in the presence of anti-CD3/anti-CD28 Ab 
(0.1 μg/mL) as activators that were added at the beginning of cell culture. 
? After 48 h cells were collected, washed twice with 10 mL of PBS/2%BSA, and 
centrifuged at 1200 g for 10 min at RT. Finally, samples were resuspended in at least 1 mL 
PBS/2%BSA for DR staining. 
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From each sample, 7 aliquots of 100 μL were prepared: 5 were used for staining of each 
DR, one was used as a control of secondary Ab and one as a negative control. DR staining was 
performed as previously detailed in section 2.4. 
? In each experiment, a sample of 1×106 PBMC was labelled with mouse anti-
human CD4-APC-Cy7, added according to the manufacturer’s recommendations. 
? Samples were incubated for 30 min at RT in the dark.  
? After incubation, the cells were washed with 1 mL PBS/BSA, and the pellets 
were resuspended in 100 μL of PBS/BSA.  
? 5 μL of 7-AAD was added to each sample and left for incubation for 5 min on 
ice in the dark. 
? After incubation, 250 μL of PBS/2%BSA was added and then samples were 
immediately analysed. 
Viable, early apoptotic (EA) and late apoptotic (LA) CD4+ T cells were identified by 3-
color flow cytometric analysis according to an established method (Lecoueur et al., 1997). 
 
3.3.1.3. PBMC culture and DA effect on apoptotic cells 
 
? PBMC, isolated from buffy coat samples or fresh blood of healthy subjects, 
were resuspended at the final number of 0.5 x 106 PBMC cells per well in RPMI/10 % FBS for 
subsequent culture for 48 h at 37 °C in a moist atmosphere of 5 % CO2 in the presence/absence 
of anti-CD3/anti-CD28 Ab (0.1 μg/mL) activators.  
? Different concentrations of DA, L-DOPA and pramipexole were added at the 
beginning of cell culture.  
? After 48 h, the cells were collected, washed twice with 1 mL of PBS/BSA, 
centrifuged at 1200 g for 10 min at RT and resuspended. 
? The samples were incubated with mouse anti-human CD4-APC-Cy7 for 30 
minutes at the RT in the dark. 
? After incubation samples were washed with 1 mL PBS/BSA and pellets were 
resuspended in 100 μL of PBS/BSA. 
? In each sample, 5 μL of 7-AAD was added and incubated for 5 min on ice in the 
dark. 
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? After incubation, 250 μL of PBS/BSA was added to the samples, which were 
immediately analysed. 
Viable, EA and LA CD4+ T cells were identified by 3-color flow cytometric analysis 
according to established methods (Lecoeur et al., 1997). 
 
3.3.2. Analysis of obtained results 
 
3.3.2.1. Expression of DR on cultured CD4+ T cells 
 
In order to distinguish viable and apoptotic CD4+ T cells, a 3-color flow cytometric 
method was applied to identify three different subpopulations by an already established method 
(Lecoueur et al., 1997). The following gating strategy was used: first, lymphocytes were 
identified on the dot plot in the typical region of low SSC and FSC; then, CD4+ positive cells 
were identified among gated lymphocytes. By the expression of the 7AAD marker, the 
following populations were defined within the defined population of CD4+ T cells: viable, EA 
and LA (Fig. 12). 
 
 
Fig. 12 Gating strategy used to identify viable and apoptotic CD4+ T cells in human PBMC after 48 h 
of culture. Total lymphocytes were identified on a biparametric dot plot SSC vs. FSC (left panel, 
region LY). From the cells in the LY region, CD4+ T cells were selected by using the FSC vs. CD4 
dot plot (middle panel). Finally, 7-AAD expression was assessed by a single-parameter histogram 
(lower panel), and CD4+T cell subset was further divided on: viable, EA and LA cells. 
 
The frequency of all DR was examined on such a defined cell population (live, EA and 
LA). Results showed that all five examined DR were significantly higher in EA and LA cells in 
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comparison to viable cells, and the frequency of D1-like DR D1 and D5 were also significantly 
higher in LA cells, in comparison to EA cells. However, stimulation with anti-CD3/anti-CD28 
Ab significantly increased the expression of all DR on viable cells, without affecting DR 
expression on EA or LA cells (Fig 13). 
 
3.3.2.2. Effects of DA and dopaminergic agents on CD4+ T cell apoptosis 
 
Preliminary experiments were carried out on buffy coat samples in order to establish the 
best experimental settings. Resting and activated cells were cultivated in standard conditions. 
Anti-CD3 and anti-CD28 Ab were used as activators in order to mimic conditions the most 
similar to physiological ones. 
The difference between resting and activated conditions were obtained among late 
apoptotic (LA) cells, without treatment, (*,=P<0.05) and in the presence of 1 μM DA 
(**,=P<0.01) (Fig. 14). 
Treatment with DA at concentrations 1μM and 100μM did not influence the 
percentages of live or LA CD4+ T cells, in neither resting nor activated conditions. The results 
revealed significance influenced by the DA treatment only in activated EA cells, at the 
concentration of 100 μM, when compared to activated control conditions (b, P<0.01) (Fig. 14). 
 
 
Fig. 13 Expression of D1-like (left panel) and D2-like (right panel) receptor subtypes on: viable, EA 
and LA CD4+ T cells cultured in resting conditions (open columns) and in the presence of soluble anti-
CD3/anti-CD28 Ab (0.1 μg/mL) (dashed columns). Results are presented as a mean±SEM of 13 
healthy subjects. *, P<0.01 vs. resting; #, P<0.01 vs. viable cells; §, P<0.01 vs. EA cells. 
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Fig. 14 Effect of different dopamine concentrations on: A) live cells, B) EA and C) LA cells, expressed 
as a percentage of total CD4+ T cells in human PBMC after 48 h culture. Results are presented as a 
mean±SEM of BC samples (n=5). *, P<0.05 and **, P< 0.01 vs. resting conditions. b, P<0.01 vs. 
activated control conditions. 
 
The obtained results of experiments performed on buffy coat samples helped to develop 
and validate a method, as well as standardise culture conditions for following experiments with 
peripheral blood of healthy subjects. 
A curve was drawn employing concentrations of DA ranging from 1 to 100 μM. The 
preliminary results, obtained from the fresh blood of 5 healthy subjects, revealed significant 
differences between resting and activated cultivated conditions, in each cell population 
examined: live, EA and LA cell groups. Namely, activation seems to reduce the percentage of 
live cells, while increasing the percentages of EA and LA cells (Fig. 15). 
Furthermore, the results have shown that DA has a pro-apoptotic effect at 
concentrations of 100 μM, by decreasing the percentage of live, and increasing the percentage 
of EA cells (Fig. 15). 
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Fig. 15 Effect of different concentrations of DA on: A) live cells, B) early apoptotic and C) late 
apoptotic cells, expressed as a percentage of total CD4+ T cells in human PBMC after 48 h culture. 
Results are presented as a mean±SEM of HS (n=5). *, P<0.05 and **, P< 0.01 vs. resting. a, P<0.05 
vs. control. 
 
A higher concentration of DA (100 μM) was found to be toxic for PBMC in vitro in our 
experimental settings. On the basis of these results, DA was added at the maximum 
concentration of 50 μM for comparative experiments between buffy coat samples and healthy 
subjects PBMC proliferation test (Fig. 15). 
A further effect of L-DOPA was examined, including concentrations of L-DOPA 
ranging from 1 to 100 μM. In resting conditions, treatment with L-DOPA in highest 
concentrations reduced the percentage of live cells and increased EA and LA, implying a pro-
apoptotic effect of L-DOPA (Fig. 16).  
On the other hand, activation in control conditions (without the treatment) increased 
only the percentage of LA. It seems that activation reversed the pro-apoptotic effect of L-
DOPA, since it decreased the percentage of live cells and increased the percentages of EA and 
late apoptotic cells (Fig. 16). 
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Fig. 16 Effect of different concentrations of L-DOPA on: A) live cells, B) early apoptotic and C) late 
apoptotic cells, expressed as a % of total CD4+ T cells in human PBMC after 48 h culture. Results are 
presented as a mean±SEM of HS (n=5). *, P<0.05; **, P< 0.01 and ***, P<0.001 vs. resting 
conditions. a, P<0.05; b, P<0.01; c, P<0.001 and d, P<0.0001 vs. corresponding control conditions. 
 
So far, treatment with pramipexole did not exert any significant effect on apoptotic 
process of CD4+ T cells (Fig. 17). As expected, activation led to an increase in the percentage 
of LA cell population in control conditions. 
 
 
 
 
Fig. 17 Effect of different concentrations of pramipexole on: A) live cells, B) early apoptotic and C) 
late apoptotic cells, expressed as a percentage of total CD4+ T cells in human PBMC after 48 h 
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culture. Results are presented as a mean±SEM of HS (n=5). *, P<0.05 and **, P< 0.01 vs. resting 
conditions. 
 
Conclusions, implications and future perspectives 
 
Results have shown a higher expression of DR in apoptotic cells (both EA and LA) in 
comparison to viable cells after 48 h of cultivation. Activation with anti-CD3/anti-CD28 Ab 
led to an increase in the percentage of CD4+ T cells that are expressing DR in viable cells, 
without altering apoptotic cells. High expression of DR in apoptotic cells and stimulation-
induced DR increase in cultured CD4+ T cells suggests the involvement of DR in the apoptotic 
process and further supports the involvement of DR in the functional regulation of activated 
cells, requiring further investigations to assess the role of DR subtypes in the modulation of 
specific responses (Kustrimovic et al., 2014). 
Furthermore, the addition of high concentrations of DA (100 μM) and L-DOPA (100 
μM) profoundly affect survival and death of activated CD4+ T cells. On the other hand, 
pramipexole did not affect CD4+ T cell viability at all. 
Interestingly, it can be proposed that in resting cells dopaminergic pathways participate 
mainly in apoptotic processes (as suggested by the high proportion of apoptotic cells 
expressing DR), while their functional relevance increases in activated cells (in line with 
stimulation-induced upregulation of DR in viable cells). 
Further in vitro findings are necessary in order to add knowledge about the sensitivity 
of CD4+ T cell, to DA and other dopaminergic agents presently in clinical use. 
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3.4. DA effect on CD4+ T cells proliferation and DR expression 
 
Saha et al., have shown that physiological concentrations of DA (53.9 pM) may inhibit 
the proliferation of human CD4+ T cells through the activation of D1-like receptors, in both 
healthy individuals (Saha et al., 2001a) and lung carcinoma patients (Saha et al., 2001b). 
On the other hand, Giorelli et al., 2005 reported diminished mRNA and protein levels 
of D1-like DR D5, but not of D2-like DR D3, in PBMCs from untreated relapsing-remitting 
multiple sclerosis patients, and showed in vitro that DA (1 μg/mL) reduced T cell proliferation 
in PBMC from healthy subjects, but not from MS patients.  
 
Aims 
 
The aim was to explore expression of DR on proliferating and non-proliferating cells 
and to understand if proliferation of peripheral CD4+ T cell is affected by DA and 
dopaminergic agents. 
 
Subjects enrolled in the study 
 
In the first part of the study, whose aim was to show DR expression on proliferating 
cells in vitro, PBMC were isolated from buffy coat samples (n = 3-4). 
The second part of the experiments were dedicated to examinining the effects of DA, L-
DOPA and pramipexole on proliferation of CD4+ T cells. PBMC were isolated from venous 
blood obtained from buffy coat samples (n = 4) and healthy subjects (n=5). 
 
3.4.1. PBMC isolation, CPD staining and cultivation 
 
PBMC isolation was performed from 20-25 mL of whole blood samples by using 
Ficoll-Paque Plus density (1.077 g/mL) gradient centrifugation for purifying lymphocytes as 
previously described. Before putting PBMC in the culture, cells were stained for proliferation 
test with Cell Proliferation Dye eFluor® 670. 
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Cell staining with Cell Proliferation Dye eFluor® 670 (CPD) 
 
? Cells were washed with 10 mL of PBS, at 400 g, 10 min, RT. 
? Pellets were resuspended in 1 mL of 0.1% FBS/PBS. 
? Dye colour was added to the cell suspension at the final concentration 2.5 µM. 
? Cells were incubated at RT for 8 min, protected from light. 
? The reaction was stopped by addition of equal volume of pre-warmed FBS and 
incubation at 37°C for 10 min. 
? Samples were washed 3 times with RPMI/10% FBS, at 400 g, 5 min.  
? Supernatants were removed, and pellets were resuspended and prepared for cell 
counting with Trypane blue. 
After CPD staining, PBMC were washed, counted and adjusted to the final 
concentration of 1x106 cells in 1 mL of RPMI/10 % FBS. Cells were cultured for 4 days at 37 
°C in 48 well plate, in a moist atmosphere of 5 % CO2, with anti-CD3/anti-CD28 Ab (0.1 
μg/mL) added at the beginning of cell culture. All treatments, DA, L-DOPA or pramipexole, 
were added at the beginning of cell culture. After 4 days cells were collected, washed twice 
with 1 mL of PBS/BSA at 1200 g for 10 min at RT. Supernatants were removed and pellets 
were resuspended for two steps labelling with DR. 
From each subject 7 aliquots were prepared: 5 were used for DR staining, 1 was used as 
a control for the secondary PEGAR Ab, and 1 was used as negative control (no Ab). The 
staining protocol consisted of two steps of indirect labelling procedure (primary Ab for one of 
the five DR + secondary Ab labelled with PE):  
? Each aliquot was labelled with rabbit anti-human D1-like (D1 and D5) or anti-
human D2-like (D3, D4, and D5) DR (dilution 1:100)  
? Samples were incubated for 30 min on ice in the dark.  
? After incubation, cells were washed with PBS/BSA (1200 g for 5 min at RT). 
? Samples were resuspended in 200 μl of PBS/BSA and 10 μl of PEGAR Ab was 
added, following incubation for 30 min on ice in the dark. 
? After incubation, samples were washed and resuspended in 50 μL PBS/BSA. 
? APC-Cy7- conjugated mouse anti-human CD4 was added to each aliquot, 
according to manufacturer’s recommendations.  
? Samples were incubated for 30 min in dark at RT. 
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? After incubation, samples were washed with 1 mL of PBS/BSA (1200 g for 5 
min at RT). 
? Samples were resuspended in 350 μL PBS and kept on ice until analysis.  
The acquisition was then performed on a BD FACSCanto II flow cytometer 
(BectonDickinson Italy, Milan, Italy) with BD FACSDiva software (version 6.1.3). 
Lymphocytes were identified by their classical FSC, SSC signals and a minimum of 20.000 
lymphocytes from each sample were collected in the gate. Data were analysed with FlowJo 
software (version 8.3.2). The results were expressed as a percentage of positive cells (%). 
 
3.4.2. Analysis of results obtained 
 
3.4.2.1. Expression of DR on proliferating CD4+ T cells 
 
In order to distinguish proliferating and non-proliferating CD4+ T cells, flow 
cytometric method was applied to identify these two different subpopulations by 2-color flow 
cytometric analysis. Following gating strategy was used: first, lymphocytes (LY) were gated on 
the dot plot in the typical region of low SSC and FSC, CD4+ positive cells were then identified 
among gated lymphocytes. On the basis of expression of CPD marker, within the defined CD4+ 
T cell population, proliferating and non-proliferating cells were identified (Fig. 18). 
 
Fig. 18 Gating strategy used to identify proliferating and non-proliferating (resting) CD4+ T cells in 
human PBMC after 4 days of culture. Total lymphocytes were identified on a biparametric dot plot SSC 
vs. FSC (left panel, region LY) and from the cells in the LY region, CD4+ T cells were selected using 
the FSC vs. CD4 dot plot (right, upper panel). Finally, CPD expression was assessed by a single-
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parameter histogram (lower panel), and CD4+T cell subset was further divided on proliferating and 
resting (non-proliferating) cells. 
 
DR expression on proliferating cells confirmed expression of all five DR, although 
present in different extension: D1-like DR D1 were expressed by 11.7±0.8% of total CD4+ T 
cells and DR D5 by 14.3±6.0%, while the D2-like DR D2 by 9.4±3.5%, D3 by 4.7 ±2.1 %, and 
D4 by 10.8±2.1 % (Figure 19).  
Among non-proliferating cells, data have shown that CD4+ T lymphocytes expressed 
all the five DR. However, expression of each of DR was always less than 5%, with following 
frequency: D1-like DR D1 were expressed by 4.1±1.0% of total CD4+ T cells and D5 by 
2.7±0.6%, while the D2-like DR D2 by 3.4±0.6%, D3 by 3.1±1.1%, and D4 by 4.8±0.6% 
(Figure 19). 
 
 
Fig. 19 Expression of DR on CD4+ non-proliferating and proliferating cells cultivated for 4 days under 
standard conditions, in the presence of anti-CD3/anti-CD28 (0.1 μg/mL). Results are presented as a 
mean±SEM of buffy coat samples (n=3-4). 
 
3.4.2.2. Effects of DA and dopaminergic agents on CD4+ T cell proliferation 
 
Based on obtained results regarding apoptosis and influence of DA and L-DOPA on 
cell viability (section 3.5.2.), further concentrations of DA and DA agents were chosen for 
proliferation assay. 
Comparing levels of proliferation of activated CD4+ T cells isolated from buffy coats 
samples and healthy subjects, no major differences were obtained so far. DA, L-DOPA and 
pramipexole added in different concentrations, did not affect proliferation of CD4+ T cells, 
neither in the buffy coat samples or in fresh blood samples obtained from healthy subjects 
(Figure 20). Interestingly, pramipexole treatment at concentrations 0.1 and 1 μM decrease of 
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CD4+ T cell proliferation in healthy subjects in comparison to CD4+ T cell obtained from 
buffy coats (Fig. 20). 
 
  
 
 
Fig. 20 Effect of DA (A), L-DOPA (B) and pramipexole (C) on the proliferation of CD4+ T cells 
isolated from buffy coat samples (n=4, empty circles) or healthy subjects (n=5, filled circles) and 
cultivated under standard conditions, in the presence of anti-CD3/anti-CD28 (0.1 μg/mL). Results are 
presented as a mean±SEM. *, P <0.05 vs. buffy coat samples a, P<0.05 vs. control conditions. 
 
Conclusions, implications and future perspectives 
 
Our data have shown that proliferating and non-proliferating CD4+ T lymphocytes 
expressed all the five DR, although in different expression levels. Interestingly, there was a 
trend of proliferating cells expressing DR in higher percentages, but these results were 
exploratory (n=3-4) and part of an investigation that is still ongoing in order to increase the 
number of samples. 
So far, tested concentrations of dopaminergic agonists, including DA itself, have not 
shown any major effects on proliferation of CD4+ T cells. 
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3.5. Functional response of CD4+ T naïve and memory subsets 
 
Upon stimulation by the presentation of novel Ags by dendritic cells, T lymphocytes 
become activated and go through the clonal expansion process creating Ag-specific 
lymphocyte pool. The differentiation of these cells leads to the clonal expansion of both 
“effector” cells, which immediately fight the foreign pathogen, and “memory” cells. Memory is 
a peculiar feature of the acquired immune system, which persists for a long time and is capable 
of reactivation in a subsequent encounter with same Ag. The pool of memory cells CD4+ T 
cells is heterogenic, phenotypically and functionally. According to the localisation and 
expression of specific markers, memory T cells are divided into central and effector memory 
cells T cells, TCM and TEM respectively. The TCM cells express CCR7 and CD62L and produce 
IL-2 upon stimulation. T effector memory cells do not express CCR7 marker and have a low 
CD62L expression, and produce IFN-γ and IL-4 upon stimulation (Sallusto et al., 1999). The 
established model propose that TCM mediate reactive memory, by homing to T cell areas of 
secondary lymphoid organs and readily proliferating and differentiating into effector cells upon 
antigenic stimulation, while TEM afford protective memory, by migrating to inflamed peripheral 
tissues and displaying immediate effector function (Lanzavecchia and Sallusto 2000; Sallusto 
et al., 2004).  
Immunological memory and specific memory CD4+ T cells provides the basis for 
successful protection against a variety of pathogens and successful vaccines applications 
(MacLeod et al., 2009). Since some of the activated cells die following the first response, the 
remaining memory cells are present at higher frequencies than the original naïve T cell. This 
higher frequency of memory, Ag-specific cells increases the likelihood of detection of re-
infection quickly. Second, the difference between naïve and memory cells is that memory cells 
are able to make effector responses more rapidly than primary responding cells (Swain et al., 
2006).  
In vitro effects of a common recall Ag, such as TTd on naïve and memory CD4+ T cell 
frequencies and a qualitative response evoked by this Ag, were used as a well-established 
system to explore the ability of the peripheral immune system to recognise it. 
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Aims 
 
1) The aim of this part of the study was to examine the expression of DR on peripheral 
CD4+ T subsets: Tn, TCM, and TEM by means of a novel flow cytometric method. 
2) To investigate the role of DA pathways in CD4+ Tn, TCM, and TEM cells, and their 
responses to recall Ag tetanus toxoid. 
 
Subjects enrolled in study 
 
Whole blood samples were obtained from adult healthy donors (n = 30) and were used 
for this part of the study. 
 
3.5.1. DR staining on CD4+ T naïve, TCM and TEM lymphocytes in whole blood 
 
Phenotyping of DR on Tn, TCM and TEM memory CD4+ T cells was performed by a 5-
color flow cytometric analysis by use of a two-step protocol which allowed the identification of 
all the five DR on different cell subsets. A method for DR staining in whole blood was 
performed as already established DR staining method in our laboratory (Kustrimovic et al., 
2014).  
? Each sample was prepared as 100 μL of a whole fresh blood added to BD tube. 
? From each subject 7 aliquots were prepared as follow: 5 were used for DR 
staining, 1 was used as a control for the secondary PEGAR Ab, and 1 was used as negative 
control (no Ab). 
? In order to remove the erythrocytes, 3 mL of a lysis buffer (containing NH4Cl 
8.248 g/L, KHCO3 1.0 g/L and EDTA 0.0368 g/L) were added to each sample.  
? Incubation was performed at RT for 5 min, during which samples were gently 
vortexed.  
? Samples were then centrifuged at 1200 g for 5 min at RT, supernatants were 
removed and cells were washed one time with 1 mL of PBS (pH 7.4) supplemented with 1 % 
BSA (PBS/BSA). 
? Pellets were resuspended in 50 μL PBS/BSA. 
Primary anti-DR Ab (final dilution 1:100) was added to the samples and incubated for 
30 min on ice in the dark. 
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? Cells were washed once with PBS/BSA at 1200 g for 5 min at RT. 
? Pellets were resuspended in 200 μL of PBS/BSA and 10 μL of PEGAR Ab was 
added. 
? Samples were incubated for 30 min on ice in the dark. 
? After incubation, samples were washed with 1 mL of PBS/BSA (1200 g for 5 
min at RT) and resuspended in 50 μL PBS/BSA. 
? A cocktail of pre-titrated PerCPCy5.5-conjugated mouse anti-human CD3, 
FITC-conjugated mouse anti-human CD45RA, APC-Cy7- conjugated mouse anti-human CD4, 
and AlexaFluor 647- conjugated mouse anti-human CCR7 was added to all samples. 
Samples were incubated for 30 min in dark at RT, after which were washed with 1 mL 
of PBS/BSA (1200 g for 5 min at RT). 
? Finally, samples were resuspended in 350 μL PBS and kept on ice until analysis. 
The acquisition was then performed on a BD FACSCanto II flow cytometer 
(BectonDickinson Italy, Milan, Italy) with BD FACSDiva software (version 6.1.3). 
Lymphocytes were identified by their classical FSC and SSC signals and a minimum of 20.000 
lymphocytes from each sample were collected in the gate. Data were analysed with FlowJo 
software (version 8.3.2). 
The results were finally expressed as a percentage of positive cells (%) identified as T 
lymphocytes, CD4+ T lymphocytes, and the following CD4+ T lymphocyte subsets: naïve 
(CD3+CD4+CD45RA+CCR7+), T central memory (CD3+CD4+CD45RA-CCR7+), and T 
effector memory (CD3+CD4+CD45RA-CCR7-) cells. 
 
3.5.2. T naïve/memory cell subsets characterisation and in vitro responses 
 
PBMC were isolated from the peripheral blood of healthy subjects by density gradient 
centrifugation as previously described (section 3.3.1.1.). 
? Prepared samples of isolated PBMC were resuspended at the final concentration 
of 0.5x106 cells in 500 μL of RPMI/10%FBS for subsequent culture: 48 h at 37°C in a moist 
atmosphere of 5% CO2. 
? Cells were cultivated with/without anti-CD3/anti-CD28 ab (0.1 μg/mL), and in 
the presence/absence of TTd (3 μg/mL) added at the beginning of cell culture. 
? After 48 h, cells were harvested and washed in PBS/1%BSA. 
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? Supernatants were removed and the pellet was resuspended and prepared for 
flow cytometric analysis of CD4+ Tn/TCM/TEM cells (by staining CD3/CD4/CD45RA/CCR7) 
subsets (section 3.5.1.). 
 
3.5.3. Analysis of obtained results 
 
3.5.3.1. Expression of DR in CD4+ Tn, TCM and TEM lymphocytes 
 
To identify CD4+ T naïve/memory cell subsets, the following gating strategy was 
applied: first, lymphocytes were gated on the scatter dot plot in the typical region of low SSC 
and FSC; CD3 and CD4 double positive cells were then identified among gated lymphocytes, 
by use of a biparametric dot plot CD45RA vs CCR7 were further identified T naïve 
(CD3+CD4+ CD45RA+CCR7+), TCM (CD3+CD4+CD45RA-CCR7+), and TEM 
(CD3+CD4+CD45RA-CCR7-). DR expression was assessed by a single-parameter histogram 
in desired subpopulations of CD4+ T cells (Fig. 21). 
 
Fig. 21 Gating strategy used to identify CD4+ T naïve, TCM and TEM cells. Total lymphocytes were 
identified on a biparametric dot plot SSC vs FSC (R1) (left panel). CD3+CD4+ T cells in R1 were 
selected by using the CD3 vs CD4 dot plot (R2), further specific subsets of CD4+ T cell subsets in R2 
were identified by a biparametric dot plot CD45RA vs CCR7. DR expression was assessed by a 
single-parameter histogram, where dark lines represent DR+ cells and light lines represent negative 
controls (cells stained with only secondary PEGAR ab), showing the analysis of DR D5 in a 
representative sample (right panels). 
The frequencies of total CD4+ T cells and defined subsets: Tn, TCM and TEM included 
in the study are summarised in table 13. 
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Table 13. Frequencies of CD4+ T naïve/memory subsets 
Lymphocyte subsets  mean±SEM 
CD4+ % of CD3+ 67.6±1.8 
T naïve % of total CD3+CD4+ 37.2±1.4 
TCM % of total CD3+CD4+ 24.8 ±0.9 
TEM % of total CD3+CD4+ 27.9±1.0 
 
DR+ cells were enumerated in Tn, TCM, and TEM cells. Expression of DR D1, DR D5, 
and DR D3, was significantly higher in Tn cells compared to TCM and TEM cells (**, P<0.0001), 
the same trend occurred in the case of DR D4 (*, P<0.01) and DR D2 (#, P<0.05), but with the 
different significance. The differences between TCM and TEM expression of each DR were not 
observed (Fig. 22). 
 
 
Fig. 22 Comparison of the expression of individual DR among naïve T cells, TCM and TEM cells. 
Results are presented as mean±SEM of 30 HS. **, P<0.0001 vs. TCM and TEM; *, P<0.01 vs. TCM and 
TEM and #, P<0.05 vs. TCM and TEM. 
 
3.5.3.2. Effects of TTd on the frequency of CD4+ T naïve and memory subsets 
 
Incubation of PBMC for 48 h with recall Ag TTd (3 μg/mL) decreased Tn and 
increased TEM cells (Figure 23). Co-incubation with either the D1-like DR agonist SKF-38393 
(1 μM), or the D2-like DR agonists pramipexole (1 μM), did not affect T naïve/memory cell 
frequency and did not modify the effects of TTd in PBMC isolated from HS (data not shown). 
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Figure 23. Effects of TTd in PBMC obtained from healthy subjects. Data are expressed as percentage 
variation with respect to control conditions (without TTd), and are means±SEM of n = 6-8 separate 
experiments each performed in duplicate. *, P<0.05 and **, P<0.01. 
 
These results are part of our manuscript entitled “Dopaminergic receptors on CD4+ T 
naïve and memory lymphocytes correlate with motor impairment in patients with Parkinson’s 
disease” Kustrimovic N, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Comi C, 
Mauri M, Minafra B, Sanchez-Guajardo V, Marino F, Cosentino M. (2016) Sci Rep. Sep 
22;6:33738 (Appendix 1.). 
 
Conclusions, implications and future perspectives 
 
Ex vivo results have shown the expression of all the five DR on human Tn, TCM, and 
TEM cells, to a different extent. Tn cells express higher levels of all the five different DR 
receptors, in comparison to TCM or TEM cell subsets. Obtained findings have opened the 
possibility to explore in more details relationship with the functional status of these cells, ex 
vivo and in vitro. 
So far, validated and developed in vitro method, could be used as an assay to test the 
function of memory CD4+ T cells towards recall Ag, and might potentially have relevance for 
a wide range of different fields of T cell biology research in health and disease. 
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3.6. T regulatory cell function 
 
Regulatory CD4+ T cells are suppressor cells that suppress other immune cells by 
various mechanisms (Sakaguchi et al., 2008). Characteristic markers of Treg cells are 
transcription factor Foxp3 and CD25. Treg cells are defined as T cells in charge of suppressing 
potentially deleterious activities of T helper cells.  
Recently, has been shown that in the human CD4+CD25high T lymphocyte fraction, 
both D1-like and D2-like DR, as well as several α- and β-AR subtypes and TH are 
constitutively expressed, and substantial amounts of DA, NA and A can be found (Cosentino et 
al., 2007). Endogenous DA release results in down-regulation of CD4+CD25high T cell-
dependent inhibition of CD4+ T effector lymphocyte proliferation, possibly through an 
autocrine/ paracrine loop involving DR D5 pathways and resulting in down-regulation of the 
regulatory function (Cosentino et al., 2007). 
 
Aims 
 
Several specific aims have been set: 
1) to assess DR expression on Treg cells obtained from peripheral blood of healthy 
subjects by the flow cytometry method, 
2) to examine in vitro Treg-induced inhibition of Teff proliferation, 
3) to characterise secretion of cytokines (IL-10 and TGF-?) by Treg alone, and to 
characterise Treg induced suppression of production of cytokines IFN-γ and TNF-α, by Teff 
cells, and to characterise effects of SKF 38393 (1 μM) and pramipexole (1 μM) on cytokine 
production 
4) to examine the relevance of the in vitro dopaminergic modulation of dopamine 
(1 μM) and L-DOPA (1 μM) on the function of CD4+CD25+ enriched population of T cells. 
 
Subjects enrolled in study 
 
1) For the first part of ex vivo DR expression explorative study, 32 healthy subjects 
have been enrolled. 
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2) To investigate in vitro Teff proliferation and Treg-induced inhibition preliminary 
experiments were with cells isolated from buffy coat samples (n=7). On the basis of this set of 
experiments, further study was focused on Treg and Teff cells obtained from HS (n=10). 
3) To characterise of in vitro cytokine production by Teff and Treg cells, our study 
enrolled healthy subjects (n=5). 
4) Aiming to explore effects of DA (1μM) and L-DOPA (1μM) on suppressive 
potential of Treg cells on Teff proliferation, Treg and Teff cells obtained from HS (n=7), PD 
patients on dopaminergic therapy (n = 10) and patients who had never been treated with 
antiparkinson drugs (n = 5). 
 
3.6.1. Immunofluorescent staining of DR on T regulatory cells in whole blood 
 
? 100 μL of peripheral venous blood sample was added to FACS-tubes. 
? 3 mL of lysis solution was added in order to remove erythrocytes. 
? Samples were incubated for 5 min at RT and vortexed gently. 
? Cells were centrifuged at 1200 g for 5 min RT and supernatants were carefully 
removed and additionally washed with 1 mL of PBS/1%BSA. 
? The ellet was resuspended in: 
? 50 μL PBS/BSA + anti-DA receptors Ab [final dilution 1:100], 
? 50 μL PBS/BSA (as a negative control) 
? Samples were incubated for 30 min on ice and subsequently washed with 1 mL 
of PBS/1%BSA. 
? Pellet was resuspended with 200 μL PBS/BSA, and 10 μL of PEGAR Ab was 
added. 
? Samples were incubated for 30 min in ice and wash with 1 mL of PBS/1%BSA. 
? The pellet was resuspended in 50 μL PBS/1%BSA. 
? A cocktail of the following antibodies was added: CD4APCCy5, CD25PECy7 
and CD127PerCPCy5.5 according to manufacturer’s recommendations. 
? Samples were incubated for 20 min at RT in the dark after what were washed 
with 1 mL of PBS/1%BSA. 
? Finally, the pellet was resuspended in 350 μL PBS and samples were kept on ice 
until flow cytometric acquisition. 
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By usage of this method CD4+ T cell subsets was identified as conventional Treg 
(CD4+CD25highCD127low) and subsequently, expression of five different subtypes of DR 
was examined.  
The acquisition was performed on a BD FACSCanto II flow cytometer (Becton 
Dickinson Italy, Milan, Italy) with BD FACSDiva software (version 6.1.3). Identification of 
lymphocytes was assessed by FSC and SSC signals and a minimum of 20.000 lymphocytes 
from each sample were collected in the gate. Data were analysed with FlowJo software 
(version 8.3.2). The results were expressed as a percentage of CD4+ cells (%). 
 
Separation of T effector and T regulatory cells 
 
Separation of PBMC by Ficoll-Hypaque method was performed initially as previously 
reported (section 3.3.1.1.). 
The isolation of CD4+CD25+ regulatory T cells was performed in two-step procedure 
with human CD4+CD25+ Regulatory T cell Isolation Kit (Miltenyi Biotec) according to the 
manufacturer’s instructions.  
 
Magnetic labelling of non-CD4+ cells 
 
? A defined number of PBMC was passed through 30-μm-nylon mesh in order to 
remove cell clusters that may clog the columns. 
? The cell suspension was centrifuged at 400 g, 10 min, RT. 
? The cell pellet was resuspended in Milteny Buffer (PBS/0.5% BSA/EDTA 2 
mM).  
? 10 μL (for 107 cells) CD4+ T cells Biotin-Antibody Cocktail, consisting of 
biotin-conjugated monoclonal anti-human antibodies, CD8, CD14, CD15, CD16, CD19, CD36, 
CD56, CD123, TCR γ/δ and CD235a was added into samples and mixed well and incubated 
for 10 min, in dark, at +4°C. 
? 20 μL (for 107 cells) Anti-biotin MicroBeads was added into samples mixed 
well and incubated for 15 min, in dark, at +4°C. 
? Samples were washed with 10 mL of Miltenyi Buffer and obtained pellet was 
resuspended in 500 μL of Miltenyi Buffer. 
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Magnetic separation: depletion of non-CD4+ cells 
 
? LD column was placed in the magnetic field of a suitable MACS Separator. 
? The column was prepared by rinsing with 3 mL of Miltenyi Buffer. 
? The cell suspension was applied onto the column. 
? After the cell suspension has passed the column was additionally washed three 
more times with 3 mL of Miltenyi Buffer.  
? The effluent was collected and consisted of unlabelled pre-enriched CD4+ cell 
fraction. 
 
Magnetic labelling of CD4+ CD25+T regulatory cells 
 
? The obtained effluent was centrifuged at 300 g, 10 min, RT. 
? Supernatant was removed and 10 μL (for 107 cells) of CD25 MicroBeads was 
added. 
? Samples were mixed well and incubated for 15 min, in dark, at +4°C, after 
which samples were washed in 10 mL of Miltenyi Buffer. 
? Samples were resuspended in 500 μL of Miltenyi Buffer. 
 
Magnetic separation: Positive selection of CD4+ CD25+ T regulatory cells 
 
? MS column was placed in the magnetic field of a suitable MACS Separator. 
? The column was prepared by rinsing with 500 μL of Miltenyi Buffer. 
? The cell suspension was applied onto the column and after it has passed the 
column was additionally washed 3 times with 2 mL of Miltenyi Buffer. 
? Flow-through containing T effector cells (unlabelled for CD25) was collected. 
? The column was removed from the separator and placed it in a suitable 
collection tube. 
? 1 mL of Miltenyi Buffer was pipetted onto the column and immediately flushed 
out by firmly pushing the plunger into the column. The cells that have been flushed out were 
CD25 labelled cells (T regulatory cells). 
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? In order to make sure that collection of cells was complete, the last step was 
repeated a second time. 
Both Treg and Teff viability more than 99% assessed by the Trypan Blue exclusion test. 
The purity of separated Teff and Treg was checked by flow cytometry. Briefly, 1x106 
of isolated PBMC, Teff, and Treg cells were taken and incubated with anti CD4-APC-Cy7, 
CD25-PR and CD127-AF647 Ab for 20 min in dark at RT. After the incubation samples were 
washed and resuspended in 350 μL of PBS and left on the ice. The acquisition was then 
performed on a BD FACSCanto II flow cytometer (Becton Dickinson Italy, Milan, Italy) with 
BD FACSDiva software (version 6.1.3). 
Results have shown that CD4+CD25highCD127low cells were present in separated 
populations as following percentages: 7.1±0.2% in Teff cells (Fig. 24), in Treg subpopulation 
76.1±3.2% have shown significant enrichment and in PBMC was only 7.9±1.6% (Fig. 25). 
 
Figure 24. Purity of separated T effector CD4+ cells 
 
 
Figure 25. Purity of separated T regulatory CD4+ cells 
 
 
T effector cell staining with Cell Proliferation Dye eFluor® 670 (CPD) 
 
? A desirable number of cells was washed with PBS 400 g, 10 min, RT. 
? Supernatants were carefully removed. 
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? Pellets were resuspended in 1 mL of 0.1% FBS/PBS working solution. 
? Dye colour was added to cell suspension (final concentration 2.5 µM). 
? Cells were incubated at RT for 8 min, protected from light. 
? The reaction was stopped by addition of equal volume of pre-warmed FBS and 
incubated for 10 min at 37°C for colour efflux. 
? Samples were washed 3 times 400 g, 5 min, with RPMI/10%FBS. 
? Supernatants were removed, and pellets were resuspended and prepared for cell 
counting with Trypan blue colour. 
This way Teff cells were prepared for the following cultivation.  
 
In vitro Treg-Teff cell co-culture 
 
Teff and Treg cells were obtained by magnetic separation as previously described. Both 
types of cells were plated alone or in co-culture (different Teff:Treg ratios) and cultivated 
under standard conditions, in RPMI 1640 medium supplemented with 10% heath-inactivated 
FBS, 2mM glutamine and 100 U/mL penicillin/streptomycin, at the final concentration 1 x 105 
cells/mL in the 96-well plate for 4 days, with/ without PHA (5 μg/mL) and IL-2 (40 ng/mL) 
that were added at the beginning of cell culture. Where specified, DA (1 μM), L-DOPA (1 
μM), D1-like DR agonist (SKF 38393, 1 μM) and D2-like DR agonist (pramipexole, 1 μM) 
were added at the beginning of cell culture. 
After 4 days, cells were collected and prepared for the further FACS Flow analysis. 
 
3.6.2. Flow cytometric analysis of Treg suppression capacity after in vitro 
cultivation 
 
Proliferation assay was quantified, by already established and validated method by flow 
cytometry, by usage of CPD dye enabling identification of Teff cells that are in proliferation, 
and thus indirectly enabling a measure of Treg suppressive effects on Teff cells proliferation. 
Briefly, at the end of cell culture, cells were collected and centrifuged: 1200 g, 5 min, RT, and 
pellets were resuspended in 350 µL of PBS. Samples were kept on ice prior to flow cytometry 
acquisition. 
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3.6.3. Quantification of cytokines by ELISA test 
 
Both Teff and Treg cell subpopulations were obtained by magnetic separation as 
previously described. For subsequent in vitro tests both type of cells was resuspended in RPMI 
1640 medium supplemented with 10% heath-inactivated FBS, 2mM glutamine and 100 U/mL 
penicillin/streptomycin. 1 x 104 cells of Teff or Treg cells were plated alone or in co-culture 
(Teff:Treg ratio = 1:1) and cultivated in standard conditions, RPMI/10% FBS for 48 h at 37°C 
in a moist atmosphere of 5% CO2, with or without PHA (5 μg/mL) and IL-2 (40ng/mL). In 
order to explore the effects of D1-like DR agonist (SKF 38393, 1μM) and D2-like DR agonist 
(pramipexole, 1μM) on the production of INF-γ and TNF-α cytokines by Teff and IL-10 and 
TGF-β cytokines by Treg, supernatants from 48 h conditioned cultures were analysed by 
ELISA. Results were compared with the cytokine secretion from the same culture without 
treatments. 
 
3.6.4. Analysis of obtained results 
 
In order to define Treg cells in the peripheral blood of healthy subjects, flow cytometric 
method was applied using the specifically created gating strategy. First, lymphocytes (LY) 
were gated on the dot plot in the typical region of low SSC and FSC, CD4+ positive T cells 
were then identified among gated lymphocytes. By the expression of the CD25 and CD127 
markers, within the defined CD4+ T cells, the population of CD25highCD127low cells was 
defined (often referred as conventional Treg) (Fig. 26). 
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Fig. 26 Gating strategy used to identify DR expression on total CD4+ T cells and conventional Treg 
(CD4+CD25highCD127low) in the peripheral blood of healthy subjects. Total lymphocytes were 
identified on a biparametric dot plot SSC vs. FSC (upper left, region LY), to exclude monocytes, 
granulocytes, and debris. From the cells in the LY region, CD4+ T cells were selected by using the 
FSC vs. CD4 dot plot (upper middle panel). CD4+T cell subset was further divided on biparametric 
dot plot CD127 vs. CD25 and cells defined as CD25highCD127low were selected. DR expression on 
total CD4+ T cells (upper, right panel) or on CD25highCD127low cells (lower, right panel) was 
assessed by a single-parameter histogram, where red lines represent DR+ cells and blue lines represent 
negative controls (cells stained with only secondary PEGAR ab). 
 
3.6.4.1. DR expression on T regulatory cells 
 
Results have shown percentages of total CD4+ T cells (51.0±7.9) and conventional 
Treg CD4+CD25highCD127low cells as 9.3±0.5 (mean±SEM). Further, conventional Treg 
(CD4+CD25highCD127low) expressed all five examined DR in following percentages: the D1-
like receptors, DR D1 14.8±2.0% and DR D5 by 14.4±1.9%, and the D2-like receptors: DR D2 
12.5±1.9%, DR D3 12.0±1.8% and DR D4 13.7±1.8% of conventional Treg (Fig. 27). So far 
results have not revealed any difference in the percentages of conventional Treg expressing 
different subtypes of DR. 
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Figure 27 Percentage of CD4+CD25highCD127low T cells in the peripheral blood of HS that are 
expressing different subtypes of DR. Results are presented as mean±SEM of 32 subjects. 
 
3.6.4.2. Proliferation and inhibition assay 
 
In order to discrete proliferating and resting Teff cells and Treg-induced inhibition, 2-
color flow cytometric method was applied. Proliferation assay was quantified, by already 
established and validated method by flow cytometry, by usage of CPD dye enabling 
identification of Teff cells that are in proliferation (Fig 28A), and thus indirectly enabling a 
measure of Treg suppressive effects on T effector cells proliferation (Fig 28B).  
Following gating strategy was used: first, lymphocytes were identified on the dot plot in 
the typical region of low SSC and FSC, and then CPD+ positive cells were identified among 
gated lymphocytes. By the expression of the CPD colour, within the previously defined 
population of CD4+ T cells, proliferating and resting Teff cells were examined (Fig. 28). 
 
DR D1 DR D5 DR D2 DR D3 DR D4
0
5
10
15
20
25
D1-like D2-like
C
D
4+
C
D
25
h
ig
h
C
D
12
7l
o
w
 T
 c
el
ls
 (
%
)
136 
 
 
Fig. 28 Gating strategy used to identify proliferating and resting Teff cells alone (A) or in the presence 
of Treg cells (ratio 1:1) (B) obtained from HS, after 4 days of cultivation in standard conditions. Total 
lymphocytes were identified on a biparametric dot plot SSC vs. FSC (left panels, region LY). From 
the cells in the LY region, CPD+ cells were selected by using the FSC vs. CPD dot plot (right, upper 
panels). Finally, proliferating and resting Teff cells were assessed by a single-parameter histogram 
(right, lower panels). 
 
The first part of a study aimed to develop and validate an in vitro models to investigate 
and characterise suppressive effect of Treg cells on Teff proliferation. In this regard were 
performed experiments of Teff-Treg co-culture with different ratios of Treg cells. Preliminary 
experiments were performed on cells obtained from buffy coat samples. On the basis of this 
results, showing the suppressive capacity of Treg on Teff proliferation and that this effect is 
dose dependent (Figure 29A) further experiments on peripheral blood from healthy subjects 
were performed. 
  
Figure 29 Curve of inhibition of Teff proliferation by Treg in buffy coat samples (n=7, A) and 
healthy subjects (n=9, B) cultivated in the presence of PHA (5 μg/mL) and IL-2 (40ng/mL). Black 
bar represents Teff cultured alone, while open bar represents co-culture of Treg and Teff in different 
ratios. Results are presented as a mean±SEM. *, P<0.05, ***, P<0.0001 vs. control. 
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Obtained results showed that Teff cells, obtained from peripheral blood of healthy 
subjects when cultivated alone, proliferate at 74.58±13.24% (Figure 29B), while in co-culture 
this proliferation was significantly diminished in presence of Treg cells at ratio 1:1, 1:0.5 and 
1:0.25 (33.16±3.52%; p<0.0001, 40.40±4.33%; p<0.0001, 53.05±7.48%; p<0.05, respectively) 
(Figure 29B). 
 
3.6.4.3. Effects of DA and L-DOPA on Treg-dependent suppression on Teff 
proliferation  
 
The ability of DA (1 μM) or L-DOPA (1 μM) to influence the suppressive potential of 
Treg cells was tested. Co-culture assays were performed as described above in cells obtained 
from 9 healthy subjects. In HS Teff proliferation was suppressed in the presence of Treg cells, 
however, DA and L-DOPA have restored proliferation of Teff cells trough inhibition of 
suppressive capacity of Treg cells (Figure 30).  
  
  
 
 
Figure 30 Percentage of proliferating Teff cells isolated from HS (n=7, panel A), patients who had 
never been treated with antiparkinson drugs (n=5, panel B) and PD patients on dopaminergic 
therapy (n=10, panel C) cultivated under standard conditions in the presence of PHA (5 μg/mL) and 
IL-2 (40 ng/mL), alone (open bar), or in co-culture with Treg cells at ratio 1:1 (black bar) or in the 
presence of DA (light grey bars) or L-DOPA (dark grey bars) for 96 h. Results are presented as a 
mean±SEM. *, P<0.05, **, P<0.01 vs. Teff cells. 
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3.6.4.4. Dopaminergic modulation of cytokine production of Teff and Treg cell 
subsets 
 
A) Production of proinflammatory cytokines by Teff cells 
 
After preliminary experiments performed (on 3-4 replicates) on non-activated Teff cells 
(data not shown), where we have shown only trace amounts of produced cytokines or even 
under detection level, the most reliable experimental design was considered to be established, 
and the same experimental conditions and design were used in all future experiments where 
Teff cells were always activated with PHA (5 μg/mL), alone (as a control) or in co-culture with 
Treg cells always in ratio 1:1, in all cytokine production experiments.  
Results obtained in a group of healthy subjects have shown that activated Teff cells 
produce 34.8±9.1 pg/mL of IFN-γ, and have reduced production on to 4.4±1.1 pg/mL in the 
presence of the same number of Treg (Figure 31, left). Further analysis has revealed that when 
cultivated alone Teff cells, in the presence of SKF 38393 or pramipexole, produced 23.4±9.0 
pg/mL and 23.5±7.1 pg/mL, respectively. Teff cells when co-cultivated with the Treg cells in 
the presence of SKF 38393 or pramipexole, reduced their production to 6.0±1.1 pg/mL and 
8.2±1.2 pg/mL, respectively suggesting that neither of employed agonist nor D1-like nor D2-
like DR agonist, have influenced suppressor potential of Treg cells (Figure 31). 
 
 
 
Figure 31 Production of INF-γ by resting (open bars) or activated with PHA (5 μg/mL) (black bars) 
Teff or Treg cells cultivated alone, or in the co-culture (grey bars) under standard conditions (panel 
A) and in the presence of D1-like DR agonist, SKF 38393 (1μM) or D2-like DR agonist, 
pramipexole (1μM) (panel B) for 48h in HS. Results are presented as a mean±SEM of 6 subjects. *, 
P<0.05 and **, P<0.01 vs. Teff+PHA; $, P<0.0001 vs. activated Teff alone. 
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Further, results have shown that activated Teff cells alone produce 247.2±19.1 pg/mL 
of TNF-α, while when cultivated in the presence of Treg (1:1 ratio) with PHA (5μg/mL), 
production of TNF-α was profoundly reduced to the 11.8±4.8 pg/mL (Figure 32, left). Teff 
cells cultivated in the presence of SKF 38393 or pramipexole produce lower quantities of 
examined cytokine, 109.0±43.3 pg/mL and 102.0±37.6 pg/mL, respectively. Nevertheless, 
either of applied DR agonists was not able to interfere with the suppressive potential of Treg 
cells (Figure 32). 
  
Figure 32 Production of TNF-α by resting (open bars) or activated with PHA (5 μg/mL) (black 
bars) Teff or Treg cells cultivated alone or in the co-culture (grey bars) under standard conditions 
(left panel) and in the presence of D1-like DR agonist, SKF 38393 (1μM) or D2-like DR agonist, 
pramipexole (1μM) (right panel) for 48h in HS. Results are presented as a mean±SEM of 6 subjects. 
****, P<0.0001 vs. Teff+PHA; $, P<0.0001 vs. Teff alone. 
 
B) Production of anti-inflammatory cytokines by Treg cells 
 
Obtained results have shown that activated Treg cells produce 17.81±6.78 pg/mL of IL-
10 when cultivated under standard conditions. Neither D1-like or D2-like DR agonist have 
influenced IL-10 production potential of Treg cells (Fig. 33). 
 
  
Figure 33 Production of IL-10 (panel A) and TGF-β (panel B) by activated Treg cells cultivated 
in standard conditions with addition of PHA (5 μg/mL) (open bars), in the presence of D1-like 
DR agonist, SKF 38393 (1 μM) (light grey bars) or D2-like DR agonist, pramipexole (1 μM) 
(dark grey bars) after 48h in HS (n=6). Results are presented as a mean±SEM. 
 
0
100
200
300
TN
F-
?
 (p
g/
m
l)
****
Teff Treg Teff+Treg
RPMI/10%FBS+PHA
RPMI%10%FBS
0
10
20
30
SKF 38393 (1?M) Pramipexole (1?M)control
A)
IL
-1
0 
(p
g
/m
l)
0
100
200
300
400
SKF 38393 (1?M) Pramipexole (1?M)control
B)
TG
F
- ?
 (
pg
/m
L)
140 
 
Further, the capability of Treg cells to produce TGF-β was tested. Obtained results have 
shown that Treg cells produce TGF-β in high amounts, 314.0±18.8 pg/mL when cultivated in 
standard conditions (RPMI/10%FBS) in the presence of activators. Obtained results have 
shown that neither of DR agonist applied did not influence the production of TGF-β by Treg 
cells (Fig. 33). 
 
Conclusions, implications and future perspectives 
 
Presented in vitro method was developed and validated through numerous pilot 
experiments conducted on buffy coat samples in which data showed suppressive Treg cell 
capacity. Further experiments were done with fresh blood from healthy subjects and have 
shown the same inhibitory capacity of Treg cells (at the ratios of 1:0.5 and 1:0.25 Treg cell 
dilutions). 
In addition, effects of DA and L-DOPA treatments seems to suppress Treg suppressive 
capacity in healthy subjects, since Teff cell proliferation is restored in comparison to co-culture 
control conditions (Treg + Teff cells, 1:1). Interestingly, the same effect of DA and L-DOPA as 
in healthy subjects was observed in PD-dn, but not in PD-dt group. Results suggest that 
dopaminergic agents influenced the suppressive capacity of Treg cells in healthy subjects and 
drug naïve PD patients, but not in patients that are on dopaminergic replacement therapy. 
Treg cells suppressed production of IFN-γ and TNF-α from Teff cells. Treatment with 
SKF 38393 and pramipexole did not influence the suppressive capacity of Treg. Neither IL-10 
or TGF-β production from Treg cells was influenced by SKF 38393 and pramipexole 
treatments. 
Due to the simplicity of Treg suppressive function assay, numerous variables including 
type of activation, cell number, and degree of proliferation can be manipulated within a single 
experiment. One of the weaknesses of in vitro Treg suppression assay is that Teff cells are 
sometimes hypo-proliferative, even in response to PHA stimulation (Thornton et al., 2004). In 
our conditions, the activation status of Teff cells is usually checked by flow cytometry method, 
based on the characteristically morphological phenotype of activated cells, and samples that 
were not fully activated were excluded from further procedures. 
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3.7. Model of commitment of naïve CD4+ T cells  
 
Naïve CD4+ T cells may acquire diverse phenotypes depending on stimulation of 
surrounding microenvironment (Zhu et al., 2010). The critical determinants for T cell 
differentiation are a network of cytokines involved in different phases of the complex process 
that these cells are going through. Cytokines are important for induction, priming phase of Th 
differentiation, expansion of different T cell subsets (growth and survival factors), autocrine 
positive/negative feedback loop and stabilisation of the population and finally lineage 
plasticity. 
Th17 cells have been recognised as a lineage separate from Th1 and Th2 cells, and also 
differentiation of Th17 cells is inhibited by factors, both IFN-γ and IL-4, that support Th1/Th2 
differentiation (Harrington et al., 2005; Park et al., 2005).  
 
Aims 
 
Several specific aims were proposed for this part of the study: 
1) In first part of study, ex vivo phenotypic characterisation of Th1, Th2, and Th17 
cell subsets was performed by flow cytometry analysis and DR expression was assessed on 
each Th defined subpopulations, 
2) To develop and validate reliable in vitro Th1/Th2/Th17 polarisation and 
cultivation method (buffy coat samples), 
3) To explore the role of dopaminergic modulation on polarisation and 
differentiation process of Th1, Th2 and Th17 subset in healthy subjects. 
 
Subjects enrolled in study 
 
1) Ex vivo determination of DR expression in different Th subsets was done on 
peripheral blood samples from healthy subjects (n=38). 
2) For preliminary in vitro experiments, naïve CD4+ T cells were isolated from buffy 
coat samples (n = 4), and followed by further experiments performed on cells isolated from 
peripheral blood of healthy subjects (n =4). 
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3.7.1. Frequency of CD4+ Th1, Th2 and Th17 T cell subsets in peripheral blood 
 
Standard protocol for isolation of PBMC was used (section 3.3.1.1.). 
From PBMC fraction, human naïve CD4+ T cells were isolated using the naïve CD4+ T 
cell isolation kit II (Miltenyi Biotec) according to the manufacturer’s protocol.  
The frequency of different Th subsets (Th1/Th2/Th17) among CD4+ T lymphocytes 
was analysed by a 4-color flow cytometric analysis. In this panel, CD4 was used as lineage 
marker and for identification of T cell subsets, three chemokine receptors were used: CXCR3 
(CD183), CCR4 (CD194) and CCR6 (CD196), as markers for Th1, Th2 and Th17 subsets, 
respectively. T helper subsets were defined as Th1 (CXCR3+CCR4-CCR6-), Th2 (CXCR3-
CCR4+CCR6-), Th17 (CXCR3-CCR4-CCR6+) and Th1/Th17 (CXCR3+CCR4-CCR6+). 
Flow cytometry staining was performed directly from whole blood, obtaining 
approximately 1 x 106 cells from 100µl of whole blood sample. 
? 100 μL of peripheral venous blood sample was added to FACS-tubes. 
? A cocktail of the following antibodies was added: CD4 APCCy5, CCR4 PECy7, 
CXCR3 AF488 and CCR6 PerCP-Cy5.5 according to manufacturer’s recommendations. 
? Samples were incubated for 30 min at RT in the dark. 
? 3 mL of lysis solution was added in order to remove erythrocytes. 
? Samples were incubated for 5 min at RT and vortexed gently. 
? Cells were centrifuged at 400 x g for 5 min RT and supernatants were carefully 
removed and additionally washed with 1 mL of PBS/1%BSA. 
? Pellets were resuspended in 350 μL PBS and samples were kept on ice until 
flow cytometric acquisition. 
 
Expression of DR on CD4+ Th1, Th2, and Th17 cell subsets 
 
Immunophenotyping of DR on CD4+ lymphocytes on different subsets of T helper cells 
was performed by two-step, 5 – color flow cytometric analysis from the whole blood. 
? Each sample was prepared as 100 μL of a whole fresh blood added to BD tube. 
? A cocktail of the following antibodies was added: CD4 APCCy5, CCR4 PECy7, 
CXCR3 AF488 and CCR6 PerCP-Cy5.5 according to manufacturer’s recommendations. 
? Samples were incubated for 30 min at RT in the dark. 
143 
 
? 3 mL of lysis solution was added in order to remove erythrocytes. 
? Samples were incubated for 5 min at RT and vortexed gently. 
? Cells were centrifuged at 400 g for 5 min RT and supernatants were carefully 
removed and additionally washed with 1 mL of PBS/1%BSA. 
? The pellet was resuspended in: 
? 50 μL PBS/BSA + anti-DA receptors Ab [final dilution 1:100], 
? 50 μL PBS/BSA (as a negative control) and 
? Samples were incubated for 30 min on ice and subsequently washed with 1 mL 
of PBS/1%BSA. 
? The pellet was resuspended with 200 μL PBS/BSA, and 10 μL of PEGAR Ab 
was added. 
? Samples were incubated for 30 min in ice and wash with 1 mL of PBS/1%BSA. 
? Finally, the pellet was resuspended in 350 μL PBS and samples were kept on ice 
until flow cytometric acquisition. 
Flow cytometric analysis was performed on BD FACSCanto II, and a minimum of 
20 000 cells was analysed from each sample. The results were finally expressed as percentage 
of positive cells (%). 
 
Purification and sorting of naïve CD4+ T cell isolation for in vitro cultivation 
 
For the optimal performance, it was important to obtain single-cell suspension before 
magnetic labelling thus, cells were passed through 30 μm nylon mesh to remove cell clumps. 
? PBMC number was determined. 
? Cells were centrifuged at 600 g, 10 min, RT and supernatants were removed. 
? Cells were resuspended in Miltenyi Buffer (PBS pH 7.2, free of Ca2+ and Mg2+, 
containing 0,5% BSA and 2 mM EDTA). 
? Naïve CD4+ T cell biotin-Ab cocktail was added, mixed well and incubated 5 
min, at +4 °C. 
? Incubation was stopped by adding ice-cold Miltenyi buffer. 
? Naïve CD4+ T cell MicroBeads cocktail was added, mixed well and incubated 
for another 10 min, at +4 °C. 
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? Meanwhile, LS Miltenyi Biotec column was prepared by rinsing with 3 mL of 
Miltenyi Buffer. 
? After incubation, the cell suspension was directly applied onto the column and 
flow-through containing unlabeled, enriched naïve CD4+ T cells were collected. 
? The column was washed additionally three times with 2 mL of Miltenyi Buffer 
and all unlabeled cells passed through were collected. 
? Cells were centrifuged 600 g, 10 min, at RT and resuspended in culture medium 
to determine cell number and viability by Trypan blue exclusion. 
After immunomagnetic sorting purity of separated naïve CD4+ T lymphocyte, 
population was checked by flow cytometry. 
Briefly, 1x106 of isolated, naïve CD4+ T lymphocyte cells were taken and incubated 
with anti CD3-PerCPCy5.5, CD4-PECy7, CD45RA-FITC and CCR7-AF647 Ab for 30 min, in 
dark, at RT. After the incubation samples were washed and resuspended in 350 μL of PBS and 
left on the ice. The acquisition was then performed on a BD FACSCanto II flow cytometer 
(Becton Dickinson Italy, Milan, Italy) with BD FACSDiva software (version 6.1.3). 
Identification of lymphocytes was assessed by FSC and SSC signals, for a minimum of 
20.000 lymphocytes from each sample collected in the gate and data were analysed with 
FlowJo software (version 8.3.2). 
To exclude debris and the potential presence of other cells, lymphocyte cells were 
gated, then CD3+CD4+ double positive T cells were identified and finally, naïve CD4+ T cells 
were assessed as an enriched CCR7+CD45RA+ cells population (Fig. 34). The purity of 
isolated naïve CD4+ T cells was more than 95% assessed by flow cytometry identified as naïve 
T cells subset (CD3+CD4+CD45RA+CCR7+). 
 
Figure 34 Purity of separated naïve CD4+ T lymphocyte population 
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In vitro cell culture and T cell differentiation assay 
 
Separated naïve CD4+ T cells were cultured in U-bottomed 96-well plates primed 
with anti-CD3/CD28 Ab, with/without DA or L-DOPA, added at the beginning of cell 
culture, under different polarising conditions (Table 14). Cells were placed in the incubator 
for 4 days, at 37 °C in a moist atmosphere of 5% CO2 with a minimum disturbance. After 4 
days of priming, cells were observed under a light microscope to confirm clusters of T cell 
activation. Samples were gently pipetted to break up clumps and washed at 600 g, 5min, RT. 
Supernatants were very carefully aspirated and replenished with fresh medium supplemented 
with human recombinant IL-2 (10 ng/mL or 2 ng/mL, as indicated in the table), and left for 
another 3 days to obtain preferably Th cell subsets expansion. 
 
Table 14. Polarisation condition of 7 days in vitro naïve CD4+ T cell differentiation 
 Th0 Th1 Th2 Th17 
Day 0 ? 
IL-12  
(10 ng/mL) 
anti-IL-4 Ab  
(10 μg/mL) 
IL-4  
(10 ng/mL) 
anti-INF-γ Ab  
(10 μg/mL) 
IL-1β (10 ng/mL) 
IL-6 (50 ng/mL)  
TGF-β (5 ng/mL) 
anti-INF-γ  
anti-IL4 Ab  
(both 10 μg/mL) 
Day 4 
IL-2  
(10 ng/mL) 
IL-2  
(10 ng/mL) 
IL-2  
(10 ng/mL) 
IL-2  
(2 ng/mL) 
 
 
 
Intracellular cytokine staining and flow cytometry acquisition 
 
? After 7 days, cells were collected, washed (600 g for 5 min at RT) and counted 
to obtained growth index (GI) in each polarisation route (Table 15). 
? Growth index was expressed as a ratio, a final number of cells after 7 days of 
culture divided with initial number of cells, and viability of cells was expressed as a % at day 
7. 
? Cells were counted with Trypan and adjusted to concentration of 1 x 106 
cells/mL for each sample. 
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? Each sample was additionally stimulated with: PMA (50 ng/mL), Ionomycine 
(Calcium Ionophore, 1μg/mL) and BD GolgiStop Protein Transport Inhibitor for 5h, at 37°C in 
a moist atmosphere of 5% CO2, prior to intracellular cytokine staining. 
? After 5 h of incubation, cells were washed and cell number in each sample was 
adjusted for analysis of intracellular cytokine expression.  
? Cells were stained with Human Th1/Th2/Th17 Phenotyping Kit according to the 
manufacturer’s protocol. 
 
Table 15. Different Th cell subsets GI and viability after 7 days of cell culture 
Th0 Th1 Th2 Th17 
GI viability GI Viability GI viability GI viability 
2.64±0.65 90.0±6.4 2.33±0.87 89.3±5.5 1.82±0.51 89.3±6.2 1.72±0.32 90.0±6.4 
 
Intracellular cytokine staining of cells  
 
? Cells were centrifuged at 1200 g, 5 min at RT. 
? Supernatant was removed and cells were washed once again with 1 mL of 
2%FBS/PBS. 
? After removing the supernatants, pellets were vortexed (to avoid cell 
aggregation) and resuspended in 1 mL of cold BD Cytofix Buffer and incubated at RT 
for 15 min. 
? After incubation, samples were centrifuged at 1200 g, 5 min, RT. 
? Samples were washed with 1 mL of 2%FBS/PBS, 1200 g, 5 min, RT and pellet 
were resuspended in 1 mL of 2%FBS/PBS and left overnight at +4 °C. 
? The day after, samples were centrifuged (1400 g for 5 min at RT) and the buffer 
was removed. 
? Samples were resuspended in 1 mL of 1X BD Perm/Wash buffer and incubated 
at RT for 15 min, after which were centrifuged at 1400 g, 5 min, RT and supernatant 
were carefully removed.  
? Fixed and permeabilised cells were resuspended in 50 µL of BD Perm/Wash 
buffer and 20 µL of Ab-cocktail (human Th1/Th2/Th17 cocktail containing: 
CD4PerCP-Cy5.5 clone SK3; IL-17A PE clone N49-653; IFN-? FITC clone B27 and 
147 
 
IL-4 APC clone MP4-25D2) or isotype control (Ig Isotype control, human CD4 PerCP-
Cy5.5) were added and incubated 20 min, at RT in the dark. 
? Samples were washed with 1 mL of Perm/Wash solution, and finally 
resuspended in 350 μl of 2%FBS/PBS (stain buffer) and kept on ice prior to flow cytometric 
analysis. 
The acquisition was performed on a BD FACSCanto II flow cytometer (Becton 
Dickinson Italy, Milan, Italy) with BD FACSDiva software (version 6.1.3). Total CD4+ T cells 
were identified on a biparametric dot plot SSC vs FSC to exclude possible presence of debris, 
and a minimum of 20.000 lymphocytes from each sample collected in the gate and data were 
analysed with FlowJo software (version 8.3.2). 
 
3.7.2. Analysis of obtained results 
 
3.7.2.1. Flow cytometric analysis of CD4+ T helper subsets 
 
In order to define different subsets of T helper cells in the peripheral blood of healthy 
subjects, flow cytometric method was applied using the specifically created gating strategy. 
First, lymphocytes were gated on the dot plot in the typical region of low SSC and FSC, CD4+ 
positive cells were then identified among gated lymphocytes. By the expression of the CXCR3 
and CCR4 markers, within the defined population of CD4+ T cells, following populations were 
defined: preTh1 and preTh2 subsets, respectively. PreTh1 cells were defined as 
CD4+CXCR3+CCR4-, while preTh2 were defined as CD4+CXCR3-CCR4+. Among the 
previously defined CXCR3+CCR4- preTh1 cells, two following subsets were defined as 
Th1/Th17 (CXCR3+CCR4-CCR6+) and Th1 (CXCR3+CCR4-CCR6-); and among CXCR3-
CCR4+ preTh2 cells, other two subsets were defined as Th17 (CXCR3-CCR4+ CCR6+) and 
Th2 (CXCR3-CCR4+ CCR6-) (Fig. 35). 
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Fig. 35 Gating strategy used to identify specific Th cell subsets in the peripheral blood. Total 
lymphocytes were identified on a biparametric dot plot SSC vs. FSC (left panel, region LY), to 
exclude monocytes, granulocytes and debris. From the cells in the LY region, CD4+ cells were 
selected by using the FSC vs. CD4 dot plot (right, upper panel). Further specific subsets of CD4+ T 
cell subsets were identified by a biparametric dot plot CCR4 vs CXCR3 (down middle panel). Finally, 
additional, specific Th cell subsets were further identified on the basis of CCR6 Th17 specific marker. 
 
3.7.2.2. DR expression on Th1, Th2, Th17 and Th1/Th17 cells 
 
The frequencies of total CD4+ T cells and defined subsets: Th1, Th2, Th17, and 
Th1/Th17 CD4+ T cell included in the study, are presented in Table 16. 
 
Table 16. Frequencies of CD4+ T helper cell subsets 
Lymphocyte subsets  mean±SEM 
CD4+ % of total Ly 47.0±1.3 
Th1 % of CD4+ 14.5±1.0 
Th2 % of CD4+ 7.7±0.7 
Th17 % of CD4+ 9.2±0.7 
Th1/Th17 % of CD4+ 11.9±0.9 
 
Four different subsets of CD4+ T helper cells were identified by means of the above-
described gating strategy. In defined subsets of T helper cells was sought to define the 
percentage of cells that are expressing diverse DR subtypes (Fig. 36). 
 
CXCR3-CCR4+ CXCR3+CCR4-
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Figure 36 Expression of DR on Th1 (**, P<0.01 vs DR D2 and DR D4; ***, P<0.001 vs DR D2 and DR 
D3; *, P<0.05 vs DR D2 and DR D5) (A), Th2 (*, P<0.05 vs DR D2 and DR D4; *, P<0.05 vs DR D2 and 
DR D4) (B), Th17 (***, P<0.001 vs all other receptor subtypes) (C) and Th1/Th17 (D) cells subsets in 
the peripheral blood of HS. Results are presented as mean±SEM of 38 subjects. 
 
DR expression on Th1 cells confirmed expression of all five DR (Fig. 36A), although 
present in different extension: D1-like DR D1 were expressed by 5.8±1.1% of total CD4+ T 
cells and DR D5 by 8.8±1.4%, while the D2-like DR D2 by 2.3±0.3%, D3 by 4.6 ±0.9 %, and 
D4 by 3.4±1.0 % (Figure 36A). Among Th1 subset, DR D1 expression was significantly higher 
(*,P<0.01) from DR D2 and DR D4; DR D5 expression was significantly higher (***,P<0.001) 
than DR D2 and DR D3 and expression of DR D3 was significantly higher (*,P<0.05) than DR 
D2. 
DR expression on Th2 cells confirmed expression of all five DR (Fig. 36B). D1-like 
DR D1 were expressed by 8.0±1.4% of total CD4+ T cells and DR D5 by 9.5±1.4%, while the 
D2-like DR D2 by 4.7±0.6%, D3 by 8.6 ±1.4 %, and D4 by 5.8±1.2 % (Figure 36B). Among 
Th2 subset, DR D3 and DR D5 expressions were increased significantly (*,P<0.05) when 
compared to expression of DR D2 and DR D4. 
DR expression on Th17 cells confirmed expression of all five DR (Fig. 36C). D1-like 
DR D1 were expressed by 21.8±3.4% of total CD4+ T cells and DR D5 by 25.2±3.6%, while 
the D2-like DR D2 by 2.9±0.5%, D3 by 13.4 ±2.3 %, and D4 by 43.2±3.9 % (Figure 36C). 
Among Th17 subset, DR D2 was expressed at the lowest percentage of Th17 cells while DR D4 
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were expressed at the highest percentage of this CD4+ subset compared to others DR 
examined. 
On Th1/Th17 cells, D1-like DR D1 were expressed by 16.5±2.8% of total CD4+ T cells 
and DR D5 by 22.0±3.4%, while the D2-like DR D2 by 2.5±0.4%, D3 by 9.0 ±1.8 %, and D4 by 
28.9±3.8 % (Figure 36D). Among Th1/Th17 subset, DR D2 and DR D3 expressions were 
lower (***,P<0.001) than all other receptors, while DR D4 expression was significantly higher 
(**,P<0.01) compared to the expression of DR D1. 
 
3.7.2.3. In vitro CD4+ T naïve cell commitment 
 
Further expansion of this method included in vitro polarisation of isolated naïve CD4+ 
T cells towards Th1, Th2 and Th17 subpopulation. Preliminary experiments were done on 
naïve CD4+ T cells obtained from 4 buffy coat samples (Figure 37). 
 
   
Fig. 37 Polarisation of naïve CD4+ T cells isolated from BC samples (n=4) by in vitro priming and 
expansion for 7 days under specific cultivation conditions, towards Th1 (panel A), Th2 (panel B) and 
Th17 (panel C). Percentage of CD4+ cells that are producing specific cytokine was assessed by 
intracellular staining after stimulation with PMA and ionomycin prior to intracellular staining 
procedure. 
 
Treatment of CD4+ T naïve cells with IL-12+ neutralising anti-IL-4 Ab gave rise to 
IFN-γ+ cells in comparison to Th0 conditions (63.5±2.2% vs. 31.9±8.6%, P<0.05). In the 
presence of IL-4 and anti-IFN-γ Ab, expression of IL-4+ cells increased (21.9 ±7.0% vs. 8.3 
±2.5%, P<0.05) compared to Th0 conditions. Percentage of IL-17A+ cells, raised in the 
presence of IL-1β, IL-6, TGF-β and anti- IFN-γ Ab and anti-IL-4 Ab, and was 6.1±1.3% vs. 
2.9 ±1.0% (P<0.05) control conditions. 
Obtained preliminary results have confirmed that experimental conditions are likely 
appropriate to study lineage-specific differentiation of CD4+ T naïve cells and the effects of 
dopaminergic agents. 
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3.7.2.4. Dopaminergic modulation of CD4+ T naïve cell commitment 
 
So far, experiments with dopaminergic agents, DA (1μM) and L-DOPA (1μM), did not 
show any effects on Th1 differentiation route of CD4+ T naïve cells development. 
Nevertheless, the trend of increase in INF-γ+CD4+ T cells under Th1 polarising conditions was 
observed in all experimental conditions compared to control, Th0 polarisation conditions 
(*,P<0.05 and **,P<0.01 vs. Th0 conditions) (Figure 38). 
 
Fig. 38 Effects of DA (1 μM) and L-DOPA (1 μM) treatments on Th1 polarisation route. Naive 
CD4+ T cells were isolated from peripheral blood of HS (n=4). Polarisation towards Th1 cells was 
obtained in the presence of IL-12 (10 ng/mL) and anti-IL-4 Ab (10 μg/mL) with addition of IL-2 
(10 ng/mL) and anti-CD3 and anti-CD28 Ab. Percentage of CD4+ T cells that are producing 
specific cytokine was assessed by intracellular staining after stimulation with PMA and ionomycin 
prior to intracellular staining procedure. Results are presented as mean±SEM of 4 subjects. *, 
P<0.05 and **, P<0.01 vs. Th0 control conditions. 
 
IL-4+ cell expression was 13.2 ±10.9% in basal conditions, and no significance was 
observed so far compared to DA (10.5 ±3.6%) or L-DOPA (10.1 ±3.5%) treatments (Fig. 39). 
 
Figure 39 Effects of DA (1 μM) and L-DOPA (1 μM) treatments on Th2 polarisation route. Naive 
CD4+ T cells were isolated from peripheral blood of HS (n=4). Polarisation towards Th2 cells was 
obtained in the presence of IL-4 (10 ng/mL) and anti-IFN-γ Ab (10 μg/mL) with addition of IL-2 
(10 ng/mL) and anti-CD3 and anti-CD28 Ab. Percentage of CD4+ T cells that are producing 
specific cytokine was assessed by intracellular staining after stimulation with PMA and ionomycin 
prior to intracellular staining procedure. Results are presented as mean±SEM of 4 subjects. *, 
P<0.05 vs. Th0 control conditions. 
 
Basal expression of Th17+ cells was under 5% (3.9 ±1.3%), and the treatments were 
ineffective DA (3.4 ±1.7%), and L-DOPA (3.9 ±1.6%) (Fig. 40). 
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Figure 40 Effects of DA (1 μM) and L-DOPA (1 μM) treatments on Th17 polarisation route. 
Naive CD4+ T cells were isolated from peripheral blood of HS (n=4). Polarisation towards Th17 
cells was obtained in the presence of IL-1β (10 ng/mL) IL-6 (50 ng/mL) TGF-β (5 ng/mL) and 
neutralising antibodies: anti-INF-γ anti-IL4 Ab (both 10 μg/mL); with addition of IL-2 (2 ng/mL) 
and anti-CD3 and anti-CD28 Ab. Percentage of CD4+ T cells that were producing specific 
cytokine was assessed by intracellular staining after stimulation with PMA and ionomycin prior to 
intracellular staining procedure. Results are presented as mean±SEM of 4 subjects. *, P<0.05 vs. 
Th0 control conditions. 
 
Conclusions, implications and future perspectives 
 
So far, ex vivo results have shown the expression of all the five DR on defined T helper 
subsets: Th1, Th2, Th17 and Th1/Th17, although to a different extent this notion is opening the 
possibility to explore relationship with the functional status of these cells in more detail. 
Conditions needed for the optimal in vitro Th1 and Th2 priming are well described in 
the literature, and are considering addition of IL-12 and IFN-γ or IL-2 and IL-4, respectively 
(O’Garra et al., 2011; Zhuet al., 2010). Different efforts have been made in identification of 
human Th17 cells, since the factors regulating mechanisms driving the differentiation of Th17 
cell and their function are unclear. Recent report indicates that in humans, RORγt expression in 
Th17 cells and naïve CD4+ T cells polarisation conditions are induced by IL-1β, and further 
enhanced by IL-6, and are suppressed by TGF-β and IL-12 (Acosta-Rodriguez et al., 2007). In 
our hands, optimal in vitro condition mimicking the Th17 polarisation route was obtained by 
IL-1β, IL-6 and TGF-β cytokine combination, and was not suppressed by IL-2. One must have 
in mind that these results are just preliminary and that this part of investigation is still ongoing 
in order to increase number of samples. 
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Discussion and conclusions  
 
The rationale of the presented research plan included the comprehensive evaluation of 
the relevance of the dopaminergic modulation of phenotypical and functional characteristics of 
human CD4+ T cell subsets. For each of the explored CD4+ T cell subsets, the first step was 
characterisation of the “dopaminergic phenotype” of circulating CD4+ T lymphocyte subsets 
(ex vivo) that served as a base line for the evidence of existence of different DR, followed by 
the application of in vitro functional experiments for each specific subset. 
The principal aim of the study was to develop and validate experimental in vitro 
methods devised to investigate the effects of DA agents on the functional responses of CD4+ T 
lymphocyte and the role of DA pathways in CD4+ T lymphocytes, namely: (i) CD4+ T naïve 
(Tn), T central memory (TCM) and T effector memory (TEM) cells, and their responses to recall 
Ag; (ii) CD4+ T regulatory cells (Treg), and their suppressive effects on T effector cells (Teff) 
and (iii) CD4+ T naïve cells, and their ability to differentiate towards different T helper (Th) 
lineages (Th1/Th2/Th17). 
For each set of experiments and applied and developed methods, preliminary 
experiments were carried out on buffy coat samples in order to establish the best experimental 
settings. The obtained results of experiments performed on buffy coat samples helped to 
develop and validate a method, and standardise culture conditions for following experiments 
with peripheral blood of healthy subjects. As specified, for each experiment, cells were 
cultivated in standard conditions, and when it was needed in both resting and activated 
conditions, anti-CD3 and anti-CD28 Ab were used as activators in order to mimic conditions 
most similar to the physiological condition. The number of samples for each experiment was 
obtained from a minimum of 5 subjects, whenever possible. 
? Results obtained from the ex vivo experiments have shown the expression of all the five 
DR on a different CD4+ human T lymphocytes subpopulations, to a different extent, opening 
the possibility to explore in more detail the patterns of DR expression among different CD4+ T 
cell subsets, and the relationship with the functional status of these cells in vitro. The presence 
of DR on immune cells and dopaminergic pathways demonstrated regulation of crucial human 
immune functions such as cell apoptosis or proliferation. So far, studies performed with human 
T cells suggested that both D1-like (DR D1, DR D5) and D2-like (DR D2, DR D3 and DR D4) 
receptor types contribute to the regulation of T cell functions, and various CD4+ T cell subsets 
have shown to express different arrangements of DR offering different possibilities for 
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modulation and manipulation of dopaminergic pathways on these cells (Levite et al., 2001; 
Ilani et al., 2004; Besser at al., 2005; Sarkar et al., 2006; Watanabe et al., 2006; Cosentino et 
al., 2007; Nakano et al., 2009; Pacheco et al., 2009; Prado et al., 2013; Kustrimovic et al., 
2014; Levite, 2016; Kustrimovic et al., 2016). Both human Teff and Treg expressed D1-like 
and D2-like receptors on their surface (Cosentino et al., 2007). 
? The most interesting observation in relation to the presented data was that among 
human lymphocytes, CD4+CD25+ Treg cells exhibit a peculiar sensitivity to the effects of DA, 
which is supported by previously published data by our group stating that endogenous DA 
subserves an autocrine/paracrine regulatory loop (Cosentino et al., 2007). Our data suggested 
that dopaminergic agents (DA and L-DOPA, 1 μM) have significant effects on suppressive 
capacity of Treg cells in HS. Furthermore, the results suggest that DA and L-DOPA also have a 
significant influence on the suppressive capacity of Treg cells in PD-dn, but not in PD-dt. 
Saunders et al. have also shown impaired abilities of Treg isolated from PD to suppress Teff 
cell function, which is in the line with our findings, and suggests that Treg disfunction is linked 
to PD pathobiology (Saunders et al., 2012). 
? Dopaminergic modulation of Treg function has been reported to profoundly affect 
neurodegenerative processes in animal models of neuronal injury (Kipnis et al., 2004; 
Reynolds et al., 2007). Kipnis et al., 2004 revealed that Treg cell exposure to DA in vitro, 
before their systemic injection into mice (animal model of neuronal survival), reduced their 
suppressive activity in vivo. The same authors found that mouse Treg express functional D1-
like receptors and that DA binding can suppress the suppressive activity of Treg on Teff cells 
(Kipnis et al., 2004). The mechanism, by which Treg suppress metabolic function in effector 
cells, includes the induction of apoptosis by competition for and deprivation of IL-2 (Stone et 
al., 2009). In consequtive studies, it was shown that D1-like receptor dependent activation on 
Treg leads to suppression of their suppressive function, and their ability to suppress Teff cells, 
and finally Teffs remained activated (Cosentino et al., 2007; Nakano et al., 2008). In this 
manner DA can indirectly affect Teff cells activation status and functional response. 
Pharmacological studies performed with different antagonists showed that reserpine-induced 
suppression of Treg function was due to DR D1, and not DR D5 stimulation.  
? In the present study, we performed an analysis of Ag-specific CD4+ T cell responses in 
humans, creating an in vitro model in which we used the exposure of PBMC to acute Ag 
exposure (48h), in particular the common recall Ag, tetanus toxoid. This model was used as a 
well established system to explore the ability of the peripheral immune system to recognise 
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TTd Ag and to investigate qualitative memory T cell, more specifically, both responses of 
naïve and memory CD4+ T cell frequencies evoked by an Ag. Our results provide a complete 
characterisation of memory CD4 T cell responses against TTd, indicating that the functional 
heterogeneity of memory CD4 T cells is modulated by the TTd Ag exposure. In vitro, TTd 
treatment increased frequency of CD4+ T memory cells, showing that our method is validated 
and developed to offer a base line model for application in the further investigation of naïve 
and memory CD4+ T cell subset, as shown in PD patients in comparison to HS (Kustrimovic et 
al., 2016). In the future, this model could be applied in similar pathologies where peripheral 
adaptive immune cell response is involved in an ongoing neuroinflammation process in the 
CNS, such as MS. To this end, our recently published data examined effects of dopaminergic 
substitution therapy and dopamine on CD4+ T naïve and memory lymphocytes in PD patients 
and in healthy subjects, showing that there is excessive association between DR expression on 
T lymphocytes and motor dysfunction, assessed by UPDRS Part III score (Kustrimovic et al., 
2016). Collectively, in total and CD4+ T naïve cells, expression of D1-like DR decreased, 
while in T memory cells D2-like increase with increasing score (Kustrimovic et al., 2016). In 
the second part, in vitro effects of α-syn were assessed on both CD4+ naïve and memory cells, 
showing an increase in CD4+ T memory cells, to a possibly different extent in PD patients in 
comparison to HS, and also to a different extent of DR affection within specific subset patterns 
(Kustrimovic et al., 2016). This finding further supports the involvement of peripheral adaptive 
immunity in PD. Interestingly, so far we did not observe any effects of SKF 38393 or 
pramipexole on the frequency of naïve/memory T cells (Kustrimovic et al., 2016). 
? Nakano et al., 2008 studied the effects of dopaminergic analogues on the interaction 
between monocyte-derived DCs (MO-DCs) and allogeneic, naïve CD4+ T cells from healthy 
volunteers and revealed that D1-like receptor blockade reduced, and D2-like receptor blockade 
increased IL-17 secretion by the T cells, showing that release of DA from MO-DCs, causes 
Th2 differentiation and polarisation (Nakano et al., 2009). Collectively, the conclusion was that 
MO-DCs contain DA that can release upon Ag-specific interaction with naïve CD4+ T cells, 
and that released DA can induce Th2 polarisation. Furthermore, it has been revealed that in 
DCs from DR D5 knockout mice, LPS-induced IL-23 and IL-12 cytokines production was 
impaired, and consequently activation and proliferation of Ag-specific CD4+ T cells was 
attenuated (Prado et al., 2012). Further in vivo studies revealed the role of DR D5 in murine 
model of MS, showing significant reduction of the percentage of Th17 cells infiltrating the 
CNS, and no effects on Th1 cell subsets (Prado et al., 2012; Pacheco et al., 2014). Another 
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interesting in vivo study addressed the role of DA through its D1-like receptor in cutanous 
immune response in Th subsets polarisation, where it was shown that DA promote Th2-cell 
differentiation and mast cell degranuation, without effecting Th1 cell function (Mori et al., 
2013). Considering this background, our goal was to develop and validate an in vitro method 
for the polarisation of human naïve CD4+ T cell and their commitment. Different efforts have 
been made in identification of human Th17 cells, since the factors regulating mechanisms 
driving the differentiation of Th17 cells and their functions are unclear. A recent report 
indicates that in humans, RORγt expression in Th17 cells and naïve CD4+ T cells polarisation 
conditions are induced by IL-1β, and further enhanced by IL-6, and on the other hand are 
suppressed by TGF-β, IL-2 and IL-12 (Acosta-Rodriguez et al., 2007; La Cava et al., 2008). In 
our experience, optimal in vitro condition mimicking the Th17 polarisation route was obtained 
by IL-1β, IL-6 and TGF-β cytokine combination, and was not suppressed by IL-2. So far, our 
in vitro data have shown no significant effect of DA or L-DOPA on the polarisation process of 
defined T helper subsets: Th1, Th2 and Th17. Nevertheless, it must be emphasised that our 
results are very preliminary, and this component of the investigation is still ongoing in order to 
increase the number of samples - so further in vitro findings are necessary in order to carefully 
add knowledge to this complex issue. 
? It has been shown that peripheral T lymphocytes are more prone to apoptotic process, 
thus decrease number of CD4 + T cells may be used to follow up progression of the PD 
disease. So far, our in vitro results suggest that dopaminergic agents show that DA and L-
DOPA concentration in range (1-50 μM) did not have any significant influence on CD4+ T cell 
viability, while much higher concentrations of both agens (100 μM) induced non-specific 
effects in T cells, which were likely toxic and killed them. Thus, very high concentrations can’t 
be used for induction of specific and beneficial DA effects, and should also be avoided in 
further experimental procedures. Our data is rather consistent with a Bergquist et al., 1997 
study that claims that B cells, and not T cells, are sensitive to the DA concentration (10 nM), 
than later studies by Besser et al., 2005 and Levite, 2012 claiming that DA induce direct and 
very potent effects on T cells at low concentrations (of 10 nM). Bergquist et al., 1997 have also 
pointed out that, at high concentration, dopamine has negative effects on PBMC by elevating 
the synthesis of the apoptotic markers (Bcl-2/Bax and Fas/FasL) and finaly elevating the level 
of apoptosis (by ~ 2.8-fold) (Bergquist et al., 1997). 
? Most of the studies demonstrate DA as a negative regulator of T cell proliferation in 
both healthy subjects and pathological conditions (Saha et al., 2001). Bergquist et al, 1997 also 
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revealed that DA significantly inhibited the proliferation and production of cytokines (IFN-γ 
and IL-4) at the very high concentration (10 –100 μM) by PBMC in response to mitogens 
(ConA and PWM) (Bergquist et al., 1997). In 2000, the same group confirmed that these high 
concentrations of DA (10 –100 μM) also inhibited the LPS-induced binding of NF-ĸB to the 
promoter of TNF-α (thus inhibiting production of this pro-inflammatory cytokine), and that 
lower concentrations of DA (1 μM– 10 nM) did not induce such inhibitory effects (Bergquist et 
al., 2000). Ghosh et al., 2003 revealed that human T cells in vitro stimulated with anti-CD3 and 
treated with 3-5 ng/mL DA significantly inhibited proliferation of these cells. A 
pharmacological study with antagonists revealed that DA inhibited T cells activated with anti-
CD3 Ab, through the DR D2 and DR D3. So far, our data did not show any significant effect of 
dopaminergic agents on CD4+ T cell proliferation. However, the concentrations of DA used in 
those in vitro experiments were similar to those that we applied, and also to the physiological 
plasma level of this neurotransmitter, but the method to obtained proliferation of T cells was 
assessed by incorporation of 3H thymidine, and after a 3-day culture, while our method 
involved the use of a CPD marker which was measured after 4 days of cell culture. 
The molecular and pharmacological heterogeneity of DR potentially represents an 
opportunity to develop targeted immunomodulating strategies. The main working hypothesis 
was that different subsets expressed different patterns of DR, which may offer possibilities for 
immuno-pharmacological manipulations, and the possibility to repurpose dopaminergic agents 
currently used in the pharmacotherapy of various diseases. 
Recently, (Chen et al., 2013; Gonzalez et al., 2013) demonstrated that genetic 
deficiency of the highest affinity DR, the DR D3, in murine model of PD attenuates 
neuroinflammation and subsequent neurodegeneration, induced by acute intoxication with 
MPTP. Based on these findings Elgueta et al., 2017 show that treatment of MPTP-intoxicated 
mice with DR D3-selective antagonist, PG01037 attenuated loss of dopaminergic neurons in 
the nigrostriatal pathway and resulted in significant improvement of locomotor impairment. 
Further analyses of PG01037 therapeutic potential show that it could be mediated by the 
induction of an intermediate M1/M2-like phenotype in astrocytes, which could transmit an 
anti-inflammatory signal to microglial cells (Elgueta et al., 2017). Taken together, they 
concluded that these findings can contribute to a better knowledge of the physiopathology of 
PD, but they also provide the clues for new therapeutic approaches for the treatment of this 
neurodegenerative disorder. 
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In certain pathophysiological conditions, a dysfunction of dopaminergic system might 
be expressed by: (i) impaired DA levels in CNS and/or at the periphery, (ii) abnormal DA 
production, (iii) abnormal DR expression and/or response to DA, and possibly (iv) impaired 
dopaminergic signalling, hence testing different concentrations of DA analogues in vitro that 
potentially affect different T cell subsets that are expressing different patterns of DR might 
even vary in healthy individuals and cells obtained from individuals that are suffering from 
certain pathological conditions (in the first line model of Parkinson’s disease).  
An understanding of the distinct families of molecules present in different T cell subsets 
actually provides the tools for distinguishing these cell types in both diagnosis and therapy, as 
well as understanding the molecular basis for T cell functions, such as: proliferation, apoptosis, 
cytokine production, suppressive, anti-inflammatory or neuroprotective functions, etc. These 
are of great importance as a prognostic marker if the association between DR expression on T 
lymphocytes is shown to be associated with a disease’s symptoms or severity during the course 
of lifetime (Kustrimovic et al., 2016). 
Understanding functional modifications occurring in peripheral immunity in healthy 
individuals, but also during different pathological processes, and above all the contribution of 
dopaminergic pathways in different dopamine-related diseases conditions will lead to a better 
understanding of physiopathology, and will provide a better exploitation of currently available 
dopaminergic drugs, possibly also to the development of innovative pharmacological 
approaches. 
Dopamine-induced effects on T cells are very sensitive, and the most important factors 
that are dictating the outcomes could be attributed to chosen activators and activation 
conditions of T cells, applied concentrations of DA or agonist, specific subset of CD4+ T cells 
that DA interacts with, and finally, the particular type of DR that will be activated by DA. 
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Table 17. Summarising experimental methods, results and effects of dopaminergic agonist 
Assay DR expression results Effects of dopaminergic agonist (all are in vitro methods) 
In vitro apoptotic 
assay of CD4+ T 
cells cultivated as 
PBMC (48h) (Flow 
cytometry) 
High expression of DR in apoptotic cells 
and stimulation-induced ↑ % of all 
examined DR  
Effects on CD4+ T cell viability 
DA (only 100 μM) 
+++  
 
L-DOPA (only 100 
μM) 
+++ 
Pramipexole (0,1-100 μM) 
– 
In vitro proliferating 
assay of CD4+ T 
cells cultivated as 
PBMC (96h) (Flow 
cytometry) 
Both proliferating and non-proliferating 
CD4+ T lymphocytes expressed all the five 
DR  
Proliferating cells express higher 
percentages of DR 
Effects on CD4+ T cell proliferation 
DA (1-50 μM) 
– 
 
L-DOPA (1-50 μM) 
– 
 
Pramipexole (0,1-100 μM) 
– 
Functional responses 
of T naïve/memory 
subset (48h) (Flow 
cytometry) 
Ex vivo: 1. the expression of all the five 
DR on human T naïve, TCM and TEM cells 
2. T naïve cells express higher levels of 
DR than TCM or TEM subsets 
In vitro: developed method to test function 
of CD4+ T cell memory towards recall Ag  
Effects on a frequencies of human T naïve, TCM and TEM cells 
 
 
 
SKF 38393 (1 μM) 
– 
 
 
 
 
Pramipexole (1 μM) 
– 
Treg cell functions 
(96h)  (Flow 
cytometry and 
ELISA assay) 
 
 
Ex vivo: conventional Treg 
(CD4+CD25highCD127low) expressed all 
Effects on Treg suppressive capacity in Teff/Treg co-culture (1:1) 
HS group PD-dn group PD-dt group 
DA (1 
μM)   + 
L-DOPA 
(1 μM)  + 
DA (1 
μM)   + 
L-DOPA 
(1 μM) + 
DA (1 
μM)   – 
L-DOPA (1 
μM)   – 
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five DRs 
 
 
In vitro: suppressive Treg cell capacity in 
co-culture with Teff cells in all groups 
 
 
 
Effects on Teff cytokine production in Teff/Treg co-culture (1:1) in HS 
INF-γ TNF-α 
SKF 38393 (1 
μM)    — 
Pramipexole (1 
μM)    — 
SKF 38393 (1 
μM)    — 
Pramipexole (1 
μM)    — 
Effects on Treg cytokine production (cultivated alone) in HS 
IL-10 TGF-β 
SKF 38393 (1 
μM)    — 
Pramipexole (1 
μM)    — 
SKF 38393 (1 
μM)    — 
Pramipexole (1 
μM)    — 
Comitmment of 
naïve T cells (7 
days) (Flow 
cytometry) 
Ex vivo: expression of all the five DR on 
defined T helper subsets: Th1, Th2, Th17 
and Th1/Th17 
In vitro: set up of optimal condition 
mimicking for each specific polarisation 
route (Th1, Th2 and Th17) 
Effects on a lineage-specific differentiation of CD4+ T naïve cells 
 
DA (1 μM) 
– 
 
 
L-DOPA (1 μM) 
– 
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Summary of the results: 
 
1. Results have shown the expression of all the five DR on human CD3+CD4+ T 
lymphocytes to a different extent. Relative prevalence of D1-like over D2-like DR in 
CD3+CD4+ T cells may imply that effects of DA on these cells are mediated mainly through 
D1-like DR. 
 
2. High expression of DR in cells undergoing apoptotic process and stimulation-induced DR 
increase in cultured CD4+ T cells suggests the involvement of DR in the apoptotic process, 
and further supports the involvement of DR in the functional regulation of activated cells, 
requiring further investigations to assess the role of DR subtypes in the modulation of 
specific responses. 
 
3. Possibly, in resting cells dopaminergic pathways participate mainly in apoptotic processes 
(as suggested by the high proportion of apoptotic cells expressing DR), while their functional 
relevance increases in activated cells (in line with stimulation-induced upregulation of DR in 
viable cells). 
 
4. Ex vivo data have shown that proliferating and non-proliferating CD4+ T lymphocytes 
expressed all the five DR, in different expression levels. Interestingly, a trend of proliferating 
cells expressing DR in higher percentages was shown. Tested concentrations of dopaminergic 
agonists have not shown any major effects on proliferation of CD4+ T cells. 
 
5. All the five DR were shown to be expressed ex vivo on each of the following human T 
naïve, TCM and TEM subsets. T naïve cells expressed higher levels of DR than TCM or TEM 
subsets. 
 
6. We have developed and validated an in vitro method to test the functional response and 
balance of frequency of naïve/memory CD4+ T cell in response to a common recall Ag 
(TTd). Furthermore, treatments with SKF 38393 and pramipexole did not show any effect on 
the frequencies of human T naïve, TCM or TEM cells. 
 
7. Obtained results from ex vivo experiments have shown that conventional Treg 
(CD4+CD25highCD127low) expressed all five DR. 
 
8. Presented in vitro, a method was developed and validated through numerous pilot 
experiments on buffy coat samples in which suppressive Treg cell capacity was shown. 
Experiments done with fresh blood from HS have shown the same inhibitory capacity of Treg 
cells. 
 
9. Effects of DA and L-DOPA treatments suppress Treg suppressive capacity in HS, since 
Teff cell proliferation is restored in comparison to co-culture control conditions (Treg + Teff 
cells, 1:1). The same effect of DA and L-DOPA as in HS, was observed in PD-dn, but not in 
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in PD-dt group, suggesting that dopaminergic agents influence the suppressive capacity of 
Treg cells in HS and PD-dn, but not in PD-dt. 
 
10. Treg cells suppressed the production of IFN-γ and TNF-α from Teff cells. Treatment with 
SKF 38393 and pramipexole did not influence suppressive capacity of Treg. Neither IL-10 
nor TGF-β production by Treg cells was influenced by SKF 38393 and pramipexole 
treatments. 
 
11. Ex vivo data have shown the expression of all the five DR on defined T helper subsets: 
Th1, Th2, Th17 and Th1/Th17; to a different extent this notion is opening the possibility of 
exploring in more detail the relationship with the functional status of these cells. 
 
12. We have developed and validated an in vitro method optimal condition mimicking 
specific polarisation routes (Th1/Th2/Th17). Obtained preliminary results have confirmed 
that experimental conditions are likely appropriate to study lineage-specific differentiation of 
CD4+ T naïve cells and the effects of dopaminergic agents.  
 
13. So far, experiments with dopaminergic agents (DA and L-DOPA) did not show any 
effects on Th1/Th2 or Th17 differentiation route of CD4+ T naïve cells development. These 
results are very preliminary and are part of an ongoing investigation, in order to increase 
number of samples. 
 
The results of the presented data have shown that CD4+ T cells play a relevant role in 
the PD pathological condition, and in particular intrinsic dopaminergic pathways in Treg cells 
may represent a target for pharmacotherapeutic intervention. Further in vitro findings are still 
necessary in order to add knowledge about the sensitivity of CD4+ T cell to DA and other 
dopaminergic agents presently in clinical use. 
Furthermore, it seems quite inconsistent that, to the best of our knowledge, no studies  
regarding possible immunomodulating effects of dopaminergic agents currently employed for 
the symptomatic treatment of PD have so far been explored. This is clearly another large area 
where thorough research may provide unpredictable findings, possibily contributing to a 
better understanding of the mechanism(s) of action of dopaminergic agents currently used in 
pharmacotherapy. 
In both directions of our research approach (ex vivo examination of CD4+ T cell phenotype 
and in vitro models develop for characterisation and testing different CD4+ T cell subsets 
functions), by combining this two diverse experimental approaches, we fulfilled the 
expectations to generate and validate new methods to better describe the whole picture of 
CD4+ T cell subsets function and phenotype. Of course, one must consider that models have 
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limitations and that these models need further validation, but they could be a good starting 
point to uncover dopaminergic pathways in healthy subjects, as well as alterations present in 
dopamine-related diseases. 
For the comparison of immune responses in vitro and in vivo, it is fundamental to 
understand how so far described in vitro functional responses of CD4+ T cells can be 
translated to the in vivo system. Careful analysis of in vitro data obtained so far should be 
translated into the in vivo system, and obtained responses to different concentrations of 
dopaminergic agonist in vitro should be used for predicting the effects of dopaminergic 
agents in biological systems, providing a better understanding of dopamine modulation of 
different CD4+ T cell subsets in vivo. 
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V. FUTURE PERSPECTIVES  
 
Despite all discrepancies of the in vitro data experiments that different studies bring to us, 
our general knowledge about dopaminergic effects on T cells is growing. Some essential 
experiments are missing in this specific area, and to this end should bring new findings to the 
genuine in vitro and in vivo predictions, thus some questions remains opened. 
In my opinion, the experiments that need to be performed in the future are listed below: 
(i) Interestingly, the expression of DR on proliferating and, at the same time non-
proliferating cells have shown a trend of higher expression of all DRs on 
proliferating in comparison to non-proliferating CD4+ T cells. These data are part 
of preliminary experiments (n=3-4), so further experiments are needed to examine 
this specific, possible effect of dopaminergic agonist on CD4+ T proliferating 
cells. 
(ii) As dopamine is the physiological neurotransmitter, its own effects are more 
precious than those of artificial agonists (such as SKF 3839), so I propose that, all 
the future experiments should always be started from the basic settlement (e.g. 
knowing that DA concentration of 10 nM will give a specific physiological 
response of CD4+ T cell in our experimental settings and conditions. 
(iii) Testing the effects of dopamine agonist (in first instance L-DOPA and 
pramipexole) that are currently used in the clinical practice, and comparing their 
effects to the one of dopamine, will add new insights to the body of growing 
evidence and will clear the direction for new therapeutical approaches. 
(iv) Dopamine-induced effect which was confirmed/shown so far should be completed 
with sufficient experimentation showing that specific effects are exerted by 
specific DR subtypes on the basis of an antagonists study using highly selective 
DR antagonist. 
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VI. Appendix 1 
 
Attached file 1: Dopaminergic receptors on CD4+ T naive and memory lymphocytes 
correlate with motor impairment in patients with Parkinson’s disease. Kustrimovic N, 
Rasini E, Bombelli R, Aleksic I, Blandini F, Comi C, Mauri M, Minafra B, Riboldazzi G, 
Sanchez-Guajardo V, Marino F, Cosentino M. Sci Rep. 2016;6:33738. 
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Abstract 
My contribution to the presented manuscript entitled “Dopaminergic receptors on 
CD4+ T naïve and memory lymphocytes correlate with motor impairment in patients with 
Parkinson’s disease” published online on 22 September, 2016 (doi: 10.1038/srep33738) in 
Scientific Reports, involved developing a research program on the dopaminergic modulation 
of CD4+ T lymphocytes as part of my work for the PhD Course in Clinical and Experimental 
Medicine and Medical Humanities, University of Insubria (XXIX cycle). 
As the extent of the experimental work done so far is beyond the scope of my thesis 
and manuscript (listed below), it is expected that additional manuscripts will be published in 
the nearest future. 
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T Naive and Memory Lymphocytes 
Correlate with Motor Impairment in 
Patients with Parkinson’s Disease
Natasa Kustrimovic?, Emanuela Rasini?, Massimiliano Legnaro??? ????????Bombelli?, 
Iva Aleksic?, Fabio Blandini?, Cristoforo Comi?, Marco Mauri?, Brigida Minafra?, 
Giulio Riboldazzi?, Vanesa Sanchez-Guajardo?, Franca Marino? & Marco Cosentino?
Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons in substantia nigra pars 
compacta, α-synuclein (α-syn)-rich intraneuronal inclusions (Lewy bodies), and microglial activation. 
???????????????????????????????? ??+? ??????????????????????????????????????????????? ??? ?????
the mainstay of PD treatment is dopaminergic substitution therapy and dopamine is an established 
??????????????????????? ???????????? ?????????????? ??????????? ??+ T naive and memory 
??????????????? ?????????????????? ?????????????????????? ?????????????????????? ?????????????????????
(DR) expression. In addition, the in vitro???????????α????? ????????????? ?? ??+ T naive and memory 
cells. Results showed extensive association between DR expression in T lymphocytes and motor 
????????????????????????? ?? ????? ???????????????????????????? ??+ T naive cells expression of D?-
like DR decrease, while in T memory cells D?-like DR increase with increasing score. In vitro, α-syn 
?????????? ??+? ? ??????????????????????????? ?????????????????? ?????????????????? ??????????????? ??
??????????? ?????????????????????????????????? ?????????????????????????????????????????????????????????
adaptive immunity in PD, and may contribute to develop novel immunotherapies for PD, as well as to 
better use of current dopaminergic antiparkinson drugs.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, a"ecting an estimated 7 to 
10 million people worldwide and resulting in both motor and cognitive disturbances1–3. #e main neuropatho-
logical features of PD are the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, 
the appearance of intraneuronal inclusions called Lewy bodies, and the occurrence of microglial activation. 
Microglial cells in particular are key players in neuroin$ammation and neurodegeneration, and peripheral adap-
tive immunity has been recently proposed as a major determinant in the regulation of microglial function during 
neurodegenerative disease4–7.
Over the last 15 years, several studies described the occurrence of peculiar modi%cations of peripheral immu-
nity in PD, such as decreased CD4+ /CD8+ T-cell ratios, fewer CD4+ CD25+ T cells and increased ratios of 
interferon (IFN)-γ -producing to interleukin (IL)-4-producing T cells8, as well as decreased CD4+ T lympho-
cytes and CD19+ B cells9,10. Both CD8+ and CD4+ T cells (but not B cells) were identi%ed in the brain in both 
postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse 
model of PD, and evidence obtained in the animal model pointed to CD4+ T cells as main determinants of 
T cell-mediated dopaminergic cell death11. Remarkably, Saunders et al.12 recently reported that PD patients have 
increased e"ector/memory CD4+ T cells and decreased CD31+ and α 4β 7+ CD4+ T cells, which are associated 
with progressive motor dysfunction, suggesting a direct relationship between chronic immune stimulation and 
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Neurodegenerative Diseases, “C. Mondino”, National Neurological Institute, Pavia, Italy. ?Movement Disorders 
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PD neuropathology and disease severity, as well as strengthening the idea that in PD the lead actors among adap-
tive immune system cells are CD4+ T lymphocytes.
No therapies are currently available for the neurodegenerative processes underlying PD, and symptomatic 
treatments rely on the dopamine (DA) precursor l-DOPA as well on dopaminergic agonists and on other indi-
rect dopaminergic agents. Dopaminergic drugs relieve to some extent the loss of brain dopaminergic neurons 
occurring in PD, although, as disease progresses, both nonmotor and motor symptoms emerge that are resistant 
to dopaminergic medications13. Interestingly DA, besides its role as brain neurotransmitter, is also an established 
transmitter connecting the nervous and the immune system, as well as immune cells and peripheral tissues14–16. 
DA a"ects both innate and adaptive immune system cells, and immune cells produce DA, which may act as 
autocrine/paracrine mediator on immune cells themselves and on neighboring cells17–22. Among T lymphocytes, 
CD4+ T cells may represent a major target for DA. DA subserves an (auto)inhibitory loop in human CD4+ 
CD25high regulatory T lymphocytes, a specialized T cell subset playing a key role in the control of immune home-
ostasis23, and dendritic cells-derived DA a"ects the di"erentiation of naive CD4+ T cells24. #e e"ects of DA are 
exerted through 5 di"erent dopaminergic receptors (DR) grouped into the D1-like (D1 and D5) and the D2-like 
(D2, D3 and D4)
25,26. Immune cells express all DR and in particular CD4+ T cells express both D1-like and D2-like 
DR23,27, with CD4+ naive T cells expressing more D1-like than D2-like DR, which on the contrary are increased 
in memory T cells28. Despite extensive evidence supporting the involvement of CD4+ T cells (and in particular 
of memory T cells) in PD pathogenesis and progression8,10–12, no information exists on DR expression on CD4+ 
T cells in PD patients. Nonetheless, a recent investigation in the MPTP mouse model of PD suggested that DR 
D3 expressed on CD4+ T cells are critical for T cell-dependent microglial activation, which %nally results in 
neurodegeneration29.
#e present study, examined CD4+ T cells, as well as naive and memory CD4+ T cell subsets, in PD patients 
and in healthy subjects, with speci%c regard to DR expression. Correlations of CD4+ T cell and cell subsets, as 
well as their respective expression of DR, were investigated with demographic and clinical features of the subjects. 
Patients on dopaminergic agents were compared with recently diagnosed patients who never received dopa-
minergic medications. In addition, in preliminary experiments the in vitro e"ects of α -synuclein (α -syn) were 
assessed on CD4+ T naive and memory cells. α -syn is a protein expressed in brain and in peripheral tissues. It is 
the main component of Lewy bodies and it may contribute to the pathogenesis of PD through di"erent concur-
rent mechanisms, including direct activation of microglial cells as well as possibly by acting as an antigen itself, 
triggering the adaptive immune response in the periphery30–32. For these reasons, the e"ects of α -syn on CD4+ 
T naive and memory cells were also compared with those of a common recall antigen like tetanus toxoid (TTd).
Results
Subjects. We enrolled 53 PD patients and 28 HS (Table 1). Patients comprised 16 subjects who had been 
never treated with antiparkinson drugs before enrollment, and were therefore drug naive (PD-dn). In compar-
ison to patients on antiparkinson drugs (PD-dt), PD-dn were younger and had on average lower H&Y stage, as 
well as UPDRS Part III score (Table 2). Plasma dopamine was 3.2 ± 5.7 nM in HS, 2.7 ± 3.3 nM in PD-dn patients 
(P = 0.779 vs. HS), and 8.0 ± 9.8 nM in PD-dt patients (P = 0.003 vs. HS).
Complete blood counts of PD patients and HS were all within normal limits (Table 3), however PD patients 
had less total lymphocytes, both in terms of absolute number (on average, about 17% less) and as percentage of 
white blood cells (− 3.5%).
Complete blood count did not di"er between PD-dn and PD-dt patients (Table 4), with the only exception of 
percentage of basophils, which were slightly lower in PD-dt.
?????????????????? ??+ T naive and memory subsets. Reduction of lymphocytes in PD patients 
was accounted for essentially by T cells (Table 3). In particular, CD4+ T cells were about 21% less in PD patients 
HS PD P
n 28 53
Gender (F/M) 11/17 17/36 0.625
Age (years) 68.8 ± 8.1 69.7 ± 9.5 0.545a
UPDRS Part II (score)b 7.2 ± 3.5
1–10 (n) 35
11–20 (n) 6
UPDRS Part III (score)c 14.0 ± 6.0
1–10 (n) 18
11–20 (n) 27
> 20 (n) 7
H&Y scale (stage) 1.6 ± 0.6
1.0 (n) 21
1.5–2.0 (n) 25
2.5–3.0 (n) 4
Table 1.  Comparison between HS and PD patients. Data are means ± SD unless otherwise indicated. Notes: 
a = by Mann-Whitney U test; b = data missing for 1 PD-dn and 11 PD-dt; c = data missing for 1 PD-dn patient.
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in comparison to HS, even if the CD4+ /CD8+ ratio did not change in patients, likely due the overall reduction 
of T lymphocytes. T lymphocyte subsets did not di"er in PD-dn and PD-dt patients in terms of absolute counts, 
even if in PD-dn patients CD3+ T cells as percentage of total lymphocytes were less (− 5.4%) and CD4+ T cells 
as percentage of CD3+ T cells were more (+6.4%) (Table 4).
To identify CD4+ T cell subsets, the gating strategy included the use of a biparametric dot plot CD45RA 
vs. CCR7, that allowed the identi%cation of T naive (CD3+ CD4+ CD45RA+ CCR7+ ), TCM (CD3+ CD4+ 
PD-dn PD-dt P
n 16 37
Gender (F/M) 7/9 10/27 0.337
Age (years) 65.6 ± 10.8 71.4 ± 8.4 0.041a
UPDRS Part II (score) 6.9 ± 4.7b 7.5 ± 2.6b 0.606d
UPDRS Part III (score) 9.9 ± 5.9d 15.6 ± 5.3 0.002a
H&Y scale (stage) 1.2 ± 0.4 1.8 ± 0.5 <0.001a
LED (mg/day) 459.4 ± 247.4
Drugs
l-DOPA (n) 27e
DA agonists (n) 27f
pramipexole (n) 19
ropinirole (n) 4
rotigotine (n) 4
Rasagiline (n) 19
Table 2.  Comparison between PD-dn and PD-dt.  Data are means ± SD unless otherwise indicated. Notes: 
a = by Student’s t test; b = data missing for 1 PD-dn and 11 PD-dt; c = data missing for 1 PD-dn patient; d = by 
Mann–Whitney U test; e = 8 taking l-DOPA alone, and 19 taking l-DOPA+ DA agents; f = 10 taking DA 
agonists alone (4) or with rasagiline (6), and 17 taking DA agonists+ l-DOPA, without (6) or with rasagiline (11).
units range HS PD P
RBC 1012/L 4.50–6.00 4.9 ± 0.4 4.7 ± 0.4 0.100a
hemoglobin g/dL 13.0–17.5 14.4 ± 1.1 14.2 ± 1.2 0.472a
hematocrit % 42.0–54.0 43.4 ± 3.6 42.6 ± 3.3 0.439a
MCH pg 27.0–32.0 29.8 ± 1.8 30.1 ± 2.3 0.253a
MCHC g/dL 32.0–36.0 33.7 ± 2.8 33.4 ± 1.7 0.780a
Platelets 109/L 150–450 238.2 ± 50.1 242.8 ± 69.1 0.853a
WBC 109/L 4.30–11.00 6.9 ± 1.6 6.6 ± 1.7 0.310a
lymphocytes
109/L 1.50–5.50 2.12 ± 0.73 1.76 ± 0.48 0.027b
% 10.0–45.0 30.8 ± 7.4 27.3 ± 6.8 0.050a
monocytes
109/L 0.2–1.1 0.5 ± 0.1 0.5 ± 0.2 0.620b
% 2.0–12.0 7.5 ± 1.9 7.5 ± 2.2 0.991b
neutrophils
109/L 1.50–5.50 4.1 ± 1.1 4.1 ± 1.4 0.781b
% 40.0–80.0 58.9 ± 8.0 62.4 ± 7.2 0.120a
eosinophils
109/L 0.0–0.8 0.2 ± 0.3 0.2 ± 0.1 0.679a
% 0.0–7.0 2.3 ± 1.6 2.3 ± 1.6 0.838a
basophils
109/L 0.0–0.2 0.0 ± 0.0 0.0 ± 0.0 0.793a
% 0.0–1.6 0.5 ± 0.2 0.5 ± 0.4 0.469a
lymphocyte subsets
CD3+
106/L 1515.0 ± 651.7 1241.0 ± 366.2 0.109a
% of total lymph 70.8 ± 9.4 69.6 ± 8.7 0.549a
CD4+
106/L 1012.0 ± 439.1 797.4 ± 263.3 0.035a
% of CD3+ 67.3 ± 10.8 64.7 ± 10.8 0.419a
CD8+
106/L 334.0 ± 162.8 274.9 ± 151.5 0.134b
% of CD3+ 23.4 ± 9.3 22.0 ± 9.7 0.562b
CD4+ /CD8+ ratio 3.8 ± 2.9 4.0 ± 3.4 0.979a
Table 3.  Complete blood count, comparison between HS and PD patients. Data are means ± SD unless 
otherwise indicated. Notes: Abbreviations: RBC, red blood cells; MCH, mean corpuscular hemoglobin; 
MCHC, mean corpuscular hemoglobin concentration; WBC, white blood cells. a = by Mann–Whitney U test; 
b = by Student’s t test.
www.nature.com/scientificreports/
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CD45RA-CCR7+ ), and TEM (CD3+ CD4+ CD45RA-CCR7-)
28. Among CD4+ T cells, PD patients showed 
decreased number of T naive cells (Fig. 1a). CD4+ TCM and TEM absolute numbers were not di"erent in PD 
patients and in HS, however TEM as percentage of total CD4+ T cells were increased in PD patients (+3.3% on 
average) (Fig. 1c). PD-dn and PD-dt patients did not di"er in either absolute number or percentage of T naive, 
TCM and TEM (Fig. 1b,d).
????????????????? ??+ T cells. DR expression was assessed at both mRNA level (in total CD4+ T cells) 
and membrane protein level (in total CD4+ T cells and in T naive and memory subsets). In comparison to cells 
from HS, CD4+ T cells from PD patients had lower mRNA levels of the D1-like DR D5 and of the D2-like DR 
D3 and D4, and higher mRNA levels of the D2-like DR D3, while D1-like DR D1 mRNA levels were not di"erent 
between cells from PD patients and HS (Fig. 2a). Interestingly, both the D1-like DR D5 and the D2-like DR D2 
mRNA levels were lower in cells from PD-dn patients compared to cells from PD-dt patients (Fig. 2b).
Flow cytometric analysis of DR expression on CD4+ T cells revealed that in PD patients DR D5+ CD4+  
T cells were decreased in terms of both absolute number and percentage of total CD4+ T cells (Fig. 2c,e), and that 
PD-dn patients had lower number and percentage of DR D1+ and D3+ CD4+ T cells in comparison to PD-dt 
subjects (Fig. 2d,f).
?????????????? ?? ??+ T naive and memory cells. In comparison to HS, PD patients had less D1-like 
DR D1+ and D5+ , as well as less D2-like DR D2+ and D3+ T naive cells, both in terms of absolute numbers and, 
for DR D3+ cells, also of percentage of total CD4+ T cells (Fig. 3a,c). PD-dn patients had less DR D1+ T naive 
cells in comparison to PD-dt patients, in terms of both absolute numbers and percentage of total CD4+ T cells 
(Fig. 3b,d).
No difference was found in DR expression in TCM and TEM between PD patients and HS, except for DR 
D3+ TCM which were higher in PD patients in terms of percentage of total CD4+ T cells, and for DR D4+ TEM 
which were higher in PD patients in terms of both absolute numbers and percentage of total CD4+ T cells (see 
Supplementary Fig. S1 and S2). DR expression on TCM or TEM did not di"er between PD-dn and PD-dt patients 
(see Supplementary Fig. S1 and S2).
????????????????????????+ T cells and demographic and clinical features of HS and PD 
patients. Age exerts major e"ects on lymphocyte function33, and in particular T naive cells may be reduced 
in elderly subjects34. In agreement with these %ndings, in HS both the absolute number as well as the percentage 
units range PD-dn PD-dt P
RBC 1012/L 4.50–6.00 4.8 ± 0.4 4.7 ± 0.4 0.250a
hemoglobin g/dL 13.0–17.5 14.4 ± 0.9 14.1 ± 1.3 0.456a
hematocrit % 42.0–54.0 43.3 ± 2.9 42.2 ± 3.4 0.324a
MCH pg 27.0–32.0 29.9 ± 1.7 30.2 ± 2.5 0.317a
MCHC g/dL 32.0–36.0 33.3 ± 1.6 33.5 ± 1.8 0.847a
Platelets 109/L 150–450 239.3 ± 48.8 244.4 ± 76.8 0.859a
WBC 109/L 4.30–11.00 6.2 ± 1.6 6.7 ± 1.7 0.400a
lymphocytes
109/L 1.50–5.50 1.63 ± 0.41 1.81 ± 0.50 0.222b
% 10.0–45.0 27.1 ± 6.6 27.5 ± 6.9 0.841b
monocytes
109/L 0.2–1.1 0.5 ± 0.2 0.5 ± 0.1 0.750a
% 2.0–12.0 8.0 ± 2.6 7.2 ± 2.0 0.221b
neutrophils
109/L 1.50–5.50 3.9 ± 1.4 4.2 ± 1.4 0.315a
% 40.0–80.0 61.6 ± 7.7 62.7 ± 7.1 0.532a
eosinophils
109/L 0.0–0.8 0.2 ± 0.1 0.2 ± 0.1 0.668a
% 0.0–7.0 2.6 ± 2.0 2.2 ± 1.5 0.581a
basophils
109/L 0.0–0.2 0.0 ± 0.0 0.0 ± 0.0 0.378a
% 0.0–1.6 0.7 ± 0.4 0.4 ± 0.3 0.019a
lymphocyte subsets
CD3+
106/L 1115.9 ± 302.0 1295.0 ± 381.8 0.143a
% of total lymph 65.9 ± 9.5 71.3 ± 7.9 0.037b
CD4+
106/L 757.3 ± 208.3 814.8 ± 284.7 0.672a
% of CD3+ 69.2 ± 12.2 62.8 ± 9.6 0.046b
CD8+
106/L 220.7 ± 134.6 299.7 ± 154.1 0.071a
% of CD3+ 19.5 ± 9.4 23.1 ± 9.8 0.220b
CD4+ /CD8+ ratio 5.3 ± 5.3 3.4 ± 1.8 0.053b
Table 4.  Complete blood count, comparison between PD-dn and PD-dt. Data are means ± SD unless 
otherwise indicated. Notes: Abbreviations: RBC, red blood cells; MCH, mean corpuscular hemoglobin; 
MCHC, mean corpuscular hemoglobin concentration; WBC, white blood cells. a = by Mann–Whitney U test; 
b = by Student’s t test.
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of CD4+ T naive cells negatively correlated with age (− 0.395 (− 0.026 to − 0.670), P = 0.037, and − 0.472 (− 0.120 
to − 0.718), P = 0.011). No correlation on the contrary was found between age and the immune pro%le in PD 
patients, either as a whole or in PD-dn and PD-dt patients.
#e relationship between disease severity and CD4+ T cells was assessed by dividing PD patients into 3 
groups according either to the UPDRS Part III score or the H&Y stage (Table 1), therea=er comparing each group 
with HS and analyzing the linear trend throughout the groups by means of ANOVA. No relationship was found 
between CD4+ T naive or memory cells and the UPDRS Part III score or the H&Y stage, with the only exception 
of a positive linear trend in the percentage of TCM cells and UPDRS Part III (see Supplementary Fig. S3).
Figure 1. CD4+ T naive and memory cells in HS and PD patients. Cells are shown as absolute numbers 
(panels a,b) and as percentage of total CD4+ T cells (c,d). Data are shown as medians with 25°–75° percentiles 
(boxes) and min-max values (whiskers). Comparisons are shown between HS and PD patients as a whole (a,c) 
and between drug naive (PD-dn) and drug treated (PD-dt) patients (b,d). Di"erences were analyzed by means 
of two-tailed Student’s t test or by Mann-Whitney test, as appropriate. P values less than 0.05 are indicated in the 
graphs.
www.nature.com/scientificreports/
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Figure 2. DR expression on CD4+ T cells from HS and from PD patients. DR expression is shown as mRNA 
levels (panels a,b) and as protein expression on the membranes of CD4+ T cells, expressed as absolute numbers 
of DR+ cells (c,d) and as percentage of total CD4+ T cells (e,f). Comparisons are shown between HS and PD 
patients as a whole (a,c,e) and between drug naive (PD-dn) and drug treated (PD-dt) patients (b,d,f). Data are 
shown as medians with 25°–75° percentiles (boxes) and min-max values (whiskers). Di"erences were analyzed 
by means of two-tailed Student’s t test or by Mann-Whitney test, as appropriate. P values less than 0.05 are 
indicated in the graphs.
www.nature.com/scientificreports/
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In PD-dt patients, no relationship was found between either CD4+ T cells as a whole or CD4+ T naive or 
memory cells and disease duration or LED (data not shown).
????????????????????? ???????????????? ??+ T cells and demographic and clinical features 
of HS and PD patients. DR mRNA levels in CD4+ T cells showed extensive correlations with the UPDRS 
Part III score (Fig. 4a). #e D1-like DR D5 mRNA levels decreased with increasing UPDRS Part III scores. In 
comparison to CD4+ T cells from HS, in cells from PD patients DR D5 mRNA levels were lower in the > 20 
UPDRS Part III score group. #e D1-like DR D1 and the D2-like DR D2, D3 and D4 mRNA levels did not show 
linear trends over the UPDRS Part III score, however DR D3 mRNA levels were higher than those in HS in the 
1–10 and 11–20 UPDRS Part III score groups, while DR D4 mRNA levels were lower in all the UPDRS Part III 
score groups (Fig. 4a). Some correlations were also observed between DR mRNA levels and H&Y stage, as DR 
D3 mRNA levels were higher than those in HS in the H&Y 1 and 2 stage groups, while DR D4 was lower in H&Y 
stage 2 (see Supplementary Fig. S4).
Figure 3. DR expression on CD4+ T naive cells from HS and from PD patients. DR+ cells are shown as 
absolute numbers (panels a,b) and as percentage of total CD4+ cells (c,d). Data are shown as medians with 
25°–75° percentiles (boxes) and min-max values (whiskers). Comparisons are shown between HS and PD 
patients as a whole (a,c) and between drug naive (PD-dn) and drug treated (PD-dt) patients (b,d). Di"erences 
were analyzed by means of two-tailed Student’s t test or by Mann-Whitney test, as appropriate. P values less than 
0.05 are indicated in the graphs.
www.nature.com/scientificreports/
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Figure 4. DR expression on CD4+ T cells and UPDRS-III score. DR expression is shown as mRNA levels 
(panel a) and as protein expression on the membranes of CD4+ T cells, expressed as absolute numbers of DR+ 
cells (b) and as percentage of total CD4+ T cells (c) Data are medians with 25°–75° percentiles (boxes) and min-
max values (whiskers). Di"erences in DR expression between HS and PD patients were analyzed by parametric 
ANOVA or Kruskal-Wallis nonparametric ANOVA, as appropriate, with either Holm-Sidak’s or Dunn’s 
adjustments for multiple comparisons, where * = P < 0.05 and ** = P < 0.01. Trend analysis in PD patients was 
performed by ANOVA post test for linear trend.
www.nature.com/scientificreports/
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Similar correlations with the UPDRS Part III score were observed for DR expression on CD4+ T cell mem-
branes, in the case of DR D5 (Fig. 4b,c). Correlations with the H&Y stage included DR D5 expression lower than 
that in HS in the H&Y 2 and 3 stage groups, and DR D3 expression lower than that in HS in the H&Y 3 stage 
groups (see Supplementary Fig. S5).
D1-like DR D1 and D5 expression on cell membranes negatively correlated with the UPDRS Part III score 
in CD4+ T naive cells, while D2-like DR D2, D3 and D4 didn’t show any major change (Fig. 5). On the con-
trary, D2-like DR D2 and D4 increased with the UPDRS Part III score in both CD4+ TCM and TEM cells, while 
D1-like DR did not change either in TCM or TEM (Fig. 5 and Supplementary Fig. S6). Only minor correlations 
were observed between DR expression and H&Y stage: D1-like DR D1 and D5 and D2-like DR D3 were reduced 
in T naive from PD patients in comparison to cells from HS, and D2-like DR D2 were increased in TCM (see 
Supplementary Fig. S7-S9).
No correlations were observed between DR mRNA levels and protein expression on CD4+ T cells or 
DR protein expression in CD4+ T naive and memory cells and age of HS or PD patients, or LED in PD-dt 
patients. However, in comparison to PD-dt patients treated with l-DOPA and dopamine agonists, those 
treated with l-DOPA alone had lower mRNA levels of DR D1 (6.0 ± 4.1 × 10
−8 vs. 10.8 ± 5.4 × 10−8, P = 0.035), 
D5 (9.7 ± 6.9 × 10
−8 vs. 20.6 ± 7.5 × 10−8, P = 0.003), and D2 (6.0 ± 4.4 × 10
−8 vs. 9.4 ± 3.3 × 10−8, P = 0.050), 
as well as less percentage of CD4+ T cells which were DR D1+ (7.2 ± 2.5% vs. 10.3 ± 3.5%, P = 0.025) or DR D3+ 
(4.5 ± 1.5% vs. 6.4 ± 1.9%, P = 0.017), and of CD4+ T naive cells which were DR D3+ (3.5 ± 1.2% vs. 7.9 ± 4.6 &, 
P = 0.009). Patients treated with l-DOPA alone had also higher UPDRS Part III score (19.0 ± 4.3 vs. 14.8 ± 5.0, 
P = 0.028) but similar H&Y stage (1.8 ± 0.7 vs. 1.8 ± 0.5, P = 0.933).
In vitro?????????????? ??+ T naive and memory cells to TTd and to α-syn. #e e"ect of α -syn on 
the frequency of CD4+ T naive and memory cells was tested on PBMC obtained from a group of 8 HS (F/M = 4/4, 
age = 58.1 ± 14.5 years) and 6 PD patients (F/M = 2/4, age = 76.7 ± 7.0 years, UPDRS Part III = 20.5 ± 3.1, 
H&Y = 1.8 ± 0.8) all treated with l-DOPA without (n = 4) and with DA agents (n = 2, in both cases rasagiline, in 
one case also ropinirole), with LED = 551.7 ± 140.1 mg/day.
Incubation of PBMC for 48 h with TTd resulted in reduced CD4+ T naive and increased TCM and TEM in both 
HS and PD patients, however the increase in TCM and TEM was higher in PD patients (Fig. 6a, le=). Incubation of 
PBMC for 48 h with either monomeric or %brillar α -syn resulted in reduced CD4+ T naive cells and increased 
TEM cells in both HS and PD, however in PD patients %brillar α -syn also increased TCM and induced a more pro-
nounced reduction of T naive cells than in HS (Fig. 6a).
Both monomeric and %brillar α -syn induced several changes in the expression of DR on CD4+ T naive and 
memory cells (Fig. 6b). In particular, monomeric α -syn increased DR D5 and D2 in T naive cells, and DR D2 in 
TCM, while %brillar α -syn increased DR D1, D2 and D4 in TCM and DR D1 and D4 in TEM.
Co-incubation of PBMC with either DA, the D1-like DR agonist SKF-38393, or the D2-like DR agonists 
7-OH-DPAT and PD-168,077 did not a"ect the frequency of CD4+ T naive and memory cells (see Supplementary 
Table S3,). SKF-38393 (1 µ M) or the D2-like DR agonist pramipexole (1 µ M) did not modify the e"ects of mono-
meric and %brillar α -syn in PBMC of either HS and of PD patients (data not shown).
Discussion
#e main result of our study is the evidence supporting an extensive association between DR expression in 
T lymphocytes and motor dysfunction, as assessed by the UPDRS Part III score, which is commonly used to 
measure disease severity in the clinical setting35. Speci%cally, in total CD4+ T cells as well as in CD4+ T naive 
cells the expression of D1-like DR D1 and D5 decrease with increasing UPDRS Part III score. On the contrary, 
D2-like DR show changes only at the mRNA level in total CD4+ T cells, do not exhibit major changes in CD4+ 
T naive cells, but show a clear trend to increased expression with increasing UPDRS Part III score in TCM and 
in TEM. #is is the %rst study showing a connection between PD severity and DR expression on CD4+ T cells, 
suggesting that dopaminergic pathways in peripheral immune cells are actively involved in PD. In addition, we 
provided preliminary evidence that α -syn might a"ect CD4+ T memory cells, possibly to a di"erent extent in PD 
patients in comparison to HS.
Our results are in line with previous studies showing decreased CD4+ T lymphocytes in PD patients9,10, and 
in particular with Saunders et al.12, who recently reported that in PD patients increased e"ector/memory CD4+ 
T cells correlated with increased motor dysfunction. In our study PD patients had decreased absolute count of 
CD4+ T naive cells, increased percentage of TEM cells, and TCM not di"erent from those in HS. Indeed, our $ow 
cytometric strategy28 allowed to distinguish between TCM, which mediate reactive memory by homing to T cell 
areas of secondary lymphoid organs, and TEM, which a"ord protective memory, by migrating to in$amed periph-
eral tissues and displaying immediate e"ector function36,37. At apparent variance with the study by Saunders 
et al.12, who reported that in PD patients e"ector/memory CD4+ T cells increased with the UPDRS Part III score, 
we did not identify any clear correlation between T naive/memory cells and the UPDRS Part III score. Saunders 
et al.12 however identi%ed T memory cells by using CD45RO expression, and found increased CD4+ T memory 
cells only in PD patients with UPDRS Part III score ≥ 31, while in our study we enrolled only 7 patients with a 
score above 20, the highest score being 24, and nonetheless we identi%ed increased TEM in PD patients, possibly 
also thanks to the speci%c $ow cytometry staining strategy which included the expression of CD45RA and CCR7, 
and allowed to distinguish between TEM and TCM
28. It remains however to be established whether the enhanced 
peripheral T memory function occurring in PD patients is mainly TEM, in line with the possibility that peripheral 
immune activation in PD has at least in part a protective role.
Concerning the general peripheral immune profile, we also observed reduced CD4+ T naive cells with 
increasing age in HS but not in PD patients. Reduction of T naive cells in elderly subjects is well described and 
is believed to result from thymic involution in combination with ongoing di"erentiation of T naive cells into 
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Figure 5. DR expression in CD4+ T naïve, TCM and TEM and UPDRS-III score. DR expression is shown as 
protein expression on the membranes of CD4+ T naïve (le=), TCM (center) and TEM (right) cells, expressed 
as absolute numbers of DR+ cells. Data are medians with 25°–75° percentiles (boxes) and min-max values 
(whiskers). Di"erences between DR levels in HS and in PD patients were analyzed by parametric ANOVA 
or Kruskal-Wallis nonparametric ANOVA, with either Holm-Sidak’s or Dunn’s adjustments for multiple 
comparisons, where * = P < 0.05 and ** = P < 0.01. Trend analysis in PD patients was performed by ANOVA 
post test for linear trend.
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antigen-experienced memory/e"ector cells34. In PD patients, the absence of correlations between T naive cell 
count and age, together with the reduced number of T naive cells in comparison to HS, is indeed in agreement 
with the hypothesis that PD is associated with increased peripheral immune exposure to antigens. A contribution 
by dysregulated thymic T cells development cannot be discarded, however, also in view of the lack of studies on 
thymic function during PD.
Although many immune cell subsets are dysregulated in PD, the key role of CD4+ T cells in the pathogen-
esis of the disease is supported by their presence, together with CD8+ T cells, in the brain in both postmortem 
human PD specimens and in the MPTP mouse model of PD, and evidence obtained in the animal model indicate 
that CD4+ T cells are determinants of T cell-mediated dopaminergic cell death11. Moreover, a recent study in 
MPTP-treated mice showed that CD4+ T cells are necessary for MPTP-induced neurodegeneration and that 
D2-like DR D3 expressed on T cells favor their activation and acquisition of the #1 in$ammatory phenotype
29.
Our results show that mRNA expression of several DR are dysregulated in CD4+ T cells from PD patients: 
in particular, in comparison to cells from HS, in cells from PD patients mRNA for the D1-like DR D5 and for 
the D2-like DR D3 and D4 are decreased, and mRNA for the D2-like DR D3 is increased (Fig. 2a,b). Flow cytom-
etry analysis of DR expression on CD4+ T cell membranes provides however a more homogeneous picture 
(Fig. 2c–f), with D1-like DR D5 clearly reduced by 30–49% in cells from PD patients. Interestingly, reduction of 
D1-like DR was evident for both DR D1 and D5 in CD4+ T naive cells (Fig. 3), while no di"erence occurred in TCM 
or TEM cells (see Supplementary Fig. S1 and S2).
Little information is available on the physiopharmacology of D1-like DR-operated pathways in T cells. D1-like 
DR D5 likely mediate the inhibitory e"ects of dopamine on proliferation and cytotoxycity of human CD4+ and 
Figure 6. E#ect of TTd, monomeric, and $brillar α-syn on the frequency of CD4+ T naive and memory 
subsets. Panel (a) E"ects of TTd (le=), monomeric (middle), and %brillar α -syn (right) in cells from HS (open 
columns) and PD patients (hatched columns). Data are expressed as percentage variation with respect to control 
conditions (without TTd or α -syn), and are means ± SEM of n = 6–8 separate experiments each performed in 
duplicate. * = P < 0.05 and ** = P < 0.01 vs. control conditions, and # = P < 0.01 vs. HS. Panel (b) monomeric 
(hatched columns), and %brillar α -syn (shaded columns) on DR expression in T naive (le=), TCM (center) and 
TEM cells (right) from 5 HS. Data are means ± SEM. * = P < 0.05 and ** = P < 0.01 vs control (open columns); 
# = P < 0.01 vs monomeric α -syn.
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CD8+ T cells38, however they also play a role in the inhibition of human CD4+ CD25high regulatory T cells, thus 
resulting in a “suppression of the suppressors”23. Interestingly, in vitro in human naive CD4+ T cells, dopamine 
via D1-like DR shi=ed T-cell di"erentiation towards #2, in response to stimulation with anti-CD3 and anti-CD28 
mAb24. Reduced D1-like DR on CD4+ T cells in PD patients might thus lead to several e"ects, such as increased 
CD4+ CD25high regulatory T cell function and increased #1/#2 balance. Saunders et al.12 however, reported 
impaired function of CD4+ CD25high regulatory T cells from PD patients, thus suggesting that reduced D1-like 
DR may have no direct e"ects on this specialized cell subset. Indeed, our preliminary unpublished data from 
another protocol, included in this same research program and aimed at investigating DR expression on CD4+  
T helper subsets, likely suggest that PD patients have a #1-biased peripheral immune pro%le. #is observation is 
in agreement with the previously reported increased ratios of IFN-γ -producing to IL-4-producing T cells in PD 
patients8, as well as with the role of D1-like DR on human CD4+ T naive cells which, according to Nakano et al.
24, 
shi= T-cell di"erentiation towards #2. It can thus be suggested that reduced D1-like DR on CD4+ T naive cells 
in PD patients impair their ability to di"erentiate towards #2, promoting a #1-biased proin$ammatory pro%le.
D1-like DR on CD4+ T lymphocytes, which are generally reduced in PD, also display a close correlation with 
PD patients motor dysfunction, as assessed by the UPDRS Part III score. Indeed, DR D5 expression diminishes 
with increased UPDRS Part III score, both at the mRNA level as well as in terms of percentage of CD4+ T cells 
which express the speci%c receptors (Fig. 4), a behavior which is evident also in CD4+ T naive cells, for both DR 
D1 and D5, but not in TCM of TEM (Fig. 5). By contrast, CD4+ TCM and TEM cells generally display a linear trend 
towards increased D2-like DR (Fig. 5 and Supplementary Fig. S6). Such close association with the UPDRS Part III 
score was not always parallel with the H&Y stage. In particular, in CD4+ T naive cells DR D1 and D5 decreased, and 
in TCM and TEM DR D2 and D4 increased with increasing UPDRS Part III score (Fig. 5 and Supplementary Fig. S6) 
but not with increasing H&Y scale stage (Supplementary Fig. S7–9). A likely explanation is that only one of the 
7 subjects with UPDRS Part III > 20 is included among the 4 subjects with H&Y 2.5–3.0 (Table 2). Whether 
UPDRS Part III scale pro%les the underlying immune dysfunction occurring in PD patients better than the H&Y 
scale remains to be established. Unfortunately, the only other study correlating CD4+ T cells and motor dysfunc-
tion in PD considered just the UPDRS Part III score12.
PD patients with more severe motor dysfunction (score > 20) have TCM cells expressing 131–134% more DR 
D2 and 112–126% more DR D4 than cells from HS, and 64–100% more DR D2 64–105% more DR D4 in com-
parison to cells from PD patients with score 1–10. #e picture is similar with TEM, as PD patients with score > 20 
have TEM cells expressing 93–112% more DR D2 and 48–71% more DR D4 than cells from HS, and 71–111% more 
DR D2 and 22–38% more DR D4 in comparison to cells from PD patients with score 1–10. As a whole, it appears 
therefore that, with increasing motor dysfunction, D1-like DR decrease on CD4+ T lymphocytes and in particu-
lar on CD4+ T naive cells, while D2-like DR, increase speci%cally on CD4+ TCM and also on TEM cells.
As discussed above, reduced D1-like DR on CD4+ T naive cells may promote a #1-biased proin$ammatory 
pro%le, and the present results suggest that such trend increases with increasing motor dysfunction. #ere is on 
the contrary paucity of data regarding the role of D2-like DR on T lymphocytes, even if Levite et al.
39 showed 
that activation of either DR D2 or D3 might induce T cell proliferation and adhesion. Of potential relevance for 
the present results, it was recently reported that, in the MPTP mouse model of PD, D2-like DR D3 expressed on 
CD4+ T cells are critical for T cell-dependent microglial activation29. If the same applied to PD patients and to 
D2-like DR-operated pathways as whole (as in PD patients DR D2 and D4, but not DR D3, correlated with motor 
impairment), increased D2-like DR in the more advanced stages of the disease might imply increased activation of 
the peripheral immune system, in turn triggering central neuroin$ammation leading to neurodegeneration and 
disease progression. Nonetheless, such %ndings should be interpreted cautiously since studies also exist showing 
that at least stimulation of the D2-like DR D4 may result in quiescence of human T cells
40. It is therefore necessary 
to clarify the role of individual DR in the modulation of memory T lymphocytes and in their relationship with 
microglia in PD. In addition, the eventual role of antiparkinson treatments on DR expression on T lymphocytes 
needs careful consideration, as discussed herea=er.
Comparison between PD-dn and PD-dt patients did not reveal any major differences in the peripheral 
immune pro%le. In particular, absolute numbers of CD3+ and CD4+ T cells were not di"erent, although per-
centage CD3+ T cells were slightly higher in PD-dt patients while percentage CD4+ T cells were slightly higher 
in PD-dn patients (Table 4), and T naive, TCM and TEM were similar in the two patient populations (Fig. 1b,d). A 
remarkable di"erence was however found in D1-like DR D1 expression in CD4+ T cells and in particular in T 
naive cells (Figs 2,3), as PD-dt patients had higher expression of DR D1 in comparison to PD-dn. #is di"erence 
might be of interest as PD-dn patients have on their T naive cells only 22–35% DR D1 in comparison to HS T 
naive cells, while PD-dt patients have on their T naive cells 41–63% DR D1 in comparison to HS T naive cells. 
Whether this is an e"ect of dopaminergic antiparkinson treatments cannot be established on the basis of the 
present results, also taking into account that no relationship was found between PD duration and/or LED and the 
immune pro%le or DR expession in CD4+ T cells and cell subsets. #e hypothesis should be nonetheless taken 
into account, since - as above discussed - D1-like DR on human CD4+ T naive cells may shi= T-cell di"erenti-
ation towards #224. Provided that this role of D1-like DR on T naive cells has any clinical relevance, it might be 
predicted that in the study which we are presently performing, aimed at investigating DR expression on CD4+ 
T helper subsets in PD patients, we will %nd less #1 cells in PD-dt patients in comparison to PD-dn patients.
α -Syn is the major component of Lewy bodies and a key factor in PD pathogenesis. Pathological α -syn 
released by degenerating neurons activates microglia to a proin$ammatory pro%le32, and directs cell migration41. 
EJux of α -syn from the brain to peripheral blood has been reported in mice and possibly in PD patients42, and 
it has been hypothesized that it might prime T cells that, in turn, would enter the brain and sustain microglia 
activation and neurodegeneration43. It has also been suggested that the presence of aberrant forms of α -syn in the 
periphery may represent a possible means for exposure as a neoantigen and subsequent activation of the adaptive 
immune system44.
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In our study, we performed preliminary experiments aimed at assessing the e"ects of di"erent forms of α -syn 
on CD4+ T naive and memory cells, in comparison to a well established recall antigen like TTd. We tested both 
monomeric and %brillar α -syn since accelerated %bril formation by certain variants of α -syn are associated to 
PD pathogenesis45,46. As expected, TTd reduced the frequency of T naive cells while increasing TCM and TEM. #e 
e"ect on TCM and TEM was however more pronounced in cells from PD patients, possibly in line with the activated 
pro%le of peripheral immune system in PD. Interestingly, both monomeric and %brillar α -syn induced a response 
which was qualitatively similar to the one evoked by TTd. Both PD patients and HS responded to the same extent 
to α -syn, with the only exception of %brillar α -syn, which increased TCM cells in PD patients but not in HS.
Available evidence of course does not allow to conclude that the responses to α -syn are actually due to rec-
ognition of the protein by T memory cells, although the response pattern is similar to that induced by TTd, and 
the ability of the peripheral immune system to recognize α -syn is also supported by the occurrence of speci%c 
antibodies in the serum of PD patients and HS47–49. Nonetheless, the ability of %brillar α -syn to increase TCM is 
suggestive, as these cells mediate reactive memory, by homing to T cell areas of secondary lymphoid organs and 
readily proliferating and di"erentiating to e"ector cells upon antigenic stimulation36,37.
It is also remarkable that incubation with α -syn a"ected DR expression on CD4+ T cells, and that in par-
ticular %brillar α -syn induced increased expression of DR D4 in both TCM and TEM, a %nding which resembles 
increased D2-like DR in TCM and TEM of PD patients with more severe motor dysfunction. Whether increased 
expression of DR corresponds to increased responsiveness, and which consequences might be implied for the 
pro/antiin$ammatory balance of peripheral (and possibly also central) immunity need to be carefully considered.
Concluding remarks and perspectives. It is noteworthy that in the present study we were unable to %nd 
any association between dopaminergic substitution treatments and the peripheral immune pro%le. Possible expla-
nations include that l-DOPA may undergo conversion to dopamine only in the brain, and that dopaminergic 
receptor agonists are usually D2-like DR selective (pramipexole, ropinirole). Rotigotine is the only dopaminergic 
agonist currently used in PD that has comparable aQnity for D2-like DR and at least for the D1-like D5, however 
our study enrolled only four subjects on rotigotine (out of a total of 53). Our study included also a group of newly 
diagnosed PD patients who never received dopaminergic treatments. #e main di"erence between newly diag-
nosed and antiparkinson-treated subjects consisted in an even lower expression of D1-like DR D1 on total CD4+ 
T cells as well as in T naive cells in newly diagnosed patients, however it remains to be established whether the 
increased D1-like DR D1 expression in antiparkinson-treated patients is actually due to antiparkinson drugs and/
or to other factors. In order to clarify this issue, we have already started a longitudinal study on a larger sample of 
drug naïve PD patients, who will be tested before and a=er pharmacological treatment.
Anyway, from a general point of view it is possible to conclude that dopaminergic substitution treatments 
have only minor, if any, impact on the peripheral immune system of PD patients, which on the other side shows 
profound di"erences in comparison to that of HS. In particular, speci%c di"erences related to dopaminergic 
pathways in immune cells de%nitely support the notion of a chronic peripheral immune activation in PD patients, 
which may a"ect disease severity. Immunotherapy is being increasingly regarded as an attractive strategy even in 
PD44, and it is therefore a priority to unravel the peripheral immune dysregulation occurring in PD patients, to 
plan adequate immunotherapeutic interventions. In addition, since antiparkinson therapy still lies mainly (if not 
only) on dopaminergic substitution therapy, detailed understanding of the role of dopaminergic pathways in the 
immune system might possibly allow a more appropriate use of available drugs, simply by better exploitation of 
their immunomodulating potential14–16,50.
Materials and Methods
Subjects. Peripheral venous blood samples were collected from patients with idiopathic PD51, either drug 
naive (PD-dn, i.e. PD patients who never received l-DOPA, DA agonists and/or other antiparkinson drugs) or on 
antiparkinson drug treatment (PD-dt), and from age- and sex-matched healthy subjects (HS). PD was diagnosed 
according to the United Kingdom Parkinson’s Disease Society Brain Bank Criteria. Patients and controls with a 
history of autoimmune or in$ammatory disorders and those receiving chronic immunosuppressive treatment 
were excluded.
Participants were recruited through the Centre for Parkinson’s Disease and Movement Disorders of the 
Neurological Service at the Ospedale di Circolo of Varese, the Interdepartmental Research Center for Parkinson’s 
Disease of the Neurological Institute “C. Mondino” of Pavia, and the Movement Disorders Center of the 
University of Piemonte Orientale, Divisione di Neurologia, Ospedale Maggiore of Novara, Italy. Healthy subjects 
were spouses and caregivers of enrolled PD patients. #e Ethics Committees of Ospedale di Circolo of Varese 
and Neurological Institute “C. Mondino” of Pavia approved the protocol and all the participants signed a written 
informed consent before enrollment. #e study was performed according to the Declaration of Helsinki and to 
the relevant ethical guidelines for research on humans.
A=er enrollment, subjects were submitted to a complete examination. PD patients were staged according to 
the criteria of Hoehn and Yahr (H&Y)52 and evaluated by means of the Uni%ed Parkinson’s Disease Rating Scale 
(UPDRS) Part III53. UPDRS Part II score was also assessed whenever possible. Data on patients and healthy con-
trols were collected using standard data forms, which included demographics, diagnostic features, family history, 
primary diagnosis, PD features, UPDRS Part III score, and Hoehn and Yahr (H&Y) stage. Antiparkinson drug 
doses were recorded at the time of enrollment and l-DOPA equivalent doses (LED) were calculated according to 
established guidelines54.
Withdrawal of 30 ml venous blood was performed a=er a fasting night, between 8:00 a.m. and 10:00 a.m., 
in EDTA-coated tubes (BD Vacutainer). Tubes were subsequently coded and stored at room temperature until 
processing, which occurred within 24 hours a=er collection. Complete blood cell count with di"erential analysis 
was conducted on separate blood samples collected in EDTA-coated tubes (BD Vacutainer). Serum levels of 
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dopamine were assayed by high-performance liquid chromatography with multielectrode electrochemical detec-
tion (HPLC-ED) according to a previously described method23.
Reagents. Bovine serum albumin (BSA) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
were purchased from Sigma, Italy. RPMI 1640, heat-inactivated fetal bovine serum (FBS), glutamine, and 
penicillin/streptomycin were obtained from Euroclone, Italy. Ficoll-Paque Plus was from Pharmacia Biotech 
(Uppsala, Sweden). Puri%ed mouse ab anti-human CD3 (code 555330, clone UCHT1, Mouse IgG1, κ ) and 
puri%ed mouse ab anti-human CD28 (code 555726, clone CD28.2, Mouse IgG1, κ ) were obtained from Becton 
Dickinson, Italy. (± )SKF-38,393 hydrochloride (cod. D047), R(+)7-OH-DPAT hydrobromide (code H168), 
PD-168,077 maleate (code P233), pramipexol dihydrochloride (code A1237), and dopamine hydrochloride (code 
H8502) were all from Sigma, Italy. Human recombinant α -synuclein and its %brillar form were a kind gi= from 
Dr. Lars Kjær and Dr. Daniel Otzen (iNANO - Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, 
Denmark), and were prepared as published before55.
????????????????????????? ?? ????????? ?????????????? ?? ??+ T cells and of DR expression in 
whole blood. Analysis of CD4+ T naive and memory subsets and of DR expression was performed accord-
ing to previously established method28. Brie$y, 100 µ l aliquots of whole blood were prepared and erythrocytes 
were removed by means of a lysis bu"er ((g/L) NH4Cl 8.248, KHCO3 1.0, EDTA 0.0368). Samples were then 
centrifuged, supernatants were removed and cells were washed in PBS (pH 7.4) supplemented with 1% BSA 
(PBS/BSA) and resuspended in PBS/BSA. Total leukocytes were counted by means of a hemocytometer and cell 
viability, determined by the Trypan blue exclusion test, was always > 99%.
From each subject 7 aliquots of 100 µ L were prepared: 5 were used for DR staining, 1 was used as control for 
the secondary PE-goat anti-rabbit (PEGAR) ab, and 1 was used as negative control (no ab). #e staining protocol 
consisted of two steps. During the %rst step each aliquot was stained for one of the %ve DR by an indirect labeling 
procedure (primary ab + secondary ab labeled with PE). During the second step all the aliquots were incubated 
with a cocktail of anti-human CD3, CD4, CD45RA and CCR7 ab for the identi%cation of T lymphocytes, CD4+ 
T lymphocytes and the following CD4+ T lymphocyte subsets: naive (CD3+ CD4+ CD45RA+ CCR7+ ), central 
memory (TCM, CD3+ CD4+ CD45RA-CCR7+ ), and e"ector memory (TEM, CD3+ CD4+ CD45RA-CCR7-). 
#e complete list of ab used in the study is shown in Supplementary Table S1.
Acquisition was then performed on a BD FACSCanto II $ow cytometer (Becton Dickinson, Milan, Italy) with 
BD FACSDiva so=ware (version 6.1.3). Lymphocytes were identi%ed by means of their classical forward scatter 
(FSC) and side scatter (SSC) signals and a minimum of 20,000 lymphocytes from each sample was collected in the 
gate. Data were analyzed with the FlowJo so=ware (version 8.3.2). #e results were %nally expressed as absolute 
numbers (106/ml) as well as percentage of positive cells (%).
Isolation of peripheral blood mononuclear cells (PBMC). PBMC were isolated from whole blood by 
using Ficoll-Paque Plus density gradient centrifugation. Cells were resuspended and, if necessary, any residual 
contaminating erythrocytes were lysed by addition of 5 mL of lysis bu"er, followed by incubation for 5 min, dur-
ing which samples were gently vortexed, and centrifugation at 100 g for 10 min at RT. Cells were washed twice 
in PBS by addition of 15 ml of PBS and centrifugation at 300 g and 10 min at RT, and resuspended at the %nal 
concentration of 10 × 106 cells in 10 ml of RPMI/10% FBS for subsequent culture. Typical PBMC preparations 
contained at least 80% lymphocytes, as assessed by $ow cytometry. Cell viability, assessed by the Trypan blue 
exclusion test was always > 99%.
??????? ?? ????????? ?? ?? ??????? ??+ T cells. CD4+ T cells were isolated from PBMC by immu-
nomagnetic sorting using Dynalbeads CD4 Positive Isolation kit (Life Technologies, code 11145D). Real-time 
PCR of DR mRNA was performed according to a previously reported method with modi%cations56. Brie$y, to 
isolate RNA, at least 50000 CD4+ T cells were resuspended in PerfectPure RNA lysis bu"er (5 Prime Gmbh, 
Hamburg, Germany), total RNA was extracted by PerfectPure RNA Cell KitTM (5 Prime Gmbh), and the amount 
of extracted RNA was estimated by spectrophotometry at λ = 260 nm. Total mRNA obtained from CD4+ T cells 
was reverse-transcribed using a random primer, high-capacity cDNA RT kit (Applied Biosystems). cDNA was 
then ampli%ed with SsoAdvanced™ Universal Probes Supermix (BIORAD) for the analysis of DR D2, DR D3, and 
DR D5 gene expression, and with SsoAdvanced™ Universal SYBR® Green Supermix (BIORAD) for analysis of DR 
D1, and DR D4 gene expression. cDNA was assayed on StepOne® System (Applied Biosystems). Real-time PCR 
conditions are shown in Supplementary Table S2.
Linearity of real-time PCR assays were tested by constructing standard curves by use of serial 10-fold dilutions 
of a standard calibrator cDNA for each gene, and regression coeQcients (r2) were always > 0.999; a melting curve 
was also performed to check for speci%city of DR D1 (melting temperature = 83.5 °C) and DR D4 (melting temper-
ature = 90 °C). Gene expression level in a given sample was represented as 2−∆Ct where ∆ Ct = [Ct (sample) - Ct 
(housekeeping gene)]. Relative expression was determined by normalization to 18 S cDNA. Analysis of the data 
were performed by StepOne so=ware™ 2.2.2- Applied Biosystems).
?????????? ?? ??+ T naive and memory subsets in cultured PBMC. Isolated PBMC were cultured 
in RPMI/10% FBS for 48 h at 37 °C in a moist atmosphere of 5% CO2, without or with anti-CD3/anti-CD28 ab 
(0.1 µ g/ml). Tetanus toxoid (TTd, 3 µ g/ml), monomeric or %brillar α -syn (both 500 nM) were added at the begin-
ning of cell culture. Cells were %nally harvested and stained for $ow cytometric analysis of naive and memory 
subsets of CD4+ T cells, as described in section regarding $ow cytometric analysis of naive and memory subsets 
of CD4+ T cells.
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Statistical analysis. Distribution of the values was assessed by the D’Agostino & Pearson normality test. 
Statistical signi%cance of the di"erences between HS and PD patients and between PD-dn and PD-dt patients 
was then analyzed by means of two-tailed Student’s t test or by the Mann-Whitney test, as appropriate, for con-
tinuous variables, and by the Fisher’s exact test for categorical variables. Correlations among continuous variables 
were assessed by Pearson or Spearman correlation analysis. Di"erences between HS and PD patients categorized 
for UPDRS Part III score or H&Y stage were analyzed by ordinary one-way ANOVA or by the Kruskal-Wallis 
test, with either Holm-Sidak’s or Dunn’s adjustments for multiple comparisons, and trend analysis in PD patients 
was performed by ANOVA post test for linear trend. Calculations were performed using commercial so=ware 
(GraphPad Prism version 5.00 for Windows, GraphPad So=ware, San Diego California USA, www.graphpad.com).
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